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Summary. Resumen 
La Barrera Hematoencefálica (BHE) es una entidad 
caracterizada por su naturaleza restrictiva al paso de sustancias. Las 
propiedades de la barrera están determinadas por la confluencia de tres 
componentes principales: 1) uniones celulares endoteliales con 
presencia de proteínas especificas intramembrana y citoplasmáticas 
unidas estrechamente al citoesqueleto. Esta circunstancia restringe la 
difusión paracelular de compuestos. Adicionalmente a las células 
endoteliales, la barrera presenta una membrana basal, en la cual se 
localizan pericitos y astrocitos, que conforman una capa que refuerza 
las propiedades de la barrera; 2) la presencia de transportadores de 
absorción y la sobreexpresión de transportadores de secreción 
combinada con el escaso transporte vesicular y la falta de fenestraciones 
y 3) metabolismo debido a la presencia de enzimas específicas, cuya 
función es proteger al cerebro. Todos estos componentes de la BHE 
son esenciales para mantener su integridad estructural, funcionalidad y 
estabilidad. En el Capítulo 1 de la Tesis se revisa con detalle la anatomía 
y fisiología de la BHE así como los mecanismos de transporte a través 
de esta barrera. 
La BHE permite el paso de sustancias esenciales al cerebro, tales 
como glucosa, oxigeno, iones, aminoácidos esenciales y algunas 
sustancias lipídicas. En situaciones fisiopatológicas, también permite el 
paso de macrófagos y otras células del sistema inmune. Sin embargo, 
debido a su naturaleza protectora de la homeostasis del cerebro, limita 
el transporte de sustancias potencialmente tóxicas, como son los 
fármacos. Estas restricciones son necesarias para mantener un óptimo 
ambiente que permita el desarrollo de las funciones neuronales, aunque 
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pueda limitar el acceso de tratamientos farmacológicos cuando son 
requeridos. La BHE, la Barrera Cerebroespinal (BCE) y otras 
estructuras son un obstáculo enorme para la administración de 
fármacos con finalidad diagnóstica o terapéutica en el interior del 
cerebro. Actualmente, existe un número creciente de patologías que 
afectan al Sistema Nervioso Central (SNC) y según las investigaciones 
más recientes en muchas de ellas existe una desregulación o disfunción 
de la BHE. Numerosos investigadores trabajan hoy en día para entender 
los principales determinantes de la velocidad y magnitud de acceso al 
cerebro a fin de mejorar el desarrollo de sistemas de liberación dirigidos 
a optimizar el paso a través de la BHE. En este sentido hay numerosas 
propuestas novedosas que facilitarán el desarrollo de candidatos capaces 
de acceder al SNC que se describen en el Capítulo 2 de la memoria. 
Con el fin de garantizar que los fármacos alcanzan su diana 
terapéutica es necesario evaluar la habilidad de los candidatos para 
cruzar la BHE, preferiblemente en las primeras fases de desarrollo de 
medicamentos. La determinación de los parámetros farmacocinéticos 
de los compuestos en desarrollo se ha facilitado gracias al uso de 
métodos experimentales in silico, in vitro e in vivo. Particularmente, los 
métodos in vitro basados en cultivos y co-cultivos de líneas celulares se 
han utilizados como métodos de cribado rápido para seleccionar los 
mejores candidatos en las etapas siguientes. Los modelos in vitro deben 
cumplir una serie de requisitos como un valor alto de resistencia 
transepitelial (TEER), baja capacidad permeable y la expresión de 
diferentes transportadores en su membrana. Mediante los coeficientes 
de permeabilidad obtenidos, se puede predecir la velocidad de acceso al 
cerebro y el momento del inicio de la acción, pero no es posible 
determinar la cantidad de fármaco que se alcanzaría en estado 
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estacionario. Sólo la fracción de fármaco libre en plasma es capaz de 
atravesar las barreras biológicas, tales como la BHE, y alcanzar la diana 
terapéutica. Por ello son necesarios nuevos modelos in vitro 
experimentales capaces de considerar todos los factores mencionados y 
predecir velocidad y cantidad de fármaco que alcanza la diana 
terapéutica, en este caso en el cerebro.  
Otro objetivo de los modelos in vitro consiste en reproducir las 
condiciones fisiopatológicas de la BHE. La morfología, la fisiología y 
consecuentemente la permeabilidad de la BHE se ven alteradas en 
numerosas enfermedades y todavía no se conoce claramente como esos 
cambios afectan al acceso de fármacos al SNC. Modelos in vitro de 
condiciones patológicas podrían ser muy útiles para encontrar 
soluciones aplicables a estas situaciones. En este sentido, el aislamiento 
de capilares se ha utilizado para estudiar ciertas condiciones patológicas 
y, recientemente, se están investigando con este propósito modelos de 
redes de fibras en 3D, modelos de chip de microfluidos y otros modelos 
de cultivos celulares. Los diversos métodos in silico, in vitro e in vivo se 
discuten en cuanto a ventajas y limitaciones en el Capítulo 3 y se justifica 
la necesidad del desarrollo de un nuevo sistema de predicción como 
objetivo central de esta Memoria. 
Durante las fases preclínicas del desarrollo de medicamentos, 
los experimentos para la determinación de la permeabilidad son 
esenciales a la hora de seleccionar moléculas candidatas para su 
posterior desarrollo clínico. La estimación del valor de permeabilidad 
de estas moléculas es un punto crítico que permitirá incorporar o 
descartar a los candidatos para las fases posteriores, por lo que el valor 
de permeabilidad obtenido debe ser lo más exacto y preciso posible. 
Para ello es necesario controlar los factores pre-experimentales, 
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experimentales y post-experimentales que pueden influir en la 
obtención de dicho valor.  
En el Capítulo 4 se revisan estas metodologías de cálculo y se 
propone un nuevo método de estimación. Tavelin y col. habían 
propuesto en 2002 una nueva ecuación para calcular la permeabilidad 
cuando el experimento de transporte no cumplía las condiciones sink o 
sumidero. También describieron la presencia de perfiles atípicos en los 
que la velocidad inicial está alterada debido a factores propios del 
investigador, o factores asociados a las características fisicoquímicas del 
compuesto, así como condicionantes propios del diseño experimental. 
El modelo non-sink clásico presenta una infra- o sobreestimación del 
valor de permeabilidad en situaciones de perfiles atípicos, es por ello 
que surgió la necesidad de diseñar una nuevo modelo para calcular la 
permeabilidad que se ha llamado MNS (modificación de la ecuación 
non-sink.). Mediante la simulación de experimentos de transporte, se ha 
explorado la capacidad predictiva del nuevo modelo MNS, para 
diferentes perfiles de cantidad-concentración frente al tiempo, 
incluyendo aquellos en los cuales la permeabilidad se ve alterada en las 
primeras fases del ensayo experimental y se ha comparado frente a los 
métodos clásicos sink y no-sink. El modelo se ha probado considerando 
diferentes niveles de variabilidad experimental y, finalmente se ha 
explorado su utilidad para la clasificación de fármacos según el sistema 
BCS (Biopharmaceutical Classification System).  
Los resultados han demostrado que el método MNS es preciso 
y exacto para el cálculo de la permeabilidad en cualquier tipo de perfil y 
en diferentes escenarios de variabilidad, bajo condiciones sink y no-sink, 
mientras que el modelo estándar No-Sink presenta una peor capacidad 
predictiva en aquellas situaciones dónde se ve alterado el paso de 
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fármaco a través de la monocapa en las fases iniciales del ensayo 
experimental. Los modelos de regresión lineal, Sink y Sink corregida, no 
son válidos en condiciones no-sink, debido a que no se cumplen las 
asunciones necesarias para su utilización, pero tampoco en condiciones 
sink donde hay una alta variabilidad experimental.  
Otros factores que pueden afectar el valor de permeabilidad 
calculado son los relativos a los protocolos o procedimientos 
normalizados de trabajo de la técnica experimental. Este aspecto se 
aborda en el Capítulo 5. En esta tesis doctoral se ha realizado un estudio 
para comparar los resultados obtenidos utilizando distintos protocolos 
que se diferenciaban fundamentalmente en la edad de las monocapas 
utilizadas (pases) y en la distinta maduración de las células antes de 
realizar el experimento (días post-sembrado), así como en el uso de 
insertos recubiertos o no con colágeno. Los resultados obtenidos 
demostraron diferencias estadísticamente significativas en el valor de 
permeabilidad según las distintas condiciones ensayadas. Es por ello 
que, la estandarización y la demostración de la idoneidad de los métodos 
experimentales son pasos necesarios para la utilización de los valores de 
permeabilidad con fines regulatorios o de predicción del 
comportamiento in vivo durante el desarrollo clínico. Generalmente, se 
ha prestado más atención a la validación de los procesos experimentales 
y menos al análisis matemático de los resultados, aunque los modelos 
matemáticos estándar presenten una serie de asunciones que no siempre 
se mantienen experimentalmente.  
Una vez controlada la fiabilidad en la obtención de la 
permeabilidad para fármacos candidatos a atravesar la BHE se procede 
al cálculo de los parámetros que rigen dichos procesos. Los parámetros 
más relevantes para la predicción de la velocidad y cantidad que 
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atraviesa la BHE son: fu, plasma (fracción de fármaco libre en plasma), Kpuu, 
brain (relación entre la concentración de fármaco libre en plasma y 
cerebro) y Vu, brain (volumen de distribución en el cerebro). Su estimación 
requiere todavía de modelos in vivo y de experimentos in vitro de cribado 
rápido conjuntamente, lo cual dificulta el cribado rápido de moléculas 
candidatas a actuar en el SNC en las fases iniciales de desarrollo clínico.  
El objetivo principal de este trabajo es el desarrollo de un nuevo 
método in vitro de cribado rápido para la predicción de la velocidad y 
cantidad de fármaco que atraviesa la BHE y se discute en el Capítulo 6. 
El sistema permite estimar los parámetros anteriormente descritos en 
un único método experimental, utilizando monocapas celulares in vitro 
bajo diferentes condiciones. A partir de relaciones entre los valores de 
permeabilidad obtenidos bajo cada condición y con el adecuado análisis 
matemático, se estiman todos los parámetros relevantes.  
Se seleccionaron diez compuestos y se estimaron sus valores de 
permeabilidad utilizando líneas celulares MDCKII y MDCKII-MDR1 
en ausencia o presencia de albúmina y homogeneizado de cerebro. Los 
ratios entre las permeabilidades obtenidas en presencia y ausencia de 
albúmina permiten estimar la fracción libre en plasma in vitro. Por otro 
lado, los ratios entre las permeabilidades en presencia y ausencia de 
homogeneizado de cerebro permiten la estimación de la fracción libre 
en cerebro in vitro. Kpuu, brain y Vu, brain se estiman a partir de la relación 
entre las permeabilidades apical y basal en condiciones estándar. Los 
parámetros in vitro se correlacionaron con los parámetros de los mismos 
compuestos obtenidos en experimentos in vivo. Con ello, se ha 
demostrado una alta capacidad predictiva del comportamiento in vivo de 
los compuestos utilizando el sistema experimental propuesto. La línea 
celular MDCKII presentó un mayor nivel de correlación frente a los 
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valores in vivo de fu, plasma, Kpuu, brain y Vu, brain (R=0.93, R=0.85 y R=0.99, 
respectivamente). Debido a su sencillez, destaca notablemente el nivel 
de correlación obtenido, a pesar del número reducido de compuestos 
con características fisicoquímicas y mecanismos de transporte asociados 
tan diversos. Modificaciones experimentales posteriores serán 
necesarias, con el fin de optimizar el método, pero los resultados 
obtenidos hasta el momento demuestran su viabilidad. Del mismo 
modo que otros modelos de cultivos celulares in vitro, el sistema es 
adecuado para la miniaturización y robotización con el objetivo de 
establecer mecanismos de cribado rápido de candidatos en el desarrollo 
de medicamentos.  
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BLOOD-BRAIN BARRIER 
Brain is the most protected organ in the body. Due to a very 
controlled brain homeostasis, there are three physiological barriers that 
restrict the access of endogenous substances and xenobiotics (drugs or 
toxins) to the central nervous system (CNS): the blood-brain barrier 
(BBB), the blood cerebrospinal fluid barrier (BCSFB) and the ependyma 
(the epithelial layer of cells covering the brain) (Figure 1) [1].  
 
Figure 1. Localization and structure of BBB and BCSF barriers. 
Adapted from Pavan et al, 2008 [1]. 
 
Even today, the majority of new drugs discovered do not cross 
the BBB [2]. In the last decade, a growing number of spin-off 
biotechnological companies from academia have started to develop new 
methods and strategies to help pharmaceutical companies target the 
brain. The CNS discovery and development paradigm in those 
companies is slowly changing to acknowledge the need for earlier BBB 
access in order to avoid clinical failures. The development programs 
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should include the use of in silico, in vitro and in situ models from the 
beginning to reduce the attrition rate later on. Nevertheless, there is still 
room for research and many unanswered questions.  
In upcoming years it will be desirable to improve the quality of 
in silico models to screen better new families of compounds, taking into 
account passive diffusion in combination with influx and efflux 
mechanisms.  
More research is required to improve in vitro cell methods to 
obtain barriers keeping the BBB phenotype, while also being easy to 
handle and offering similar dynamic properties of the human BBB 
vessels.  
Research in the area of transporters at BBB level, tight junction 
formation and changes under pathological conditions will help to design 
strategies for targeting the brain. There is a need for BBB genomic 
research to identify specific targets on the brain vasculature. Carrier-
mediated transport or receptor-mediated transport are successful 
strategies that offer a wide scenario for the development of new brain 
targeted molecules.  
 
 Chapter 1 and 2 review the anatomy and physiology of Blood 
Brain Barrier and the latest developments in Drug Delivery 
Methodologies to access the Central Nervous System (CNS). 
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IN VITRO MODELS OF BBB AND PHARMACOKINETICS 
PARAMETERS OF BRAIN DELIVERY AND 
DISTRIBUTION. 
Blood-brain barrier (BBB) controls the access of endogenous 
substances and xenobiotics to the extracellular fluid (ECF) and 
intracellular cerebral fluid (ICF). BBB is an active barrier with important 
functions for brain homeostasis and protection, formed by endothelial 
cells with high expression of tight junctions and transporters. Only the 
unbound fraction of drug in plasma can permeate through the BBB and 
interact with the target in the brain [3-6]. The most important 
parameters that govern the pharmacokinetics of drug in the CNS are fu, 
plasma, Kpuu, brain and Vu, brain. fu, plasma is the unbound fraction of drug in 
plasma, Kpuu, brain represents the ratio between unbound drug 
concentrations in brain and in blood and Vu, brain is the apparent 
distribution volume in brain. ECF concentrations could only be 
obtained using microdialysis. For ethical reasons, human cerebrospinal 
fluid concentrations (CSF) have been used as a surrogate measure of 
the ECF concentrations. De Lange et al. has recently published the 
utility of human Kpuu, CSF as reference of the ECF concentrations in 
brain [3].  
In silico, in vitro, in situ or in vivo methodologies have been 
employed to evaluate the pharmacokinetic of new drug candidates in 
the CNS [7]. Chapter 3 review the in silico, in vitro and in vivo methods 
used in drug development for CNS candidate screening. In vitro cell 
culture experiments are used as a high throughput method to select best 
candidates for further stages of the drug development process, however 
permeability coefficients (Papp) are relevant only for the rate of access 
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and the onset of action but do not determine the extent as in a steady 
state drug administration there is not a limited time for the permeation 
process. Consequently the range of adequate permeability values for 
BBB barrier is wider than that used for intestinal permeability screening 
[5, 8]. Different in vitro cell models have been used to mimic the blood-
brain barrier (BBB) [9-13]. Madin-Darby canine kidney II (MDCKII) 
cells and MDCKII transfected with the human multidrug resistance 
gene 1 (encoding P- glycoprotein, P-gp) (MDCKII-MDR1) are 
commonly used to evaluate the blood–brain barrier permeability of 
drugs [10, 14, 15] MDCK I cells show much higher transepithelial 
electric resistance (TEER) than MDCK II cells, although they bear 
similar numbers of tight junction (TJ) strands [16]. These cells display 
morphological, enzymatic, and antigenic cell markers, also found in 
cerebral endothelial cells and have been reported as a suitable model for 
this barrier. The MDCKII-MDR1 cell line was identified as the most 
promising cell line among several cell lines, for qualitative predictions 
of brain distribution, and to distinguish between compounds that pass 
the blood–brain barrier by passive diffusion and those that are 
substrates for active efflux by P-glycoprotein, P-gp [14, 15]. The P-gp 
transporter and other membrane transporters belonging to the ATP-
binding cassette family of transporters have been extensively described 
to regulate intracellular concentrations of different compounds [17-19].  
The in vivo microdialysis is the gold standard technique, allowing 
continuous monitoring with high-resolution concentration profiles of 
drugs and metabolites from (freely moving) individual subjects. 
Measurements are obtained from brain extracellular fluid, inserting one 
probe into the brain tissue and from peripheral blood stream. Then, 
unbound brain and plasma concentrations are estimated as the best 
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reference to explore drug permeation and distribution across the BBB 
[4, 5, 20-22]. However, the main disadvantage of this technique is the 
high time-consuming, which reduces its application as a high screening 
method for new drug candidates. 
 
PERMEABILITY ESTIMATION METHODS. 
 The permeability is calculated from the drug concentrations and 
accumulated amounts in acceptor chamber using either linear or 
nonlinear regression models, depending of the assumption about sink 
conditions on the receptor side [23, 24]. Tavelin et al.[24] described the 
different profiles that are usually observed between accumulated 
amounts of drug in the acceptor side versus time. Three examples of 
these profiles are represented in Figure 2. 
 
Figure 2. Profiles of accumulated amounts of drug in acceptor chamber versus time in 
permeability experiments in cell monolayers. Profile A: Drug is transported during the first 
sampling interval at a lower rate than expected; Profile B: Drug is transported linearly with a 
constant rate; Profile C: Drug is transported at a higher rate during the first sampling interval. 
 
Tavelin et al. [24] highlighted the existence of atypical profiles 
(Profiles A and C on Figure 2) and explained the possible reasons to 
these profiles. Profile A may be caused by poor temperature control at 
the beginning of the experiment, or by the fact that partitioning of the 
drug into the cell monolayer is the rate-limiting step. Profile C is 
sometimes observed when the transport of radiolabeled drugs is 
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studied. The reason may be that radiolabeled low molecular weight 
impurities (such as 3H-water) are present in the drug solution and are 
transported at a higher rate than the drug. Another reason may be that 
the cell monolayer is affected by a too harsh application of the drug 
solution. In such cases, the estimation of the permeability by the 
standard linear regression methods or even non-linear regression 
methods may not be correct. Therefore, a good estimation of 
permeability is needed to correctly classify drugs under BCS criteria. 
Chapter 4 focuses on the development of a new estimation method able 
to be used under sink and non-sink conditions and to capture the 
alteration of the initial permeation rate without biasing the permeability 
estimation. 
Simulation is an important tool for the evaluation of 
pharmacokinetic models that allows analyzing different scenarios and a 
more efficient decision making during drug development [25-33]. 
Regulatory agencies, FDA and EMA, encourage model simulation as a 
tool to increase predictability and efficiency in preclinical and clinical 
phases [34, 35].  
A second aim of this study was to use a simulation strategy to 
explore the performance of a Modified Non-Sink equation, MNS; (in 
terms of precision and accuracy) for permeability estimation in different 
types of profiles and scenarios of variability, to compare the new 
proposed model with the classical sink and non-sink approaches and to 
explore its usefulness for BCS classification. Data from cell culture 
experiments representing the different experimental profiles have been 
analyzed with all the equations to validate the new approach. The 
limitations ad advantages of the MNS equation are discussed. 
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PROTOCOL OPTIMIZATION. 
Chapter 5 deals with the factors affecting permeability 
estimation and its variability intra- and inter-laboratory. Permeability 
values and their associated variability from cell culture transport 
experiments are influenced by several factors that can be classified in 
three groups, pre-experimental, experimental and post-experimental 
factors. The adequate standardization of these factors can help to 
reduce the inter- and intra-laboratory variability in permeability values. 
For instance, the variability in permeability estimations complicates the 
comparison and combination of data from different laboratories and it 
makes necessary the careful validation of the model and the continuous 
suitability demonstration.  
Among the pre-experimental factors the most relevant are the 
cell type and source and passage number which could affect the 
monolayer differentiation, membrane composition, transporter 
expression and tight junction resistance [36, 37]. In fact, some research 
works describe differences in cell shape and size, multilayer formation 
and actin staining between the same cell sources [38]. Several cellular 
lines have been traditionally used in order to determine the in vitro 
permeability values. Caco-2, MDCK or MDCK-MDR1 cell lines are the 
most commonly used for this purpose. Caco-2 cells are the most widely 
used model for estimation of drug intestinal permeability despite its 
colonic origin [39, 40]. On the other hand MDCK epithelial cells, 
despite of its non-human and non-intestinal origin, have demonstrated 
a good correlation with Caco-2 cells results and good predictive 
performance of human oral fraction absorbed [41, 42]. MDCK-MDR1 
cells correspond to the P-gp transfected clone from MDCK and are 
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used for the study of P-gp substrates [43, 44]. MDCK and MDCK-
MDR1 lines with low values of trans-epithelial resistance (TEER) are 
used also as blood brain barrier model [10, 14, 15]. These three cell lines 
have been included in this study as the most representative barrier 
models to compare its intrinsic variability when used with the same 
protocol. The culture conditions, such as the components of the culture 
medium or the cell density, the pH or the temperature also affect the 
final characteristics of the monolayer [45, 46]. Subculture details such as 
the frequency of culture media renewal affect the expression of several 
enzymes and the kinetic parameters of the transport substrates [47, 48].  
Regarding the passage number, many researchers have 
demonstrated that changes in TEER, cell growth, mannitol flux and 
active transport are observed with passage number [49-51]. However, 
there is no consensus regarding the optimal interval of passages for 
conducting assays in order to obtain adequate and reproducible 
permeability values.  
The experimental factors can also affect the monolayer 
absorption and metabolic properties. The literature describe parameters 
involved in monolayer permeability such as media composition and pH 
of both chambers, seeding density, system shaking, plastic support 
material type, solute concentration, temperature, etc. which also affect 
the barrier properties (integrity, permeability and transporter 
expression) and the thickness of the unstirred water layer [10, 14, 15, 
37-39, 41, 43-54]. Differentiation period after confluence is a crucial 
parameter in order to obtain reproducible results as the cells suffer 
important changes in morphology, barrier properties and expression of 
transporters with time [49-51, 55, 56]. With increasing age, changes in 
cell height and shape, cell junction formation, TEER values, metabolic 
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activity, P-gp, MRP2, OATB OCTN2 and PePT1 transporters 
expression and brush border microvilli were observed [57]. The 
challenge is to determine the optimum culture period for performing 
transport assays. Moreover, features such as the sampling schedule (only 
acceptor chamber or both, number of samples, media replacement), the 
maintenance or not of sink conditions are determinant of the 
calculation method and thus influence the permeability estimate 
obtained.   
Among the post experimental factors, the variability associated 
with the analytical method is an important aspect to take into account 
as well as the estimation method (and its underlying mathematical 
assumptions) that it is an aspect often neglected [58].  
The objective of this part of the work was the evaluation of the 
effect of passage number, experimental protocol, maturation time after 
seeding and calculation method on the permeability values and their 
associated variability in cell culture transport experiments conducted in 
our laboratory using three cell lines, Caco-2, MDCK and MDCK-
MDR1. The final goal is to select the best experimental conditions for 
further method validation and to determine the sample size for 
detecting a given difference in permeability values. Three compound 
markers of transcellular permeability (Metoprolol), paracellular 
permeability (Lucifer Yellow) and P-gp functionality (Rhodamine-123) 
were used to check the performance of the cell lines and their ability to 
reach pre-established specifications. 
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NEW IN VITRO MODEL DEVELOPMENT. 
The main aim of the present work was to develop a new whole 
in vitro high throughput method to predict drug rate and extent of access 
across the BBB. This new method is presented in Chapter 6. The system 
permits using apparent permeability values (Papp) from in vitro cell 
monolayers experiments in different conditions to estimate fu, plasma, Vu, 
brain, and Kpuu, brain.  
In order to explore the feasibility of the in vitro system as a 
screening method for CNS compounds the predicted in vitro values have 
been correlated to in vivo fu, plasma, Kpuu, brain, human, Kpuu, CSF and Vu, brain values 
obtained by microdialysis by Friden et al. [59] (Table 1). Cell cultures of 
MDCKII and MDCKII-MDR1 have been used to compare its 
prediction performance and to determine the transport mechanism for 
each compound tested.   
The BBB parameters obtained with our new method were 
predictive of the in vivo behavior of candidates. in vitro fu, plasma, Kpuu, brain 
and Vu, brain calculated with Papp from MDCKII cell line presented a good 
correlation with in vivo fu, plasma, Kpuu, brain and Vu, brain published values 
(r=0.93; r=0.85 and r=0.99 respectively). Despite its simplicity the 
predictive performance is fairly good considering the reduced number 
of tested compounds with different physicochemical and transport 
properties. Further experimental modifications could be checked to 
optimize the method but the present data support its feasibility. As 
other in vitro cell culture models the system is suitable for 
miniaturization and robotization to allow high throughput 
performance. 
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The overall aim of this work was to develop a new Innovative In Vitro 
Method and Permeability Estimation Procedure to Predict Drug 
Transport across the Blood-Brain Barrier. In order to attain this 
general goal, specific objectives were considered as detailed below: 
 
 To review the state of the art of the in vitro models for Blood 
Brain Barrier and to identify the relevant parameters that a 
model should be able to predict to identify CNS drug 
candidates. 
 
 To review the mathematical estimation methods of permeability 
values from cell culture experimental data and their underlying 
assumptions and limitations.  
 
 To propose a new estimation method with a broader 
applicability in any experimental situation i.e. sink and non-sink 
and in the presence of initial rate alterations. 
 
 To optimize the experimental conditions for cell culture 
permeability experiments in order to minimize system variability 
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and to ensure the consistency of the experimental results in our 
laboratory. 
 
 To develop a new whole in vitro BBB model able to predict all 
the relevant parameters for CNS access Kpu,u, Vu, brain and fu, plasma. 
 
 To validate the prediction ability of the new in vitro models of 
Kpuu, brain, Vu, brain and fu, plasma by comparison with in vivo data from 
model drugs and to compare the prediction performance of the 
in vitro model based on MDCK cells versus the system based on 
MDCK-MDR1. 
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The brain is one of the most protected organs in the body. 
There are three barriers that control the access of endogenous 
substances and xenobiotics (drugs or toxins) to the CNS. These 
physiological structures are the blood–brain barrier (BBB), the blood–
cerebrospinal fluid barrier (BCSFB) and the ependyma (the epithelial 
layer of cells covering the brain). Figure 1 shows a scheme of the 
localization and organization of these barriers [1]. The BBB represents 
the main determinant of the effective delivery of drugs to the CNS [2-
4]. The development of new drugs targeted to the CNS require a better 
knowledge of the factors affecting BBB permeation, as well as 
predictive tools in vitro and in silico to optimize the screening at early 
stages of drug development, and to reduce the attrition rate at later 
stages. On the other hand, it is important to characterize the alteration 
of the BBB in pathological conditions.  
A good permeability through the BBB is essential if the target 
site is located in the CNS or, in contrast, can be disadvantageous if the 
action site is outside the CNS, when the drug could cause adverse 
reactions at central level. For instance, drug penetration of the BBB is 
the most challenging issue in brain tumor therapy. In addition, there is 
a growing demand of new drugs for neurodegenerative conditions such 
as Alzheimer’s, Huntington’s and Parkinson’s diseases or multiple 
sclerosis [5].  
The physicochemical factors affecting BBB permeability include 
lipophilicity, polar surface area (PSA), charge state, molecular size, 
flexibility and hydrogen-bonding potential. Nevertheless, these 
characteristics mainly affect permeability through the barrier, while the 
overall access in extent and rate (and, thus, the concentration at the 
receptor site) is also determined by other factors, such as plasma protein 
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binding, active uptake into the CNS, efflux out of the CNS and the 
degree of binding to components of brain tissue [6–9]. In this review, 
the characteristics of the BBB are described and the in vitro, in situ and 
in vivo methods to measure BBB transport, as well as the possibilities to 
enhance the BBB permeability for drugs targeted to treat brain diseases 
or injuries. The overall aim is to identify the key factors to be 
considered, when developing new, active and safe CNS drugs in an 
efficient manner.  
 
GENERAL CHARACTERISTICS OF THE BBB 
The structure of the BBB is formed by endothelial cells lining 
the cerebral microvessels [10] and is characterized by its tight-junctions 
and lack of fenestrae. The barrier function is determined not only for 
the inter-endothelial tight junctions but also for the presence of 
enzymes (such as glutamyl transpeptidase, alkaline phosphatase, 
esterases and monoamine oxidase, which are either absent or expressed 
at low levels in peripheral vessels) and the expression of uptake and 
efflux transport systems. Around the endothelial cells there is a large 
number of pericytes, perivascular antigen-presenting cells. Covering the 
vessels there is a sheath of astrocytes and the associated parenchymal 
basement membrane [11]. All these structures ensure CNS homeostasis 
and the correct neuronal function, preventing the entrance of many 
endogenous and pharmacological compounds. A basic scheme of the 
BBB architecture is provided in Figure 2 [10].  
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Figure 1. Localization and structure of blood-brain barrier and brain-cerebrospinal fluid barrier. 
Adapted with permission from [1].  
 
Endothelial cell–cell junctions in the CNS  
The effectiveness of the BBB as a restrictive barrier is due to the 
tight junctions, which provide a high trans-endothelial electrical 
resistance of 2000Ω·cm2, compared with 3–30Ω·cm2 in peripheral 
vessels. In addition, the BBB endothelial cells have a low vesicular 
transport capacity and also lack fenestrations. The inter-endothelial 
tight junctions in CNS microvessels are an intricate complex of 
transmembrane (claudins, occludin and junctional adhesion molecule 
[JAM-A] and cytoplasmic zonula occludens [ZO]-1 and [ZO]-2, 
cingulin, AF-6 and 7H6) proteins linked to the actin cytoskeleton [11-
13].  
 
Astrocytes & pericytes 
The astrocytic glia endfeet and leptomeningeal cells constitute a 
covering layer that is connected to the CNS microvessels. It has been 
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suggested that the ability of CNS endothelial cells to form a barrier is 
not intrinsic to these cells but induced by the CNS environment [14]. 
The inducing factors are likely to be low-molecular-weight molecules. 
Not fully considered is whether the basement membrane itself also 
contributes to the tightness of the brain endothelial cell monolayer and 
influences expression and or function of BBB-specific structural (tight 
junctions) and molecular (transporters and enzymes) characteristics (see 
upcoming discussion). In addition to astrocytes, epithelial cells from the 
meninges can be associated with CNS blood vessels. The role of 
astrocytes in the formation of the BBB is of great interest to scientists 
and is one of the main aspects considered during the development of in 
vitro BBB models [11]. Pericytes are cells of microvessels including 
capillaries, venules and arterioles that wrap around the endothelial cells. 
They are thought to provide structural support and vasodynamic 
capacity to the microvasculature. Although astrocytes cover 99% of the 
abluminal surface of the capillary basement membrane in brain, their 
precise role in the BBB is not well investigated. The in vitro models 
incorporating pericytes and astrocytes show significantly increased 
transendothelial electrical resistance compared with the models 
combining only endothelial cells and astrocytes [15,16]. Nakagawa et al. 
demonstrated that the presence of astrocytes elevated the trans-
endothelial electrical resistance (TEER) values by approximately 250% 
in 5 days compared with the TEER values of endothelial cells alone 
[17]. The TEER values of the triple co-cultured models were higher 
than the values of the double co-cultures. The level of TEER increased 
up to 700% in triple co-cultures compared with endothelial cells. Their 
exact role in BBB function is still an open question due to the difficulty 
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in obtaining these cells and the fact that their physiological function 
seems to be influenced by the tissue environment [11]. 
 
Figure 2. Structure of blood–brain barrier: the endothelial cells of brain micro-vessels lack 
fenestrations and present tight-junctions that restrict paracellular permeation of solutes. The 
presence of transporters (at both sides of the endothelial cells) and metabolizing enzymes 
contribute to the barrier properties. Astrocytes form a sheath covering the vessels and play a 
role in inducing barrier properties. Pericytes provide structural support and their role in the 
blood–brain barrier is an open question. Adapted with permission from [10]. 
 
Acellular layers: basement membranes 
The potential role of the acellular extracellular matrix in the 
BBB is not well known. CNS inflammation studies highlighted the 
contribution of vascular basement membranes to leukocyte 
extravasation processes and, hence, barrier functions at the level of 
postcapillary venules. Although data on the basement membrane 
composition of CNS vessels exist, the data is fragmentary and lacks 
specificity both with regards to vessel type and specific extracellular 
matrix isoforms [18–22]. Nevertheless, existing data suggest that 
biochemical variations are present between endothelial and 
parenchymal basement membranes and that basement membrane 
components contribute to microvessel integrity and function [11]. 
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Extracellular matrix receptors 
It is known that endothelial cells and astrocytes express several 
integrins and dystroglycan (a major non-integrin receptor) [20,23]. 
Microglia express some integrins also. There is evidence for the role of 
these receptors in the maintenance of BBB integrity [24-26].  
 
BBB PERMEATION 
Transport processes in the CNS 
There are two controlled pathways for molecules to cross the 
BBB, namely paracellular (junctional) and trans-endothelial routes. In 
Figure 3 the most important and currently known permeation routes to 
access the brain are depicted. 
Due to the restrictive paracellular pathway (regulated by inter-
endothelial tight junctions) the transport of hydrophilic and low-
molecular-weight compounds for this route is limited. The trans-
endothelial pathway is also restricted to hydrophilic substances due to 
the lipophilic nature of the membrane and a lower rate of pinocytosis 
than in the peripheral endothelium. Passive diffusion depends mainly 
on the lipophilicity and molecular weight. The alternative route for 
molecules that cannot cross the barrier via passive diffusion is to enter 
the CNS by interaction with endogenous transport systems located 
within the brain capillary endothelium or the neuroepithelial cells of the 
choroid plexus. The transport mechanisms are classified into three 
groups [27]: 
 Carrier-mediated transport (CMT), is responsible for the 
transport of low-molecular-weight (less than 600Da) 
compounds into the CNS. There are active and facilitated 
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diffusion carriers [28]. Many nutrients such as glucose, amino 
acids and purine bases use some CMT systems to enter into the 
brain. At least eight different nutrient transport systems have 
been identified. These systems are substrate selective but could 
be used by drugs that closely mimic the endogenous carrier 
substrates; 
 Receptor-mediated transport (RMT), allows the entrance to 
relatively large compounds (peptide and proteins) via an 
endocytotic process. Classical examples of receptors involved in 
receptor-mediated transcytosis are the insulin receptor, 
transferrin receptor and transporters for low density 
lipoprotein, leptin and insulin-like growth factors. These 
systems are studied for targeted delivery of drugs with high 
molecular weight to the brain [28]; 
 Active efflux transport (AET), is responsible for the active 
secretion of multiple drugs from the CNS into the bloodstream. 
As a consequence, AET substrates cannot effectively penetrate 
the brain. The best known AET system is P-glycoprotein (P-
gp), which limits the transport of a wide range of cationic and 
lipophilic compounds such as cytotoxic anticancer drugs, 
antibiotics, hormones and HIV protease inhibitors, into the 
brain [29,30]. Other active efflux transporters identified at the 
BBB are the MRP proteins [31–34]. The development of co-
drugs in order to inhibit the AET systems can be a strategy for 
increasing brain penetration of drugs [5]. The term ‘co-drug’ 
refers to two or more therapeutic compounds active against the 
same disease and bonded via a covalent chemical linkage. In 
Chapter 1 
 
  56 
 
Table 1 a summary of some of the transporters identified in the 
brain endothelial cells is shown [35,36]. 
 
Figure 3. Permeation mechanisms through the endothelial cells. Paracellular diffusion is 
restricted. Transcellular route includes passive diffusion, carrier-mediated transport or 
endocytosis. The presence of efflux transporters contributes to limiting the access of 
xenobiotics to the CNS. 
 
Factors involved in drug permeation through BBB & distribution 
into the brain 
If the CNS is considered as a separate pharmacokinetic 
compartment, the concentration of compounds in the brain and its 
evolution with time (i.e., the rate and extent of drug access to the brain) 
will depend on several factors, as follows: 
 The plasma concentration, defined by the drug absorption, 
distribution, metabolism and excretion characteristics; 
 The degree of plasma–protein binding as only the unbound 
fraction diffuses across the barrier; 
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 The effective permeability across the BBB, which depends on 
the combination of the passive permeability and the 
contribution of efflux and influx CMT;  
 The metabolic modification by barrier enzymes and the ‘sink 
effect’ of the continual drainage of cerebrospinal fluid (CSF); 
 The nonspecific binding to brain tissue [37,38]. On the other 
hand the relevant pharmacological information is the unbound 
drug concentration in the interstitial fluid (ISF) if the drug 
receptor is outside the cells or the intracellular concentrations 
(ICF) if the target is inside the cells.  
As can be deduced from the BBB structure, the permeability of the 
molecules is based on a number of physicochemical factors, which the 
most relevant are lipophilicity and PSA [6,39]. Lipophilicity is the main 
factor for the transcellular passage of drugs through biological 
membranes. Nevertheless, the correlations between lipophilicity and 
BBB permeability are far from perfect, and lipophilicity alone is not 
always predictive of permeability [38]. It is neither easy nor 
straightforward to identify what parameters should be used to define 
‘good brain penetration’.  
Two parameters, the ratio of brain and plasma concentrations at 
steady state denoted as Kp, and its logarithm (log BB), and BBB 
permeability, quantified as the permeability surface area product (PS), 
have been used to describe brain penetration. The first one is indicative 
of extent, while the second represents the rate of access. Kp is the most 
commonly used parameter in literature to evaluate brain penetration. 
However, this parameter represents the drug partitioning into the brain 
and not necessarily indicative of the drug unbound concentrations in 
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the ISF or the drug concentrations in the intracellular fluid in the brain 
(ICF). The relevant parameter to be measured is the ratio of the 
unbound concentration in brain over the unbound concentration in 
plasma Kp,uu [8]. In order to obtain Kp,uu values from Kp and fraction 
unbound in plasma, it is necessary another parameter Vu, brain according 
to Equation 1 [7,8]. 
Table 1. Active (ATP-binding cassette family) and facilitated diffusion (solute-carrier family) 
transporters that have been identified at the blood–brain barrier level
†
.  
Family gene name Old name Substrates 
Nutrients 
SLC2A(x) GLUT(x)1 d-glucose 
SLC16 MCT1 l-lactate 
SLC6A20 SIT Na+-imino acid 
SLC6A8 CRT Creatine 
SLC7A5 LAT1 Large neutral amino acids 
SLC15A2 PEPT2 Oligopeptides 
SLC15A3 PHT2 Oligopeptides 
SLC27A5 FATP5 Long-chain fatty acids 
SLC19A1 FOLT Folates 
SLC19A2 THTR1 Thiamines 
SLC23A1 SVCT1 l-ascorbic acid 
SLC23A2 SVCT2 l-ascorbic acid 
SLC7A1 CAT1 Cationic amino acids 
SLC38A2 ATA2 Small neutral amino acids 
SLC6A6 TAUT Taurine 
SLC1A5 ASCT2 l-Ala and others 
SLC16A2 SYSTEM T Thyroid hormones 
Neurotransmitters 
SLC6A13 GAT2/BGT1 GABA 
SLC6A4 5HTT Serotonin 
SLC29 ENT Norepinephrine 
Endogenous substrates and xenobiotics 
SLC14A1 HST1341 Urea 
SLCO1A4 OATP1A4 Cation or anion 
SLCO1A6 OATP1A6 Cation or anion 
SLC22A3 OCT3 Monoamine 
SLC22A7 OAT2 Organic anion 
SLC22A8 OAT3 Organic anion 
SLC30A1 ZRC1 Zinc 
SLCO1A2 OATP1A2 Ostreone-3-sulfate, 
methotrexate, digoxin, statins 
and levofloxacin 
SLCO1C1 OATP1C1 Thyroid hormones 
SLC22A8 OAT3 Polycyclic aromatic 
hydrocarbons, HVA, indoxyl 
sulfate, nonsteroidal anti-
inflammatory drugs, 
ostreone-3-sulphate, cefaclor, 
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ceftizoxime, bumetanide and 
furosemide 
SLCO1B1 OATP2 Digoxin and organic anions 
SLC22A5 OCTN2 Carnitine 
SLC28 CNT2 Nucleosides 
ABCB1 MDR1 Vincristine, cyclosporin A, 
digoxin, loperamide, 
doxorubicin, vinblastine, 
docetaxel, paclitaxel, 
irinotecan and morphine 
ABCC1 MRP1 Leukotriene C4 and others 
ABCC4 MRP4 Topotecan, methotrexate, 
furosemide, cyclic AMP and 
cyclic GMP 
ABCC5 MRP5 
ABCG2 BCRP Mitoxantrone, topotecan, 
irinotecan, methotrexate, 
anthracyclines, flavopiridol, 
quinazolines and imatinib 
Data from [35,36]. ABC: ATP-binding cassette family; HVA: Homovanillic acid; SLC: Solute 
carrier family. 
 
𝐾𝑝,𝑢𝑢 =
𝐶𝑢𝑏𝑟𝑎𝑖𝑛 𝐼𝑆𝐹
𝐶𝑢𝑝𝑙𝑎𝑠𝑚𝑎
=
𝐴𝑏𝑟𝑎𝑖𝑛
𝑉𝑢𝑏𝑟𝑎𝑖𝑛
⁄
𝐶𝑝·𝑓𝑢
=
𝐾𝑝
𝑓𝑢·𝑉𝑢𝑏𝑟𝑎𝑖𝑛
  Eq. 1 
Where Vu, brain represents an apparent volume of distribution or, 
in other words, the relationship between the amount of drug in the brain 
and the unbound drug concentration (its interpretation is analogous to 
Vss in pharmacokinetics not being a real aqueous volume, but the ratio 
between drug amount in the body and steady state drug concentration 
in plasma). If this value is much higher than the combination of ISF and 
ICF volumes (~ 0.8 ml/g brain) it indicates that the drug nonspecifically 
binds to the brain tissue.  
Considering the rate of access, the time to reach brain 
equilibrium, defined as the half-life, allows one to evaluate how quickly 
a compound can enter the brain. In general, however, rate of access is 
assessed through the measurement f PS product [40]. The best index of 
BBB permeability is the BBB PS product, which has units of microliter 
per min per gram and is a measure of unidirectional clearance from 
Chapter 1 
 
  60 
 
blood to brain across the BBB. The BBB PS product drug is determined 
by the total drug concentration in plasma and the unbound fraction in 
plasma that is available for transport into the brain. Nevertheless, the 
PS product per se cannot predict the unbound concentrations in brain 
[41,42]. On the other hand, unidirectional permeability per se is less 
relevant than the efflux ratio (defined as the ratio between permeability 
from basal to apical chamber (Pba) to permeability from apical to 
basolateral chamber (Pab) permeability in an in vitro cell model or as the 
ratio of the brain uptake clearance in the P-gp-deficient mice over the 
rain uptake clearance in P-gp-competent mice [43]), as this ratio reflects 
the potential limitation of brain penetration due to efflux processes. 
Another factor to take into account is that the efflux ratio depends on 
the drug concentration, and in bidirectional studies in cell culture 
experiments Pba to Pab ratio becomes one once the efflux transporter is 
saturated and its contribution is negligible [44]. Delineating the 
components of transport, that is, the passive diffusional permeability 
and the VMAX and KM parameters, is essential as a high passive 
permeability could overcome the P-gp efflux at physiological 
concentrations [45].  
 
METHODS TO MEASURE DRUG TRANSPORT INTO THE 
BRAIN  
There is a wide range of technologies to characterize the 
mechanisms of brain penetration and to evaluate the rate and extent of 
CNS access. As the complexity of the model is increased, the cost is 
higher and the throughput decreases. Therefore, methods should be 
selected with care by having in mind the main objective of the analysis, 
such as screening or lead optimization [7,8,34,46–48]. The recent 
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developments of combinatorial chemistry call for systems that can be 
used for high-throughput screening. Costly and labor-intensive in vivo 
measurements and traditional low-throughput in vivo assays of CNS 
pharmacokinetic properties are not adequate for this purpose. For this 
reason, there has been an increasing interest in in silico and high-
throughput in vitro methods for predicting in vivo properties early in the 
drug discovery process. A single in vitro method cannot describe or 
predict the in vivo properties of a new drug as it is necessary to integrate 
information about rate, extent and distribution in the brain. The 
consequence of this new concept, is that it is necessary to understand 
the meaning of the read-out of each in silico, in vitro or in vivo method, 
and integrate these data with the adequate interpretation of the results 
[6,7,46,47]. 
 
In silico methods 
In silico models of drug brain penetration attempt to predict BBB 
permeability and brain distribution on the basis of physicochemical 
parameters such as hydrogen bonding, lipid solubility and molecular 
weight. Most in silico models have been based on in vivo log BB values 
[15,49,50]. In the past, in silico models were only qualitative and classify 
the compounds as CNS(+) (penetrates into the brain) or CNS(-) (does 
not penetrate into the brain). This classification was based on whether 
a compound showed in vivo CNS efficacy or had a Kp value above 
certain level [51].  
In general, Lipinski’s rule of five as well as Abraham’s equation 
can be used to predict the passive transport of a drug molecule across 
the BBB [52]. Other sets of rules that have been proposed to predict 
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BBB permeation are the rules of Norinder and Haeberlein [53] and 
Clark [49] (box 1). 
As mentioned previously, BB is the brain to blood ratio at some 
defined time: it is a measure of the extent of drug overall brain access 
or its partitioning into the brain but not necessarily indicative of the 
pharmacological active concentrations. The significant pharmacological 
value is Kp free (defined as the steady-state unbound brain to plasma 
ratio) [7,8] and the most recent structure–brain exposure relationships 
are focused on predicting this value (Table 2) [6].  
Regarding in silico models for BBB permeability, the availability 
of logPS data has limited the development and validation of models also 
complicated by the lack of detailed knowledge on the structure activity 
relationship of transporter proteins and enzymes, but this situation has 
changed with the appearance of hybrid (in vitro/in silico) models capable 
of predicting both passive and transport-mediated function and 
software tools for screening drugs of chemical features likely to make 
them P-gp substrates [54–56]. The log PS models may be used in 
conjunction with in vivo log PS data to explore the presence of efflux or 
uptake transporter mechanisms. For example, the PS values of uptake 
transporter substrates phenylalanine and levodopa were 
underpredicted, and the PS values of P-gp substrates, digoxin, CP-
141938 and quinidine were overpredicted [57]. It would be desirable to 
extend the current in silico models to include predictions about other 
transporters at the BBB [10]. 
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Box 1. Rules proposed to predict blood–brain barrier permeation.  
Norinder & Haeberlein†.  
Rule 1: if the sum of Ns and Os atoms is five or less in a molecule, it has a high 
chance of entering the brain  
Rule 2: if log P - (Ns + Os) is greater than 0, then logBB is positive  
Clark‡, rules for good brain access:  
The sum of Ns and Os atoms should be 5 or less  
C log P – (Ns + Os) should be greater than 0  
Polar surface area should be less than 60–90 Å2  
Molecular weight should be less than 450 Da  
log D in the range of 1–3 is recommended  
†Data from [53]. ‡Data from [49]. 
 
Table 2. Summary of in silico models and physicochemical parameters used to predict brain 
penetration.  
Parameter 
predicted  
Predictor variables  Refs.  
Log BB  D Log P = log Poctanol-log Pcyclohexane  [58]  
Log BB  Vm; PSA  [59]  
Log BB  MW; Log Pcyclohexane  [60]  
Log BB  PSA; C log P  [61]  
Log BB  (N + O); Log Poctanol  [53]  
Log BB  Log BB= log (Cbrain/Cblood)  [62]  
Log BB  Molar excess refraction; 
dipolarity/polarizability; hydrogen bond 
acidity, hydrogen bond basicity and 
characteristic volumen of McGowan  
[63]  
Log BB  Hydrogen bonds accepting oxygen; nitrogen 
atoms and the number of hydrogen atoms 
bonded to these  
[64]  
Log BB  Net charge at pH 7.4; lipophilicity; PSA and 
size (reflected by the total number of aromatic 
and aliphatic ring systems (Nb[rings])  
[65]  
Log BB  Number of hydrogen-bond donors, acceptors, 
rotatable bonds, hydrophobes, log P, 
molecular weight, PSA  
Topological índices (randic, 
electrotopological, atomistic, and functional 
group). Based on eigenvalues of modified 
adjacency matrices  
(CIMI) and atomic charges binned into 
fingerprints  
[66]  
Log BB  Quantum chemical descriptors; topological 
índices; chemical descriptors  
[67]  
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Log BB  Molecular polarizability; the maximum positive 
charge; the sum of all positive partial atomic 
charges for all atoms in the molecule; the 
sum of H-bond  
factor values for all acceptor substructures in 
the molecule; the sum of H-bond factor 
values for all donor atoms in a molecule; the 
maximum H-bond acceptor descriptor in a 
molecule  
[68]  
Kp,uu  PSA  
Hydrogen-bonding acceptor groups  
[6]  
Log PS  Molar excess refraction; 
dipolarity/polarizability; hydrogen bond 
acidity, hydrogen bond basicity and 
characteristic volumen of McGowan  
[52]  
Log PS  VSAbase; Log D; TPSA  [57]  
CIMI: Chemically intuitive molecular index; PSA: Polar surface area; TPSA: Topological polar surface 
area; VSA: van der Waals surface area.  
 
In Table 2 a summary of some in silico models to predict brain 
penetration are shown [58–68]. As evident, the predicted variables used 
to be log BB or log PS, while the most used predictor variables were 
lipophilicity, MW and polar surface area. On the other hand, if the most 
relevant pharmacological parameter Kp,uu is considered, the most 
significant molecular descriptors are those related with hydrogen 
bonding as PSA and hydrogen bonding acceptor groups [6].  
In general, development of software for predicting BBB 
permeation is particularly useful for compound prioritization and may 
be applied in different phases of the drug discovery process, from 
compounds to be synthesized to those to be assayed. Nevertheless, the 
effort to develop in silico methods should be based on a holistic concept 
of CNS access including rate (permeability or PS) and extent (Kp free) 
as well as intrabrain distribution (Vu, brain) in order to construct 
meaningful predictions of the pharmacologically active concentrations 
[46]. 
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In vitro methods  
Research on drug transport across the BBB changed 
considerably with the availability of in vitro BBB systems. The 
advantages associated with any in vitro BBB model include lower 
compound requirement, the use of physiological buffers; greater 
throughput relative to in vivo models; ability to assess transport 
mechanisms; identification of early signs of cell toxicity and, generally, 
lower cost [69]. Moreover, these systems allow a detailed investigation 
without interferences from the rest of the body. However, in order to 
appropriately mimic the BBB in vivo there are some basic characteristics 
that an in vitro model must possess, as summarized in Figure 4 [10,70]. 
The in vitro model that is chosen should possess as many of these 
characteristics as possible, while at the same time remaining practical 
and feasible for moderate- to high-throughput screening [10].  
Figure 4. Characteristics of an ideal in vitro blood–brain barrier model. ACE: Angiotensin-
converting enzyme; BBB: Blood–brain barrier; BCEC: Brain capillary endothelial cells; BCRP: 
Breast cancer resistance protein; MAO: Monoamine oxidase; OATP: Organic anion transporter 
protein; P-gp: P-glycoprotein; Peff: Effective permeability TEER: Trans-endothelial electrical 
resistance. Adapted with permission from [10]. 
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Physicochemical methods for BBB  
Immobilized artificial membrane chromatography  
The immobilized artificial membrane (IAM) stationary phase 
consists of a monolayer of phosphatidylcoline covalently bound to an 
inert silica support. The resulting IAM surface is a chemically stable 
chromatographic material that simulates the lipid phase of a biological 
cell membrane and thereby affects the retention of compounds on the 
basis of solute-IAM partitioning [71]. This model has been designed as 
an alternative for estimate drug permeability through cell membranes 
[10,72]. The greater the retention time, the greater the membrane 
permeability for the drug candidate. In one study, the uptake of 26 drugs 
into the brain (basic, neutral and acidic) appeared to correlate weakly to 
the immobilized artificial membrane retention factors, although an 
improvement in regression was observed when the effects of ionization 
and solute size were taken into account [10]. The method has poor 
predictive power when brain uptake is affected by plasma protein-
binding active transport, efflux or metabolism. The main application of 
this method is the screening of multiple compounds in drug-discovery 
projects.  
Parallel artificial permeability assay  
This technology was successfully introduced to the 
pharmaceutical industry to allow useful predictions of passive oral 
absorption. Over the last 5 years researchers have modified the lipid 
composition of the artificial membrane to evaluate passive BBB 
permeability [73,74]. Parallel artificial permeability assay (PAMPA) 
model identified compounds that pass the BBB (CNS+) and those that 
poorly penetrate the BBB (CNS-). PAMPA method only shows a 
Chapter 1 
 
  67 
 
relationship with passive diffusion permeability, that is, it does not offer 
information about active transport processes. PAMPA may, therefore 
be used as an early screen for passive BBB permeation [75–77]. Other 
methods that provide information on relevant active transporters can 
be used as an additional screen to improve the PAMPA results [78,79]. 
Lipophilicity measurements  
Lipophilicity is a parameter that affects BBB permeation and 
brain distribution. Lipophilic molecules have better access to the brain 
than hydrophilic molecules, thanks to higher membrane permeability 
and nonspecific binding to proteins and lipids in brain tissue. Any 
lipophilicity measure as n-Octanol partition coefficient could be used 
for initial screening of passive permeability (as it is reflected in the rules 
of Norinder, Haeberlein and Clark [80,81]). From the current 
experimental data available it could be possible to establish the 
lipophilicity cut off to ensure a passive permeability above 150 nm/s 
[45], without forgetting that a poor passive permeability could be 
compensated by other properties of the compound and that it does not 
imply necessarily poor brain penetration due to the fact that it occurs in 
the gastrointestinal system, there is no limit in the transit time [6,46]. 
Cell-based in vitro methods  
Primary or low passage brain capillary endothelial cell cultures 
 Preparation of the in vitro BBB from primary isolated cells 
involves the isolation of capillaries and culture of endothelial cells alone 
or in combination with astrocytes or astrocyte-conditioned medium. 
Although human cells would be most ideal from a scientific point of 
view, there are ethical and tissue access constraints. The most common 
animal endothelial cells are bovine or porcine due to their availability. 
The isolation procedures that have been used most frequently can be 
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classified into nonenzymatic mechanical, combined mechanical-
enzymatic or enzymatic procedures [28,82]. The principal advantage is 
that these cells represent the closest phenotypic resemblance to the in 
vivo BBB phenotype [69]. Unfortunately, passing primary cultured cells 
will eventually lead to a loss of BBB properties as some features, such 
as BBB transporters and enzymes, can be downregulated when the 
endothelial cells are removed from the brain and grown in culture 
[10,83]. Nevertheless, the advantages of cultured endothelium include 
the potential for using pure cell populations as well as their relative 
viability compared with isolated arterioles ex situ [84].  
Although primary cultures of brain endothelium alone may 
form tight intercellular junctions, co-culture with astrocytes [85–87] 
resulted in the increased formation and complexity of endothelial tight 
junctions and induced the expression of specific BBB markers including 
GGTP, the glucose transporter isotype (GLUT-1), mouse antibody 
against human and rat transferrin receptor (OX-26) and P-gp [84]. 
Astrocytes can also be grown on the bottom of the culture well plate 
(no contact). Figure 5 illustrates both situations.  
Astrocytes isolated from newborn rats together with bovine or porcine 
endothelial cells are used as xenogenic co-culture systems, which are 
very useful in studying drug transport and BBB functionality.  
Other cells that can be included in the co-cultures are pericytes 
and fibroblasts, neurons, microglia and monocytes in order to obtain an 
optimal model. Pericytes are of special relevance because they are 
normally present at the BBB surrounded by the basement membrane 
and are responsible for inducing specific enzymes. So, it has been 
argued that pericytes are necessary to establish a cell culture model [88].  
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The major disadvantages associated with these in vitro systems 
are the time and resources required to isolate, seed and incubate the 
primary cells and the astrocytes. Furthermore, the intra- and inter-batch 
reproducibility of the primary or low passage brain capillary endothelial 
cells (BCECs) regarding phenotypic and permeability properties is 
another important disadvantage [60].  
Accepted criteria for monitoring the quality of monolayers in 
transport studies include TEER and permeability to hydrophilic 
markers such as 14C-sucrose, which reflect the degree of tight junction 
formation. Using these criteria, none of the primary endothelial cell 
culture models yet matched the in vivo conditions (TEER in the range 
>2 k·Ω·cm2 ≤8 k·Ω·cm2 [89] and sucrose permeability of 
approximately 0.3·10-7cm·s-1) [90].  
Immortalized brain endothelial cells  
To overcome the disadvantages of primary culture systems, 
various immortalized brain capillary endothelial cell lines have been 
derived but none of them generate complete tight junctions, resulting 
in ‘leaky’ barriers [70]. Therefore, these cell lines are not recommended 
for BBB permeability screening [91] but are more suited to assessing 
endothelial cell uptake of compounds and have proved to be useful in 
mechanistic and biochemical studies [60,92,93]. For this reason, 
developing immortalized cell lines that preserve a stable BBB phenotype 
is of great interest and still an area of active research. The advantage of 
immortalized cell lines is their ease of culture, their purity and the fact 
that there is no need for a periodic isolation of capillaries from brains. 
This has resulted in the generation of a number of immortalized, 
transformed, transfected and transduced cell lines. Some of the cell lines 
that have been generated by transfection of primary rat endothelial cells 
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include the RBE4 cell line [29], RBEC1 cell line [94] and TR-BBB13 cell 
line [95]. A recent review listed 18 brain-derived endothelial cell lines 
[70]. Some strategies can be used to enhance their barriers properties as 
the inclusion of phosphodiesterase inhibitors, glucocorticoids and 
interferon-a, b, which increase the tightness of these monolayers [96–
99]. In addition, a human brain immortalized endothelial cell line was 
established by transfection of the human telomerase or SV40 T antigen. 
This cell line (hCMEC/D3) represents a stable, well characterized and 
cell differentiated human brain endothelial cell line [100].  
 
Figure 5. Structure of co-cultures of endothelial cells and astrocytes. 
 
Tridimensional hollow-fiber BBB model  
Since monolayer methods ignore the presence of intraluminal 
blood cells, and blood flow lack the presence of shear stress, few 
research groups have reported on the use of flow-based hollow-fiber 
models [101]. In the hollow-fiber apparatus, the endothelial cells are 
seeded intraluminally and are exposed to flow conditions, whereas glia 
cells are cultured on the extraluminal surface of the hollow-fiber tube. 
The hollow-fiber in vitro models represent an innovative development 
in in vitro BBB models with increased BBB properties [102–104].  
Cells of non-cerebral origin 
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Due to the difficulties associated with studying BBB transport 
using brain endothelial cell lines, several methods based on the use of 
noncerebral peripheral epithelial cell lines have been proposed to study 
the permeability of pharmacological compounds. Interestingly, even 
non-brain endothelial cells (EC) such as bovine aortic EC can be 
induced by glia to form complex tight junctions and express a barrier 
phenotype [84]. A well-characterized cell line is the Madin-Darby 
Canine Kidney (MDCK) cell line, which is easy to grow, achieves a 
reproducible TEER value and can be transfected with the MDR1 gene, 
resulting in the polarized expression of P-gp [10]. This transfected cell 
line has been used as a model of BBB barrier to assess the effect of P-
gp on the permeability of various compounds [105,106] and a recent 
collaborative study found that MDR1-transfected MDCK cells were the 
most representative of in vivo BBB permeability compared with other in 
vitro models, including brain capillary endothelial cells/astrocytes, 
human brain endothelial cells/astrocytes and Caco-2 cell lines (human 
colon adenoma derived cell line) [15,107]. MDR1- transfected MDCK 
cells have also shown high absorptive transport for CNS(+) drugs and 
low absorptive transport for CNS(-) drugs [107] and, consequently, may 
be a suitable model for BBB permeation. One important characteristic 
is that this cell line has sufficient restrictive paracellular transport, 
although the MDCK epithelial cells differ from brain endothelial cells 
in factors including growth, metabolism and transport properties, and 
also morphologically. The BCEC is squamous with a large surface area 
and so there is a lower cell density per unit surface area of endothelium 
(<1000 cells mm-2), whereas the kidney cell is cuboidal in shape, 
resulting in a smaller surface area, and a consequent greater cell density 
per unit area of membrane (>10,000 cells mm-2) [108]. Therefore, 
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MDCK cells produce a relatively higher transverse area of intercellular 
junctions (compared with brain endothelial cells) and paracellular 
transport could be overestimated with this cell line. In addition, while 
P-gp is one of the most important efflux transporters at the BBB and 
transfection of MDCK cells with the MDR1 gene compensates for this, 
there are also other efflux proteins, such as breast cancer resistance 
protein [109] and organic anion transporting polypeptide [110], present 
in brain capillary endothelial cells, that may also play a role in overall 
CNS penetration. If using the MDR1- transfected MDCK cell line, it is 
important not to rule out the potential effects of these other efflux 
transporters present in the in vivo BBB [111]. Another kind of 
endothelial cell, LLC-PK1 (Lewis Lung porcine kidney cells), is 
characterized by the expression of endogenous drug transporters. This 
cell line has also been used to examine the possible role of P-gp as a 
determinant of brain penetration in co-cultures with astrocytes [112].  
Other noncerebral epithelial cell lines, such as Caco-2 cells, have 
also been employed to determine the drug permeability in the BBB. 
Caco-2 was developed as a permeation model for gastrointestinal 
absorption and some companies have extended its use to screening 
BBB permeability. Caco-2 incorporates lipid bilayer membranes, P-gp 
efflux and some other transporters. However, they present some 
disadvantages, as with MDCK cells, such as different morphological 
characteristics, lower tight-junction resistance and different lipid 
composition resulting in significant differences with co-cultures of 
endothelial cells and astrocytes [69]. In addition, ECV304 cell line, 
which is a bladder carcinoma cell with epithelial and endothelial 
properties, has been proposed as a model for the BBB [108]. This cell 
line has been co-cultured with C6 glioma cells or in C6-conditioned 
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media; however, although it demonstrated many of the key features of 
the BBB, it was found to have low TEER values (indicative of poor 
paracellular restrictive properties) and a lack of P-gp expression 
[113,114]. The basal TEER of this cell line monolayer could be 
enhanced by human 1321N1 astrocytes and primary rat astrocytes [98]. 
On the other hand, stem cells are potential barrier precursors. Human 
umbilical vein endothelial cells (HUVECs) were transplanted in athymic 
mouse brain and neovascularization of grafted endothelial cells was 
studied. Results indicate that endothelial cells from an ectopic origin 
have the potential to form a BBB after grafting in the CNS [115]. An 
associated problem of the use of in vitro cell cultures is the variability. 
BBB culture systems has been the subject of a concerted action funded 
by the European Commission entitled ‘Drug transport across the BBB: 
new experimental strategies’ involving 21 research groups from nine 
European countries [82]. The focus of this action was on the 
optimization, harmonization and validation of cell cultures and to 
develop and study new strategies for drug transport to the brain. In the 
same line of research, several academic researchers working on BBB 
formed the International Brain Barriers Society in the summer of 2006 
[302]. Their aim is to encourage scientific and clinical research on the 
biological barriers in the CNS. This demonstrates the scientific 
community’s awareness about the need for more efforts to develop 
effective CNS therapies. Another EU-funded project (oriented towards 
the validation of intestinal cell models) ‘Memtrans’ used an approach 
that could be extrapolated to other barriers than the BBB. The objective 
of the Memtrans project was to characterize the cell systems in different 
laboratories using markers of the critical model variables as the 
paracellular permeability, transcellular one and transporters expression 
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levels. The next step would be using these markers as weighting factors 
to translate (or to convert) permeability values of one laboratory to 
another allowing to the combination of data from different sources or 
even different cell models [116,117]. This last point would be of 
particular impact in the QSAR model development where one of the 
main limitations is the size of the databases.  
New in vitro methods  
Equilibrium dialysis with brain homogenates  
A standard equilibrium dialysis assay, described by Maurer et al., 
is used to measure the transport of the test compound through two 
chambers separated by a dialysis membrane. The compound is dialyzed 
between plasma and buffer, then between brain homogenate and buffer. 
From this, the free drug in brain (fu, brain) and free drug in plasma (fu, plasma) 
are calculated. This is an inexpensive method that is easy to perform 
[118,119].  
Binding studies in brain slices  
Becker and Liu [120] and Friden [6] have proposed a new 
method to estimate free fraction in brain (fu ,brain) in which they used 
brain slices instead of brain homogenate. This modification of the 
technique retains the cellular structure of the brain and, in consequence, 
any differences between ISF and ICF can be captured in the obtained 
fu, brain values. Table 3 summarized all the above in vitro methods: 
PAMPA-BBB [73,75–77,121,122], immobilized artificial membrane 
[121,122], lipophilicity measurement-partition methods [80,81], 
equilibrium dialysis [118,119], isolated brain capillaries [97,23–128], 
primary isolated cells [90,97,124–126, 129–138], immortalized 
endothelial cell lines [91,102–104,139,140], tridimensional hollow-fiber 
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BBB model [101–104], non-brain endothelial cell lines [74,106–
107,112–115,141–145] and brain slices [6,120]. 
Table 3. Main in vitro methods for permeability predictions.  
Method  Use advantages  Ref.  
PAMPA-BBB  Prediction of passive permeability High-throughput  [73,75–
77,121,122]  
Immobilized artificial 
membrane  
Prediction of passive permeability Chromatographic 
method  
[121,122]  
Lipophilicity 
measurement–
partition methods  
Correlation with passive permeability  [80,81]  
Equilibrium dialysis  Provides insights on brain distribution, Kp,uu  [118,119]  
Isolated brain 
capillaries  
Morphologic and biochemical studies  [97,123–128]  
Primary isolated cells  
BCEC  
Bovine  Morphologic and transport studies  [129–136]  
Porcine  Transport studies  [137,138]  
Co-culture BCEC-astrocytes  
Transport studies  [90,97,124–126]  
Immortalized endothelial cell lines  
RBE4  Mechanistic and biochemical studies  [91,102–104, 
139,140]  
Tridimensional 
hollow-fiber BBB 
model  
Paracellular transport  [101–104]  
Nonbrain endothelial cell lines  
Caco-2  P-gp efflux assay  [141]  
MDCK  Passive BBB permeability predictions  [74,106,107,142]  
MDCK-MDR1  Passive and efflux transport  [74,107]  
ECV304/C6  Permeability across the BBB (limited)  [113,114,143–
145]  
LLC-PK1  Passive and efflux transport  [112]  
Stem cells  Passive BBB permeability predictions  
Transplant to mice brain  
[115]  
Brain slices  Determination of the free fraction (fu, plasma, fu, 
brain)  
[6,120]  
BBB: Blood–brain barrier; BCEC: Brain capillary endothelial cells; P-gp: P-glycoprotein; 
PAMPA: Parallel artificial permeability assay. 
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Figure 6. The procedure of brain perfusion. ACA: Anterior cerebral artery; MCA: Middle 
cerebral artery; PCA: Posterior cerebral artery. Adapted with permission from [10]. 
 
In situ methods  
In situ perfusion technique  
The in situ perfusion method provides high quality BBB 
permeability data [146]. The procedure is shown in Figure 6 [10]. A 
catheter is placed in the common carotid artery of an anesthetized 
animal while closing the external carotid. In this way the blood flow is 
stopped and the pump is switched in line. The perfusate, which contains 
the reference (radiolabeled substance) and test compounds provide the 
fluid flow to the brain. Following the perfusion (conducted over a short 
time), the animal is decapitated and the compound concentration is 
determined in order to calculate a BBB PS product [5]. The particular 
advantage of the in situ perfusion technique is that there is no systemic 
exposure of the compound, and thus metabolism is avoided, except for 
that which occurs within the brain microcirculation [147]. The other 
major advantage is that there is total control over the perfusate solute 
concentration, and other constituents of the perfusion fluid can be 
varied, allowing ready characterization of saturable transport systems, 
plasma protein binding and the effects of regulatory modifiers, 
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hormones and neurotransmitters that can be presented to the brain at 
defined concentrations [148]. In addition, the effects of pH, ionic 
content and flow rate can be monitored [149]. Moreover, the short time 
periods allow minimization of nonspecific binding. Co-administration 
of transporter inhibitor or application of techniques to transgenic 
animals that lack a transporter allows the study of the extent of 
transporter contribution to the penetration of a particular compound 
[146,150]. The major disadvantages are the number of animals, the 
significant analytical time and the level of experimental difficulty [148]. 
This makes the technique unsuitable for high-throughput screening, 
however it can be used to provide mechanistic data and information on 
factors that may be limiting brain uptake. Another disadvantage of this 
technique is that prolonged perfusion times (>20 min) are impossible 
owing to cerebral hypoxemia [90].  
 
In vivo methods  
As mentioned previously, although the in vitro systems have 
evolved into sophisticated and functional models of the BBB, they may 
result in quantitative and qualitative differences in BBB transport due 
to up or downregulation of transporters and species differences. 
Therefore, in vitro data alone cannot be used to select drug candidates. 
For example, it has been observed that the permeability can differ by 
more than 100-fold among compounds that can penetrate the brain 
[57]. No clear association was observed between the permeability and 
efflux transport in a recent study [9]. Rather, it is necessary to correlate 
observations made using an in vitro BBB model to in vivo studies [27]. In 
vivo brain experiments provide the most reliable reference information 
for testing and validating other models. There are various in vivo 
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methods that have been used to assess drug uptake into the brain, 
including the single carotid injection technique, in situ perfusion 
technique, intravenous injection technique, brain efflux index and 
intracerebral microdialysis [42]. Although not suitable for high-
throughput compound screening, various imaging techniques (i.e., 
quantitative autoradiography [QAR], MRI, positron emission 
tomography [PET] and single photon emission computed tomography) 
may be used to assess the transport properties of the BBB and are also 
more useful in the diagnosis of various CNS diseases. Moreover, in 
recent years, knockout and gene-deficient animals have been obtained 
owing to their value in assessing the role of uptake carriers and efflux 
transporters and identifying their substrates [150–152].  
In vivo brain/plasma ratio, Kp (logBB)  
In this experiment several animals are dosed (time zero) and at 
designated time points the animals are sacrificed. A sample of blood is 
retained and the brain is removed. The compound concentrations in the 
plasma and brain homogenate are measured. The concentrations are 
plotted versus time. Kp (and its logarithm logBB) is calculated as brain 
area under the curve (AUC) over plasma AUC. This parameter depends 
upon the passive diffusion characteristics, the transporters (uptake and 
efflux) at the BBB, metabolism and the relative drug binding affinity 
differences between the plasma proteins and brain tissue [34,43]. An 
advantage is that this experiment provides other pharmacokinetics 
insights, such as Cmax and the AUC. Nevertheless, Kp has limitations. 
First, the experiment requires considerable resources and it does not 
provide data for the free drug concentration in the extracellular fluid of 
the brain. Only free drug interacts with the receptor or enzyme to 
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produce the pharmacological action [83,153]. Recent studies 
demonstrated the need for an integrated approach in which 
permeability, efflux/influx data, plasma protein and tissue binding were 
used for improved CNS penetration [6–8,41,43,46,118,119,154–156]. 
Brain uptake index  
This is one of the oldest techniques (1970) to estimate the 
uptake of drugs into the brain. A quantity of radiolabeled drug is 
injected into the common carotid artery of the animal along with 
tritiated water. The purpose of including the internal standard is to 
define the amount of injected material that actually distributes to the 
brain [149]. The bolus passes through the brain within 2 s after the 
single injection; the animal is decapitated 5–15 s after injection. 
Following decapitation, the brain concentrations of test and reference 
compounds are measured and related to the plasma concentrations to 
calculate the brain uptake index (BUI) [147]. The assumptions of the 
BUI are that the reference compound is freely diffusible across the 
BBB, the drug does not back-diffuse from brain to blood and no 
metabolism occurs before decapitation [149]. The advantages of the 
BUI technique include the fact that it is fast, technically easy and 
relatively cheap and many compounds can be evaluated in a short period 
of time, which is ideal in the high-throughput setting. This procedure is 
very suitable for compounds that are labile or fast metabolized. The 
major disadvantage is that BUI offers an indirect calculation of the PS 
product [147] and, from an experimental point, of view brain extraction 
must be carried out over a very short limited time, making it difficult to 
estimate PS products less than 10 ml min-1g-1 [147]. As the external 
arteries are not ligated, the compound may also diffuse throughout the 
whole body with only 10% of the compound reaching the brain [149]. 
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Results are dependent on blood flow, brain region and time between 
injection and decapitation time, making this procedure unsuitable for 
poorly penetrating compounds [82].  
Intravenous injection technique  
In a review on BBB transport techniques, the intravenous 
injection technique was referred to as the ‘gold standard’ for assessing 
BBB permeability [148]. With this technique, a femoral vein of rats or 
mice is cannulated and the test compound is injected or, alternatively, a 
tail-vein injection may be used. At various time points during the 
experiment, arterial blood is collected either by cannulation of a femoral 
artery in rats, or by humanely killing the mice. In addition to the 
compound of interest, a plasma volume marker must also be 
administered, to correct for the amount of compound present in the 
brain microvasculature. Brain levels can be determined at the 
predetermined time points (if animals are killed over time) or at the end 
of the experiment (if arterial samples are being taken) [147,157]. One of 
the main advantages of this technique is that plasma and brain 
pharmacokinetics can be obtained, allowing for direct pharmacokinetic 
parameters to be calculated. In addition, there is increased sensitivity 
(due to greater exposure to cerebral microvessels) and it is quite easy to 
measure BBB PS products less than 0.5 ml·min-1·g-1 [147]. Other 
advantages of this technique include the BBB remaining intact and 
cerebral metabolic pathways not being compromised [14]. In addition, 
the degree of experimental difficulty is lower than that of the brain 
uptake index or in situ perfusion technique [90]. However, the major 
disadvantage with the intravenous technique is that there may be 
extensive metabolism by, and distribution into, peripheral organs, 
resulting in an inaccurate calculation of the BBB PS product, given the 
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concentration within the brain microvasculature is  unknown [157]. In 
addition, at later time points, there is the possibility of back-diffusion 
from brain to plasma, which may confound BBB PS product 
calculations [90]. Nevertheless, this technique provides a realistic 
evaluation of the brain levels that might be expected in humans, given 
that it most closely resembles the human situation. The intravenous 
technique described above is similar to the mouse brain uptake assay 
used by Raub, where a single intravenous dose of solute is administered, 
followed by blood and brain sampling at 5 min post-dose [158]. The 
five-min brain and plasma concentrations are used to calculate a 
permeability coefficient, with the presumption that metabolism, back-
flux and tissue accumulation are negligible at that time point [15]. It is a 
useful screen for BBB penetration, and may be utilized in a high-
throughput setting, to distinguish between poor and promising CNS 
candidates [10].  
Brain efflux index 
The brain efflux index technique was developed to estimate the 
efflux of drugs from brain, following microinjection of the compound 
of interest and a reference compound (14C-carboxyinulin) that has a 
limited BBB permeability. Following decapitation at variable times, the 
brain and plasma concentration of compound and reference can be 
calculated. The brain efflux index is expressed as the ratio of drug 
effluxed from the brain and the drug injected into the brain. Although 
this technique does provide useful information on the involvement of 
various efflux transporters in the brain, it is not commonly used for 
permeability screening purposes [148,159,160]. 
Intracerebral microdialysis  
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This is an invasive method that measures local concentrations 
of compounds in the extracellular fluid of the brain or the CSF. 
Intracerebral microdialysis involves direct sampling of brain interstitial 
fluid by implanting a dialysis fiber into the brain [161–165]. The 
concentration of compound that has permeated the brain following 
oral, intravenous or subcutaneous administration can be monitored 
over time within the same animal. The microdialysis probe consists of 
a semipermeable membrane, which is perfused with a physiological 
solution, whereby compounds that are small enough to traverse the 
semipermeable membrane diffuse from higher to lower concentration 
[166]. Therefore, any drug that enters the brain interstitial fluid will 
permeate the physiological solution and may be subsequently assayed 
by an appropriate technique. The major advantage of this technique is 
that it provides pharmacokinetic profiles of compounds in the brain 
without the need to kill many animals at different time points [105]. In 
addition, since both plasma and brain levels of compound can be 
determined over time, it is possible to determine the kinetics of influx 
and efflux from the brain [105]. Moreover, it can distinguish between 
parent compound and metabolite. More interestingly, the probe can be 
placed in any region of the brain, which may be useful when targeting a 
compound to a specific area of the brain (such as in brain tumors or the 
substantia nigra in Parkinson’s disease). However, if one is not 
interested in localized concentrations, this raises the issue of where to 
place the probe and whether multiple probes should be used in order 
to get an appropriate representation of drug levels throughout the brain 
[149]. Another limitation of this technique is that it greatly depends on, 
and is limited by, the sensitivity of the assay method [166], since only 
low concentrations may be present in the dialysate. Therefore the spatial 
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resolution of this technique depends on the analytical technique. HPLC 
combined with MS methods result in high selectivity and sensitivity. 
The other major disadvantage associated with intracerebral 
microdialysis is that insertion of the probe can result in chronic BBB 
disruption, as has been demonstrated by the passage of the normally 
impermeable inulin from blood to dialysate and extensive extravasation 
of serum albumin [10].  
Imaging techniques 
More recently, there has been some focus on the use of various 
imaging techniques to assess the permeability of compounds across the 
BBB, including QAR, MRI, PET and single photon emission computed 
tomography. Although these techniques are not used in high-
throughput drug discovery, they are less invasive techniques that may 
be useful for assessing BBB permeability in pathological conditions. 
The major disadvantages associated with these techniques are their 
inherent costs, labor intensity and inability to differentiate between 
parent compound and metabolites (in the case of labeled compounds).  
Quantitative autoradiography is used to visualize the 
distribution of radioactive tracers across the BBB. It involves 
intravenous administration of a radiolabeled compound into an animal, 
followed by blood sampling and brain removal after various times. The 
brain is frozen immediately and is subsequently sectioned into slices, 
placed in X-ray cassettes with a sheet of x-ray film and, following 
sufficient exposure, autoradiographs are developed and analyzed for the 
distribution-quantification of radioactivity by a computer-driven 
densitometer [167,168]. QAR has been a valuable tool in visualizing the 
brain uptake and distribution of various compounds [169–171], in 
addition to demonstrating the role of P-gp on the uptake of other 
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compounds [172]. The limitations of this technique compared with 
other imaging-based techniques is that this one is an invasive technique 
and brain concentration/distribution of a substance can only be 
measured at a single exposure time in a single animal whereas multiple 
data points can be derived from a single drug exposure using MRI or 
PET techniques described below.  
MRI involves administration of the contrasting agent 
(gadolinium-based compounds) whose appearance in the brain is 
related to the degree of BBB damage. It allows evaluation of parameters 
in the brain related to anatomy, physiology and metabolism such as 
macrophage infiltration, cytotoxic edema, cerebral blood flow, BBB 
permeability and leakage involved in brain diseases [173–175].  
Positron emission tomography has been shown to be a 
noninvasive, quantitative approach to measure the BBB PS product and 
drug transport in humans under normal and disease-state conditions 
[90]. This technique involves the intravenous administration of a 
positron-emitting radionuclide or a compound labeled with an isotope 
that emits positrons. Subsequently, one analyzes the data by 
pharmacokinetic models that describe the transport of tracers (uptake, 
distribution and elimination) [149,176–179]. The advantage of this 
technique is that the transport of tracers can be visualized and studied 
in whole brain over time. It is useful for diagnosis purposes such as the 
localization of tumors in the brain and also for studying BBB 
permeability and BBB transport [179–181]. This technique may provide 
a benefit in screening the brain uptake of P-gp substrates using 
inhibition experiments [90]. PET is a good method for measuring the 
rate of drug uptake into the brain and possible drug interactions at the 
BBB. Regarding the extent of uptake, PET provides information on 
Chapter 1 
 
  85 
 
total brain to blood ratios but not unbound drug ratio [7]. The RatCAP 
is a novel miniature PET scanner designed to acquire fully 3D images 
of the rat’s brain while directly attached to its head. This allows the 
animal to be completely mobile, eliminating the confounding effects of 
anesthesia on image quantitation [301]. Single photon emission 
computed tomography has also been useful as a noninvasive measure 
of BBB permeability. Following administration of a g-emitting 
compound, g scintigraphic images can be acquired using a g camera and 
distribution of the compound throughout the body can be examined. 
With this method it has been shown that technetium-labeled 
compounds may be used to assess P-gp transport activity in vivo. 
Although this technique may be useful in characterizing efflux 
transporters and BBB permeability in disease states, it will have a limited 
role in screening of compounds for potential brain uptake [10].  
Regarding the use and selection of the different methods 
described above, it is advisable to start with higher throughput methods, 
such as in silico, physicochemical properties, even though this approach 
requires the development and validation of the in silico models, which is 
a feedback mechanism from good experimental data. These techniques 
would provide initial insights on whether project compounds are 
expected to have any problems with penetrating to the therapeutic 
target. As a second step, and in parallel with the in vitro assays of drug 
absorption, distribution, metabolism and excretion optimization, three 
in vitro assays to characterize CNS properties are recommended: 
bidirectional cell permeability experiments to estimate permeability and 
efflux ratio (in a P-gp expressing system), equilibrium dialysis of blood 
plasma to calculate fu, plasma and dialysis with brain homogenate or 
brain slices to obtain fu brain [6,7,46]. After this step, screening-selected 
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compounds can be transferred to the in vivo experiments. The in vivo 
experiments will provide more in-depth assessment of penetration into 
the brain as well as feedback (validation) of the in vitro methodologies. 
If the in vivo and in vitro brain penetration data differ significantly, the 
contribution of other mechanisms, such as P-gp efflux, hepatic 
clearance, plasma protein binding and nonspecific brain tissue finding 
can be assessed using other in vitro assays. The limiting mechanisms can 
be discerned and structure modifications can be undertaken to improve 
the brain penetration properties of the compounds series [51]. 
 
STRATEGIES FOR ENHANCED DRUG DELIVERY INTO 
THE BRAIN  
A brief description of the strategies to enhance drug delivery 
into the brain is included in this section. Our aim was not to give an 
exhaustive description and the reader is advised to refer to specific 
reviews on this topic, including those by Gabathuler [182] and Alam et 
al. [183]. 
 
Local brain delivery 
Direct injection of macromolecular drugs  
Intracerebral ventricular or intrathecal drug infusion comprises 
direct injection/infusion of drug into CSF. However, in order to again 
access the brain, drugs administered in this way still have to cross 
ependymal BCSFB. Only small molecules can penetrate brain 
parenchyma. Large compounds very poorly penetrated the brain even 
when administered intraventricularly [184].  
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Direct administration into the brain parenchyma has also been 
applied [185,186]. Amgen carried out an experiment for the treatment 
of Parkinson’s disease that involved the direct infusion of glial cell-
derived neurotrophic factor into the putamen. First, they observed a 
general improvement, but in the second phase the assay was stopped 
because the results indicated that this treatment could potentially cause 
permanent damage in patients [187–189].  
Another strategy, known as ‘convection enhanced drug 
delivery,’ performs a positive pressure infusion in brain parenchyma to 
increase drug uptake. There are no positive results as yet [190,191].  
Furthermore, polymeric brain implants have been successfully 
used for the local delivery of drugs to the brain, but it has not been 
possible to obtain a global delivery into the brain [192].  
Direct injection/infusion of viral vectors  
Viruses are applicable as a biological vector system to deliver 
genetic material to brain cells. The most commonly used are adeno-
associated virus vectors and lentivirus. Important issues in viral gene 
delivery are stable transgene expression, limited immunogenicity, 
induction of an inflammatory response, cell-specific targeting efficiency, 
safety, toxicity and the need for packaging cell lines. Some viral vectors 
must be injected into the brain and they must have affinity for specific 
brain cells where genetic material is targeted. Gene transcription and the 
desired protein synthesis takes place inside the cells. Many applications 
have been demonstrated for brain gene therapy, especially using 
lentivirus as a vector [193–204]. However, some studies indicated that 
application of such elements could induce tumorgenecity. So, further 
investigation in this promising direction is needed. For instance, 
neurotropic viruses cross the BBB and are also able to infect brain cells. 
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This means that the strategy used by the viruses to cross the BBB could 
also be used to deliver molecules to the brain. Kumar et al. have shown 
that peptides derived from rabies virus enable the transvascular delivery 
of siRNA to the brain [205]. 
 
Global brain delivery 
Enhancing of passive drug delivery  
The objective of this approach is to get an enhanced passive 
transport across the BBB in order to allow large molecules to reach their 
targets. Enhanced drug delivery to the brain has been achieved in 
various ways. 
 Osmotic disruption/shrinking of the BBB by intracarotid 
administration of a hypertonic mannitol solution. After 
injection the BBB is temporarily opened and drug can access 
the brain. However, unwanted blood components can access 
neurons too and cause damage [206].  
 Intracarotid administration of alkylglycerol that enhances drug 
transport by the paracellular route [207]. 
 Application of bradykinin-analog that opens tight junctions via 
a receptor-mediated mechanism [208]. 
 Application of ‘protein-transduction domains’. These are amino 
acid sequences that are capable of enhancing delivery of large 
molecules into cells mainly by increased adsorptive-mediated 
endocytosis [209]. 
These approaches are able to enhance uptake into various tissues 
but the problem is that they do not provide the selectivity needed to 
target drugs to the brain.  
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Design of prodrugs  
Prodrugs are defined as therapeutically inactive agents that can 
be predictably transformed into active metabolites. In another words, 
prodrugs are inactive precursors of parent drugs [1]. The most common 
strategy for designing effective prodrugs relies on the increase of parent 
drug lipophilicity. Moreover, it is necessary to take into account the 
availability of the BBB for the enzymatic/chemical/spontaneous 
process to release the active drug in order to obtain a selective and 
effective prodrugs bioconversion in the brain.  
Prodrug bioconversion strategies 
 Esterase activation: this strategy consists of the lipidization of 
the active drug by forming an ester derivative [210,211]. The 
esterification reaction must be reversible and, once in the brain, 
the molecule is enzymatically converted back to the parent 
compound. This approach has been successfully used to deliver 
morphine into brain using heroin prodrugs [1]. They cross BBB 
easier and later and are converted to morphine in the brain, 
which interacts with opioid receptors [211]. Other examples are 
(R)-a-methylhistamine [212], ketoprofen [213], nipecotic acid 
[214], niflumic acid [215] and some peptides [216]. Although 
ester formation is the most commonly employed approach for 
increasing lipophilicity of polar molecules exhibiting limited 
CNS penetration, there are some limitations. Ester prodrugs 
should be stable to plasma enzymes, but sensitive to those 
present in brain tissues. This result is difficult to achieve. An 
interesting approach might be the involvement of specific 
esterases, thus drugs could be converted into ester prodrugs 
stable to plasma esterase but suitable for degradation induced 
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by specific esterases introduced in the brain by gene therapy 
strategies [217]. 
 Adenosine deaminase activation: several studies have confirmed 
that adenosine deaminase activated prodrugs significantly 
enhance CNS delivery since the activity of adenosine deaminase 
is higher in brain than in plasma [218]. 
 Oxidase activation: another approach may involve BBB 
enzymes in the delivery of drugs to CNS. In addition to esterase 
and adenosine deaminase, a variety of oxidative enzymes, 
including xanthine oxidase, monoamine oxidase and 
cytochrome-P450 enzymes, are of particular interest for their 
role in the enzymatic activity of BBB. These enzymes could be 
utilized as a biotransformation system in the conversion of 
drugs unable to cross the BBB. 
Redox chemical delivery system 
In addition to enzyme activation, other techniques to obtain 
higher drug delivery to the brain have been developed. One of most 
interesting is the chemical delivery system approach. The method is 
similar to that of prodrug formation but with the attachment of three 
different functional groups, a lipophilic group (L), a spacer (S) and a 
targetor (T). The enhanced lipophilic molecule crosses the BBB and 
then the targetor undergoes enzymatic oxidation and turns the molecule 
into a membrane impermeable moiety. The membrane impermeable 
conjugates ‘locked’ into the brain undergo sequential metabolism and 
yield the drug in the brain. The spacer function is to control the 
enzymatic rate of drug release inside the brain [1,183]. This approach 
has been used to achieve successful brain delivery of dopamine, 
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diclofenac, ibuprofen, ketoprofen, tiaprofenic acid, tolmetin, 
enkephalin TRH and kyotorphin analogues [219]. Until now, there have 
not been good results in the delivery of peptides because they can be 
rapidly inactivated by ubiquitous peptidases.  
Prodrugs & carrier mediated transport 
As discussed previously, CMT systems carry nutrients, vitamins 
or hormones into the CNS. This type of transport was firstly 
investigated in vivo with physiologic techniques [27,220]. The progress 
of molecular cloning of transporter genes and their expression in 
cultured cells, has increased our knowledge of how the transporters can 
be employed for the brain targeting of drugs [221]. The transporters of 
neutral amino acids (LAT 1), hexose (GLUT 1), monocarboxylic acids 
(MCT 1), cationic amino acids (CAT 1) and nucleosides (CNT2) are 
widely expressed at the BBB level, whereas the ascorbic acid transporter 
(SVCT2) is mainly expressed in the choroid plexus.  
In general, CMT systems are highly stereospecific for their 
substrates and one consequence of this is that neuroactive drugs are not 
transported by CMT. However, prodrugs approaches could resolve this 
problem by two different strategies: the modification of drug structure, 
enabling transport by a CMT system; or conjugating the drug with a 
nutrient able to be CMT transported. In both cases, the drugs are 
released after enzymatic cleavage from their prodrugs following 
targeting into the CNS. Both strategies may be useful or not, depending 
on the drug structure and on the transporter chosen. These approaches 
have been developed for the carriers LAT 1, GLUT 1 and SVCT 2 [1].  
The LAT 1 carrier system has been used to transport dopamine 
and 7-chlorokynurenic acid to the brain using a modified structure of 
their molecule [5]. Prodrugs transported by LAT 1 were also obtained 
Chapter 1 
 
  92 
 
by means of the conjugation of neuroactive drugs with neutral amino 
acids [222]. A prodrug of nipecotic acid was obtained by conjugation 
with tyrosine [223].  
GLUT 1 transports mainly d-glucose. Conjugation of drugs 
with d-glucose has been proposed as a strategy to improve their uptake 
into the brain. This strategy has been successfully used with opioid 
agonist peptides [224], 7-chlorokynurenic acid [225,226] and dopamine 
[227]. 
Prodrugs & receptor mediated transcytosis: 
Trojan horses  
The RMT system is used to transport endogenous large-
molecules peptides across the BBB and can be used to ferry large 
therapeutic molecules such as protein, nucleotides or nonviral plasmid 
DNA to the human brain [228]. A molecular Trojan horse is an 
endogenous peptide, or peptidomimetic monoclonal antibody, which 
enters the brain from blood via receptor-mediated transport on 
endogenous BBB transporters. (Further information is available 
elsewhere in the most recent and extensive reviews [229–232]).  
 
Strategies to inhibit efflux 
The development of molecules that inhibit the AET system can 
be a strategy of increasing brain bioaccesibility of the active drugs [5].  
Recently, codrugs l-Dopa and sulfur-containing antioxidants 
have been developed as new pharmacological tools against Parkinson’s 
disease [233] and ibuprofen and lipoic acid diamines are being used as 
potential codrugs with neuroprotective activity [234]. Rigor et al. [235] 
have demonstrated that activation of PKC isoform bI at the BBB 
rapidly decreases P-gp activity and enhances drug delivery to the brain. 
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Nasal delivery  
Intranasal administration is a strategy that has obtained 
increasing consideration in enabling brain uptake of drugs because the 
olfactory region is located at the top of the nasal cavity and it is the only 
place in the body where the CNS is in contact with the external 
environment [236,237]. In this way, drugs can be transported across the 
nasal membrane of the respiratory region via a transcellular (lipophilic 
molecules) or paracellular mechanism (hydrophilic drugs) into the CNS 
[238,239]. Intranasal delivery does not necessarily require any 
modification to therapeutic agents and is a noninvasive method of 
bypassing the BBB to deliver drugs to the CNS, as for instance 
morphine, butorphanol, capsaicin, lidocaine, dihydroergotamine, 
olanzapine, ondansetron, metaclopramide and others [240]. This 
strategy has been used in the administration of dopamine solutions. It 
has obtained promising results by combining prodrug approach and 
nasal administration with dopamine, estradiol or nipecotic acid. In a 
mouse model of Alzheimer’s disease, intranasally administered nerve 
growth factor both reduces neurodegeneration and improves 
performance in memory tasks [236,241,242]. Intranasal insulin 
improves memory, attention and functioning in patients with 
Alzheimer’s disease or mild cognitive impairment and even improves 
memory and mood in normal adult humans. This new method of 
delivery could revolutionize the treatment of Alzheimer’s disease [243–
246], stroke [247] and other brain disorders [248–250]. 
 
Nanoparticles 
Nanoparticle drug carriers consist of solid biodegradable 
particles ranging in size from 10 to 1000 nm (50–300 nm generally) 
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[251,252]. An interesting application of nanoparticles is the drug brain 
delivery of the new large molecule therapeutics now available to treat 
CNS disorders: peptides, proteins, genes and antisense drugs [253–260]. 
Nanoparticles cannot freely diffuse through the BBB and require 
receptor mediated transport through brain capillary endothelium to 
deliver their content into the brain parenchyma. They may be 
advantageously formulated in brain-targeted protective nanocontainers 
due to their poor stability in biological fluids. Nanoparticles have good 
safety profiles and provide sustained drug release. It is possible to 
prepare target-specific nanoparticles by conjugation with cell surface 
ligands. Using peptidomimetic antibodies, BBB transcytosis receptor 
brain-targeted immunoparticles can be synthesized that should make 
the delivery of entrapped actives into the brain parenchyma without 
inducing BBB permeability alteration possible. Nanoparticles made of 
polybutylcyanoacrylate have been intensively investigated, showing that 
when coated with polybutylcyanoacrylate they can deliver drugs to the 
brain by a still debated mechanism. Nanoparticles of polylactide 
homopolymers or poly(lactide-coglycolide) heteropolymers may be a 
promising alternative. However, the nanoparticle approach has 
limitations for its clinical application: potential toxicity, BBB 
permeabilization and short or lasting delivery. But this methodology, 
nevertheless, opens great opportunities for drug delivery into the brain 
[261–265]. 
 
FUTURE PERSPECTIVE 
Even today, the majority of new drugs discovered do not cross 
the BBB [266]. In the last decade, a growing number of spin-off 
biotechnological companies from academia have started to develop new 
Chapter 1 
 
  95 
 
methods and strategies to help pharmaceutical companies target the 
brain. The CNS discovery and development paradigm in those 
companies is slowly changing to acknowledge the need for earlier BBB 
access in order to avoid clinical failures. The development programs 
should include the use of in silico, in vitro and in situ models from the 
beginning to reduce the attrition rate later on. Nevertheless, there is still 
room for research and many unanswered questions.  
In upcoming years it will be desirable to improve the quality of 
in silico models to screen better new families of compounds, taking into 
account passive diffusion in combination with influx and efflux 
mechanisms.  
More research is required to improve in vitro cell methods to 
obtain barriers keeping the BBB phenotype, while also being easy to 
handle and offering similar dynamic properties of the human BBB 
vessels.  
Research in the area of transporters at BBB level, tight junction 
formation and changes under pathological conditions will help to design 
strategies for targeting the brain. There is a need for BBB genomic 
research to identify specific targets on the brain vasculature. Carrier-
mediated transport or receptor-mediated transport that are successful 
strategies that offer a wide scenario for the development of new brain 
targeted molecules.  
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INTRODUCTION 
The development of neuropharmaceutic drugs is the most 
promising sector in the pharmaceutical industry around the world. 
Diseases affecting the Central Nervous System (CNS) such as stroke, 
Alzheimer Parkinson or HIV have global population prevalence around 
25% and are among the leading causes of mortality and morbidity. One 
of the reasons of the high prevalence is the aging population. Treatment 
associated with CNS diseases has increased in recent decades and, 
consequently, the cost has also increased [1]. In fact, the cost associated 
with the treatment of these diseases is one of the highest in the 
healthcare systems worldwide. However, the high cost is not 
proportional to therapeutic efficiency because in most of cases 
treatments are directed to alleviate the symptoms of diseases, rather 
than to act on the etiology of the disease [2]. There are virtually no 
effective pharmacological treatments for most of neurological 
conditions, with the notable exceptions of mood disorders, epilepsy, 
and chronic pain. The only effective treatment for stroke is 
thrombolysis, which is a vascular treatment, not a neurological one. 
Effective treatments for Alzhiemer’s disease, Parkinson’s disease, 
stroke, traumatic brain injury, multiple sclerosis, amyotrophic lateral 
sclerosis (ALS) and brain tumors do not exist yet. The problem with 
current therapeutic approaches is not only delivery but also inadequate 
efficacy, so, the development of specific drug directed at a CNS target 
is necessary. Therefore, there is a clear imbalance between the health 
needs of the population and efficient therapeutic tools. Adequate 
treatments could allow a reduction in morbidity and mortality of these 
diseases and, probably, a decrease of the associated costs.  
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THE BLOOD-BRAIN BARRIER: ANATOMY AND 
FUNCTIONS 
The Blood Brain Barrier is a physical and a biochemical frontier 
between the blood and the brain comprising a dense cells layer 
surrounding the brain blood vessels.  
In 1885, Paul Ehrlich injected aniline dyes (IV) into rats and 
noted that all organs except the brain were blue-dyed. Subsequently, 
Edwin Goldman using trypan blue demonstrated the existence of a 
“physiological membrane” that protects the brain [3]. The function of 
this anatomic barrier is to maintain the homeostasis into the brain by 
restricting the passage of a great number of molecules [4]. Neurons 
communicate via chemical messages, consequently, the composition of 
the extracellular fluid must be kept constant to ensure that the 
interneuronal signals are sent and received successfully. Thus, the 
barrier allows the passage of nutrients and substances necessary for 
proper neuronal functioning and prevents access to potentially harmful 
substances to the brain. In addition to regulate the transport of 
substances, the blood brain barrier also acts as a metabolic and immune 
barrier. 
Anatomically, the barrier is constituted by three so-called by 
Abbott et al ‘interfaces’ [4]. The first and largest interface is the Blood 
Brain Barrier (BBB) structure constituted by the surface area of the 
brain microvessels. Microvessels wall contain endothelial cells, 
astrocytes, pericytes and an extracellular matrix. Endothelial cells of 
blood vessels in CNS are special, without fenestrations and pinocytic 
vesicles and sealed with tight junctions [5]. Some proteins are associated 
with the formation and maintenance of the tight junctions: 
transmembrane proteins (occludins, claudins and intercellular adhesion 
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molecules) and cytoplasmic proteins as zonula occludens ZO-1, ZO-2 
and ZO-3. It has been speculated that the tightness of the blood brain 
barrier depends not only on the characteristics of endothelial cells but 
the presence of other molecules that create the necessary environment 
for the manifestation of the peculiar characteristics of the barrier. 
Endothelial cells of capillaries supplying the brain are covered by a basal 
membrane (collagen type IV, laminin, fibronectin and heparan sulfate 
proteoglycan, together with collagen type IV, provides a structural 
support layer), extracellular matrix, pericytes, neuronal axons and an 
almost continuous layer of astrocytes. In this sense, it is believed that 
astrocytes and pericytes play a fundamental role in maintaining the 
structure and there are many research groups studying their influence 
on the development of in vitro models of blood-brain barrier. In fact, 
incorporation of pericytes and astrocytes to endothelial cell cultures 
provide higher transendothelial electrical resistance than other models 
[6]. However, the complete functions that have astrocytes and pericytes 
cells in the blood brain barrier are one of the outstanding issues to be 
determined in future. The role of the extracellular matrix is also not 
clear but there is evidence that contributes to vessels integrity and 
function. Figure 1 shows a schematic picture of Blood Brain Barrier 
structure. 
The epithelial cells of the choroid plexus constitute the second 
interface, the blood-cerebrospinal fluid barrier (BCSFB). This barrier 
regulates diffusion, facilitated diffusion and active transport into CSF, 
as well as active transport of metabolites from cerebrospinal fluid (CSF) 
to blood [4].  
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The third interface is constituted by the avascular arachnoid 
epithelium which envelops completely the Central Nervous System 
(CNS). The cells of this membrane also are linked by tight junctions. 
All these components determine the low barrier permeability. However, 
barrier function is not only determined by the interendothelial tight 
junctions, other factors are involved. The presence of enzymes such as 
alkaline phosphatase, glutamyl transpeptidases, esterases and 
monoamine oxidase, which are either absent or expressed at low levels 
in peripheral vessels, provide an enzymatic protection. The 
overexpression of active transporters for uptake and efflux of 
substances limit the access of a great number of xenobiotics. Efflux 
transporters, which have promiscuous selectivity return into blood 
many substances which attempt to cross the barrier. There are also a 
number of transporters selective for brain nutrients that are potential 
targets for structural analogue drugs. Moreover, the negative charge of 
the endothelial cells surface repels the negative charged compounds 
preventing their passage to the other side of the barrier.  
This means that many drugs that could be useful for the 
treatment of disorders of the central nervous system are ineffective 
when administered by conventional way due to a not reach their 
therapeutic target. The BBB is the major obstacle, though not the only 
one in limiting the options for treatment of neurological and psychiatric 
diseases. Inadequate drug levels due to several reasons such as 
metabolic drug interactions play an important role in the clinical efficacy 
and safety of drugs [7]. 
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Figure1. Scheme of Structure of Blood Brain Barrier. Adapted from Nicolazzo et al, [5] and 
reproduced with permission from Mangas-Sanjuan et al. Future Science, 2010 [8].  
 
TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER 
The most important function of the blood brain barrier is to 
maintain the optimal environment for neural function. It means 
regulating the access of both xenobiotics and normal factors (found 
within the peripheral circulation) that can alter neuronal function (ions, 
cytokines, hormones, lipids, amino acids, etc.). The diffusion across the 
barrier is determined by physicochemical parameters such as 
lipophilicity, polar surface, molecular weight, charge and others. For 
example, lipophilic molecules of small size (e.g. ethanol and caffeine) 
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can pass across the barrier following a transendothelial pathway but this 
option is not suitable for hydrophilic molecules. Moreover, the lack of 
fenestrations between endothelial cells of the blood-brain barrier 
restricts access of hydrophilic molecules via the paracellular pathway. 
However, the barrier is permeable to substances such as glucose (the 
main energetic substrate), oxygen, pyruvate, lactate, ketone bodies, 
aminoacid precursors of neurotransmitters and vitamins that cannot be 
synthesized in the central nervous system thanks to specific 
transporters. The BBB expressed an important number of transport 
proteins. The increased research in the role and function of the 
transporter systems can be used to facilitate the access to chemical 
molecules into the brain and to improve the clinical efficacy and safety 
of the neurological treatments. Transporter systems are illustrated in 
figure 2 and summarized in table 1. These are different types of 
mechanisms: 
 
(a) Carrier-mediated transporters 
Specific uptake transporters facilitate the access of endogenous 
or exogenous molecules to central nervous system. The most studied 
and one of the most effectively targeted transporters is LAT1 that 
allows not only the access of amino acids to the brain but also of drugs 
such as L-DOPA and metyl-DOPA. This transporter has clinical 
relevance in the treatment of Parkinson disease [9]. GLUT1 is one of 
the most expressed transporters in BBB and has special importance 
because facilitates the uptake of glucose which is the main energy source 
for the brain [10]. Interactions of GLUT1 with drugs used for the 
treatment of neurological diseases have been described, but the clinical 
relevance of these findings is not well-known yet. Moreover, a reduction 
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of GLUT1 expression in Alzheimer disease patients has been described 
that suggest a continuous energy restriction in the AD patients brains 
[11]. An important number of transporters including ENT1 (mediates 
the access of nucleoside drugs) [12], MCT1 (transporter of 
monocarboxylate drugs) or OATP family (mediate brain influx of 
amphiphilic compounds) have been identified and can be useful to 
mediate the access of drugs structural analogues of carrier substrates [7]. 
In order to regulate pH, the BBB has mechanisms that allow the ion 
access to central nervous system. These transporters are expressed in 
the abluminal, luminal or both sides of the membrane. The best 
characterized are the sodium pump, the sodium-potassium-two 
chloride cotransporter, the sodium-hydrogen exchanger and the 
chloride-bicarbonate exchanger.  
 
(b) Receptor mediated transport.  
This system requires the presence of membrane receptors, 
which recognize specific molecules and bind to them. This binding 
allows access of macromolecules by endocytosis. Endothelial cells 
express endogenous peptide receptor to mediate the transport of 
neuroactive peptides and proteins. Using these membrane receptors 
molecules such as insulin, transferrin, insulin-like growth factors, leptin 
and some lipoproteins can cross the BBB [13]. While this mechanism is 
very specific, their use for delivery to the brain of high molecular weight 
drugs with molecular Trojan horses has been investigated [14]. Several 
studies have shown the delivery of non-viral gene or recombinant 
proteins attached to molecular Trojan horses, following IV 
administration [13]. Especially relevant are the pharmacological effects 
obtained with gene therapy. Administration of molecular Trojan horse 
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liposomes that contain non-viral plasmid DNA has allowed 90-100% 
increase in survival time in mice with intra-cranial human brain cancer 
[15, 16] or complete normalization of striatal enzyme activity, which is 
90% decreased in Parkinson Disease [17].  
 
(c) Active efflux transporters.  
The so-called multidrug pumps can be defined as a series of 
relatively nonspecific transporters, which are capable of handling a large 
number of structurally unrelated substrates. The best known and the 
most representative is P-glycoprotein (P-gp) that reduces the access into 
the brain of a wide range of cationic and lipophilic compounds.  BCRP 
is a well-studied efflux transporter too but this transporter does not 
extensively limit brain penetration of its substrates by itself. However, a 
‘P-gp-BCRP synergy effect’ has been observed, which has been the 
subject of several hypotheses and whose mechanism still remains 
unclear. The BBB also expresses other efflux transporters in the MRP 
protein family [18]. Recent studies indicate that human and rodent BBB 
only express MRP4 at quantifiable levels [7]. The role of the efflux 
transporters in the treatment of brain disorders is well-known and 
extensively accepted. An obvious and promising strategy to increase 
access of these drugs into the brain is to minimize the effects of the 
efflux transporters. This objective may be attempted through different 
strategies including inhibiting the efflux transporter with a substrate 
with higher affinity than the drug itself or encapsulating the drug to 
mask the xenobiotic from the efflux [19]. However, excessive efflux 
transporter inhibition can result in adverse effects due to the 
indiscriminate access of xenobiotics to the brain. 
 
  
 
Table 1 Examples of relevant families of transporters for BBB drug delivery. Compiled from data presented in tables in Abbott et al. [4]. 
 
Transport system Substrate BBB direction Reference 
  Influx Efflux  
ATPases 
ABC transporters 
ABCB1 (P-gp) 
ABCC1-3 (MRP proteins)  
Lipid soluble non-polar molecules 
and conjugates 
 
X 
X 
X 
Begley 2004 [60, 61] 
 ABCC4-5 Nucleosides  X  
 ABCG2 (BCRT)    
Begley 2004 [60] 
Dauchy et al, [62] 
Solute carriers 
(SLC) 
LAT1 
GLUT1 
ENT1 
MCT1 
OCTs 
OATs 
Aminoacids 
Glucose 
Nucleosides 
Monocarboxilates 
Organic cations 
Organic anions 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Uchida, et al. [63] 
Simpson [64]; Uchida, et al [63] 
Parkinson [65] 
Kalvass, et al [66]; Roiko et al [67] 
Kalvass, et al [66] 
Gao et al [68]; Iusuf, D [69] 
Receptor mediated 
transport (RMT) 
RMT Insulin 
RMT Leptin 
RMT Transferrin (TfR) 
RMT Apolipoprotein E receptor 2 
(ApoER2) 
RMT LDL-receptor-related protein 1 
(LRP1) 
RMT Tumor necrosis factor (TNFα) 
RMT Epidermal growth factor 
RMT Receptor for advanced 
glycosylation 
Insulin 
Leptin 
Transferrin 
Lipoproteins 
Lipoproteins, Amiloid-β, 
lactoferrin α 
TNFα 
EGF 
Glycosylated proteins 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
 
X 
Banks [70] 
Banks [71] 
Visser et al. [72] 
Herz and Marschang, [73] 
Herz and Marschang, [73] 
Pan and Kastin, [74] 
Pan and Kastin, [75] 
Stern et al [76]; Deane et al. [77] 
 
Adsorptive-
mediated transport 
(AMT) 
AMT Cationised proteins 
AMT Cell penetrating peptides 
Cationised albumin 
SynB5/pAnt (43-58) 
X 
X 
 
Pardridge et al. [78] 
Drin et al. [79] 
 
Chapter 2 
 
 
  132 
 
 
 
 
 
Figure 2: Permeation mechanisms through the endothelial cells. Reproduced with permission 
from Mangas-Sanjuan et al. Future Science, 2010 [8]. 
 
From a pharmacokinetic point of view, brain could be 
considered as a separate compartment. Level of drugs in the brain 
depends a priori on effective permeability through the barrier. The 
permeability depends on the ability of the drug to diffuse passively 
combined with access through transporters. At first, it would be 
thought that the permeability depends especially on lipophilicity but 
experimental evidence indicates that correlations between lipophilicity 
and permeability are not very good [36]. In fact, though lipophilic 
derivatives are more permeable across the BBB their effective uptake to 
CNS may be lower due to reduction of the plasma concentration. The 
increased clearance of lipidized forms reduces the area under the curve 
in plasma concentration-time profile [19]. The identification of the 
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parameters that influence the permeability through the blood brain 
barrier and the determination of the different mechanisms for brain 
access are being studied by several research groups [37]. This 
information can help to the design of molecules that could get their 
therapeutic target by crossing the barrier and to development of 
strategies to facilitate the passage of existing active molecules. 
It has been postulated that the main factors, which influence the 
unbound drug concentration in the brain thus determining the 
pharmacological activity, are the drug plasma concentration, the extent 
of drug binding to plasma proteins, the enzymatic modification in the 
barrier and the drug affinity for the brain tissue [36]. 
 
IMPORTANCE OF THE DRUG DELIVERY INTO THE 
BRAIN 
Currently, the prevalence of neurological and psychiatric 
disorders is very high [1]. The treatment of these diseases is not easy 
due to, as already mentioned, the BBBs role in protecting the central 
nervous system by preventing the access of virus and xenobiotics.  This 
maintains a constant composition of cerebrospinal fluid and 
extracellular fluid, allowing optimal neuronal activity. The barrier is 
specialized in this role and is so effective that it limits access of 
therapeutics to the central nervous system. 
From a pharmacokinetic point of view, it is well established that 
only the unbound or free drug in plasma (not bound to plasma proteins 
or blood cells) is distributed to body tissues. The unbound drug is able 
to diffuse out of the vascular space and cross the tissue membranes. For 
a drug targeting the CNS, the relevant concentration is the free drug 
within in the interstitial fluid. As it has been mentioned ISF 
Chapter 2 
 
  134 
 
concentration when drug is in steady state (after multiple dosing once 
the input and output rate in the body are in equilibrium) will be 
influenced by the extent of binding to plasma proteins and the drug 
affinity for the brain tissue, however the ultimate regulator of ISF 
concentration is the drug’s ability to cross the barrier. As in any oral 
drug the pharmacological effect is dependent on the drug bioavailability 
(rate and extend of access to the systemic circulation) in a CNS drug its 
effect is conditioned by its bioaccesibility to the brain tissue. This has 
been a challenge for so called small chemical entities and is still more 
challenging to the new biopharmaceuticals with higher molecular 
weights and a much lower ability to cross any biological barrier. 
However, BBB permeation is the necessary but not sufficient condition 
for a successful CNS drug because other factors control the 
concentration-time profile at the brain target sites. CNS drug 
distribution must be also optimized and this aspect is not always 
reflected in the BBB models [37].  
On the other hand BBB disruptions and changes are common 
in some CNS conditions and neurodegenerative disorders and could be 
viewed also as a potential target for CNS therapies. 
The potential strategies to deliver the drug to its targets in the 
CNS include invasive approaches (injections or implants) of limited 
utility due to damage risk, cost and inconveniences to the patient. The 
second option is either chemical modification of the candidate or 
formulation approaches. Drug modifications often affect therapeutic 
activity and modulation of BBB properties with excipients is not free of 
risk. The most promising strategy is the utilization of the physiological 
pathways to deliver endogenous substances and nutrients to the brain 
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i.e. targeted transporter mediated delivery and receptor mediated 
delivery [38, 39].  
The development and research of these strategies requires 
adequate and validated models to obtain the proof of concept for 
efficacy of the delivery method. The BBB models for drug delivery need 
to encompass their complexity depending on their final purpose either 
screening among a big number of compounds or producing clinically 
relevant outputs (plasma and brain time profiles and concentration 
effects relationships). In this sense the development of physiology 
based pharmacokinetic pharmacodynamics models would allow the 
integration of the in vitro and the in silico information, the interspecies 
extrapolation and the incorporation of the pathological changes in the 
system responses. This bottom-up approach has proven its utility in 
other barrier modeling and in other ADME processes as intestinal 
absorption or hepatic metabolism. The bases of a mechanism-based or 
physiological based PK-PD model (PBPK-PD) are the characterization 
of the system parameters (blood flow, tissue weight or volume, enzyme 
levels or transporter expressions) that can be extrapolated among 
species or changed in pathological conditions and the input of the drug-
specific parameters including physicochemical properties, target affinity 
and any other in vitro measured property. The combination of the system 
parameters with the drug information (inputs) generate as output the 
plasma or tissue concentration times profiles.  These models can be 
constructed using programming packages such as MATLAB®, acslX®, 
or Berkeley Madonna® and there are examples of successful 
commercial PBPK simulation tools for absorption and metabolism as 
GastroPlusTM® (Simulations Plus Inc., www.simulations-plus.com), 
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SimCyp® (Simcyp, www.simcyp.com), and PK-Sim® (Bayer 
Technology Services, www.pksim.com) [40, 41].  
The applicability of this methodology to predict brain 
concentration time profiles and CNS drug distribution requires the 
identification of critical system parameters such as cerebral blood flow, 
effective brain capillary surface area, CSF turnover, extracellular fluid 
(ECF) bulk flow, metabolic enzymes and transporter expression levels 
among others i.e. the models are expensive and time consuming to 
construct, but the feasibility of the approach has been already successful 
in other areas. 
Considering the above challenges current research efforts for 
improving drug delivery to the brain should focus on: 
• Understanding physiological changes in the BBB barrier in 
pathological conditions and generating models able to mimic these 
changes. 
• Developing both cost-effective and fast in vitro screening 
methods to reduce later attrition rate as well as physiological meaningful 
in vitro tests to study drug transport mechanisms and testing delivery 
strategies 
• Identifying system physiological parameters in humans and 
animal and their equivalent on in vitro models and their mutual 
relationships to construct predictive PBPK-PD models. 
 
CONCLUSION 
Even nowadays, one of the most challenging aspect of 
developing CNS drugs is ensuring their ability to cross the blood-brain 
barrier (BBB). Our knowledge about BBB structure and function has 
improved dramatically in the last decades as well as the availability of 
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screening methods from in silico, in vitro to in situ and in vivo models. A 
growing number of innovative technologies have been developed to 
overcome the barrier properties. However, there are still many unclear 
aspects about the factors that modulate drug access and disposition in 
the brain: passive BBB permeability, carrier mediated transport 
(absorptive or secretive) and the relative degree of tissue binding 
between brain and plasma as those factors will govern the interstitial 
drug concentration-time profiles. In addition, the development of 
physiology-based pharmacokinetic-pharmacodynamic models would 
allow the integration of the in vitro and in silico information to obtain 
clinically relevant outputs (i.e. plasma and brain time profiles and 
concentration effect relationships). This bottom-up approach has 
proven its utility in other barrier modeling as the intestinal one and can 
incorporate all the recent knowledge in the area of BBB transporters 
and tight junction formation and changes under pathological conditions  
 
EXECUTIVE SUMMARY 
• The Blood Brain Barrier is a physical and a biochemical frontier 
between the blood and the brain.  This selective barrier is derived from 
the tight junctions of the endothelial cells at the brain blood vessels and 
their increased expression of transporters and metabolic enzymes as 
well as the surrounding astrocytes, pericytes and extracellular matrix.  
• There are two ways for molecules to cross the BBB: passive 
diffusion (paracelular and transendothelial transport) for small and 
lipophilic compounds and via endogenous transport system for 
hydrophilic and large molecules.  
• The three essential parameters to describe rate and extent of 
access to the CNS are: the effective permeability (as a composite of 
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diffusive and other transport mechanisms), the ratio of unbound drug 
in brain over unbound drug in plasma at steady state (extent) and the 
intra brain distribution volume. 
• Not a single in vitro model mimicking all the BBB features is 
currently available. The appearance of hybrid (in vitro/in silico) models 
capable of predicting both passive and transport-mediated function and 
software tools for screening drugs is needed but this also needs the 
validation with in vivo data. Generation of larger databases of in vivo data 
(rate and extent) in humans and animal experiments would be desirable. 
• PBPK-PD modeling strategies would allow to obtain clinically 
relevant outputs but the construction of the models still needs the 
characterization of many physiological parameters and their 
relationships between animal models and humans. 
• The utilization of non-invasive strategies by using physiological 
pathways is the most promising strategy to deliver drugs into the CNS. 
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INTRODUCTION 
The success of new CNS drug development can be evaluated in 
terms of number of new medicines and time needed for their marketing 
approval. Drugs that affect the CNS have low percentages of success 
and much time is spent on developing new formulations (10.5 years) 
[1]. However, CNS therapy is the second largest therapeutic area in the 
pharmaceutical industry. This discrepancy is mainly attributed to the 
complexity of the brain, potential side effects of centrally acting agents, 
and the low predictability of CNS animal models for humans [1]. 
Therefore, in addition to a better understanding of physiological and 
pathophysiological conditions of the brain and its diseases, methods are 
needed that are able to select drug candidates more efficiently in the 
early preclinical stages. 
In silico, in vitro and in vivo methodologies have been the subject 
of much research and development in recent years [1-3]. Several in silico 
and in vivo methods are accredited and well-established in the 
development of new drugs. In vitro methods are, however, the focus of 
much debate. There are currently no fully accepted criteria about what 
is required for an in vitro cell line method. There are many factors to take 
into account in selection of an in vitro method: transepithelial resistance 
of cell monolayers, transporter expression, ease and reproducibility and 
high ability to screen molecules. In vitro methods are however a very 
useful, even necessary, component of initial preclinical drug discovery. 
There are significant differences between the different in vitro methods 
in terms of complexity and, consequently, cost and information that 
each method can provide (Table 1). The development of these 
methodologies is essential for high throughput screening of molecules 
that allows the selection of optimal candidates for further evaluation in 
Chapter 3 
 
  146 
 
vivo. In vitro methods are not, nor will be, a substitute for the in vivo tests, 
but allow further analysis of molecules, impossible to make in vivo due 
to ethical and economic reasons. It is therefore necessary that in vitro 
systems are capable of simulating the BBB more accurately. 
 
PHYSICOCHEMICAL METHODS FOR BBB  
Traditionally, some simple methods have been used to select 
candidates for central nervous system diseases based on their 
physiochemical properties. Immobilized artificial membrane 
chromatography, parallel artificial permeability assays and lipophilicity 
measurements are the most commonly used. 
 
Immobilized artificial membrane chromatography  
Taking into account that transcellular permeation is the main 
mechanism to cross the BBB, the ability of drugs to cross the membrane 
can be well-correlated with the membrane partition and, in many cases, 
with its lipophilicity. The immobilized artificial membrane (IAM) 
stationary phase is constituted by a monolayer of phosphatidylcoline 
covalently bound to an inert silica support which is able to simulate the 
biological cell membrane [4]. A recent study carried out by Grumetto 
[5], in which interactions between acidic drugs and membrane 
phospholipids were examined, revealed that IAM technique is suitable 
to investigate drug membrane interactions and the permeation through 
the BBB, allowing the opportunity to optimize the pharmacokinetic 
properties of the candidates at the early stages in some cases. 
 
  
 
  
Table 1 Relevant in vitro models and type of information and parameters that can be obtained. Cps: compound. Pers: person 
 
Physicochemical models Cellular models Ex vivo models 
IAM 
PAMPA 
models 
Traditional 
cell models 
Stem cells 
models 
Tridimensional 
models 
Isolated 
microvessels 
Brain slices 
Throughput 
 
500 cps/pers/day 
100 
cps/pers/day 
10 
cps/pers/day 
10 
cps/pers/day 
Not determined 
10-20 
cps/pers/month 
10 
cps/pers/day 
Parameters 
obtained 
Partition 
coefficients 
aqueous 
phase/phospholipid 
Permeability  
(cm/s) 
(passive 
component) 
Permeability 
(cm/s) 
Permeability 
(cm/s) 
Permeability 
(cm/s) 
Permeability 
(cm/s) 
Fu, brain 
Vu, Brain 
Information 
provided 
Partial information 
of passive diffusion 
Drug membrane 
interactions 
Passive 
diffusion 
Passive 
diffusion and 
transporters 
contribution 
BBB 
functionality 
Passive 
diffusion and 
transporters 
contribution 
BBB 
functionality 
Passive 
diffusion and 
transporters 
contribution 
BBB 
functionality 
 
Passive diffusion 
and transporters 
contribution 
Morphological, 
pathological and 
biomedical 
details 
Passive 
diffusion and 
transporters 
contribution 
Utility for 
study of 
effect of 
disease on 
BBB 
No No Possible Yes Yes Yes No 
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Parallel artificial permeability assay  
Parallel artificial permeability assay (PAMPA) is a high 
throughput methodology, based on a lipid artificial membrane, useful 
to predict passive oral absorption. Different modifications have been 
made over the last years to improve it as a BBB permeabilityscreen [3] 
but, due to the artificial origin, no transport processes are evaluated and 
only passive diffusion correlations might be applied. Despite its 
limitations, PAMPA is able to identify compounds that pass the BBB 
(CNS+) and those that poorly penetrate the BBB (CNS-). Also, better 
predictions in brain penetration are observed compared to log D [1, 3] 
and good correlation with MDCK cell line were obtained in the 
prediction of the rate of brain penetration [1, 6, 7]. An exhaustive study 
carried out by Dagenais and colleagues [8] validated PAMPA assays 
versus in situ permeability values, demonstrating that PAMPA assay was 
able to predict 82% of the variance in the intrinsic BBB permeability. 
PAMPA assay, and the IAM previously described, can be considered 
practical, low-cost and high-throughput methods to evaluate BBB 
passive transport and facilitate chemical optimization of molecules at 
early stages in order to optimize the CNS drug discovery process.  
 
Lipophilicity measurements  
It is well-known that lipophilic compounds cross biological 
membranes more easily than hydrophilic. For these reason some 
models have been developed in order to try to predict CNS drug uptake 
using lipophilicity measurements. n-Octanol partition coefficient can be 
used for initial screening of passive permeability. From the currently 
available experimental data, it is possible to establish the lipophilicity 
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cut off to ensure a passive permeability above 150 nm/s [9]. Taking into 
account that a poor passive permeability could be compensated by other 
properties of the compound and that it does not imply necessarily poor 
brain penetration due to the fact there is no limit in the transit time as 
it occurs in the gastrointestinal system [10, 11]. In fact, despite more 
lipophilic derivatives increase the passage across the BBB they also 
increases the penetration across other biological membranes. More 
lipophilic derivatives could provide an increase of brain uptake but it 
coexists with a reduction of the plasma concentration under the curve 
(AUC) due to the coexistence of an increased clearance of lipophilic 
forms. It is well known that drug uptake in CNS is function of plasma 
AUC, so, this factor minimizes the potential increase of drug uptake 
produced by lipidization of the molecule. This pharmacokinetic rule 
described by Pardridge [12] indicates that drug passage across the BBB 
does not correlate well with lipophilic measurements 
Another useful tool to predict the brain permeation, thanks to 
the lipophilicity value, is the brain-plasma (B-P) assay, which is able to 
predict the in vivo brain/plasma (B/P) ratio [13]. This dialysis assay can 
predict the extent of the drug in the brain, based on the unbound 
fraction relationship between brain homogenate and buffer and plasma 
and buffer. The B/P ratio, as the other physicochemical measures 
described, can be used as an indicative parameter of brain penetration 
to guide structure modification to obtain derivatives with optimal brain 
access [1]. The predictability of the B-P assay was enhanced by 
introducing into the calculation the P-gp efflux ratio from the MDR1- 
MDCKII assay [14]. Therefore, B/P dialysis is a helpful tool in drug 
discovery. 
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EX-VIVO AND CELL-BASED IN VITRO METHODS  
In order to obtain more reliable predictions, cell-based in vitro 
methods were developed. The quality of the predictions of these 
methods has been increasing but there is still a way to go in this field.  
 
Isolated brain microvessels. 
The in vitro isolation of intact brain microvessels (capillaries, 
venules or arterioles) was a crucial step to study of the morphology, 
physiology and pathophysiology of the BBB. Isolated microvessels have 
been used for morphological, pathological, biochemical and drug 
delivery studies of the BBB and for identification of transporters and 
membrane receptors. The advantages of isolated capillary systems 
include the three-dimensional structure, cell differentiation and 
availability. However, the viability of the endothelium is limited, the 
isolation procedure is complicated and the isolation protocol can induce 
metabolic deficiencies. In order to overcome this disadvantages cell 
culture-based systems were developed and acquired great relevance as 
in vitro models for drug screening. 
Isolated brain microvessels have been successfully used to study 
the expression and activity of transporters. Miller et al [15-17] have used 
isolated capillaries of rodent or fish to exhaustively study the role of 
efflux transporters in limiting brain entry, the factors that regulate their 
expression and the potential targets for inhibition. Results indicate that 
the expression and activity of efflux transporters are affected by the 
presence of xenobiotics, diet, stress or disease. Their findings have 
contributed to understand the mechanisms of the barrier function and 
have offered opportunities to developed therapies or preventive 
measures for neurodegenerative diseases and brain cancer. 
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Primary or low passage brain capillary endothelial cell cultures  
The use of brain capillary endothelial cells (BCECs) is one of the most 
obvious options to predict the brain penetration. Due to the use of 
human cells is restricted by ethical reasons, bovine or porcine 
endothelial cells have been selected because of their phenotypic 
similarity to the human BCECs and their relative viability compared to 
isolated microvessels [18]. The process involves the isolation of 
capillaries and culture of endothelial cells alone or in combination with 
astrocytes or astrocyte-conditioned medium. Assays and analysis show 
a considerable loss of BBB features on primary cultured cells. For 
example, there is a down regulation of BBB transporters and enzymes 
when the endothelial cells are removed from the brain and grown in 
culture [19]. 
Tight intercellular junctions are the most important element to 
consider in an in vitro model. Tightness of the monolayer can be 
evaluated by measuring transendothelial electrical resistance (TEER). 
Primary culture of brain endothelium alone is not able to achieve high 
TEER values. So, it is necessary to co-culture with astrocytes [20] which 
increase the tight junctions and induce the expression of specific BBB 
biomarkers including GGTP, the glucose transporter isotype (GLUT-
1), transferrin receptor and P-glycoprotein (P-gp) [18]. Astrocytes 
isolated from newborn rats together with bovine or porcine endothelial 
cells are used as xenogenic co-culture systems, which are very useful in 
studying drug transport and BBB functionality.  
Different co-culture systems have been investigated, as pericytes 
and fibroblast, neurons, microglia and monocytes or pericytes-
astrocytes with endothelial cells in order to improve some properties of 
the cell model. Pericytes are of special relevance because they are 
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normally present at the BBB surrounded by the basement membrane 
and are responsible for inducing specific enzymes. So, it has been 
argued that pericytes are necessary to establish a cell culture model [21].  
The complete procedure to obtain BCECs and the various other 
cells for co-culture is time consuming. Another disadvantage is that 
BCECs rapidly de-differentiate in vitro and lose the characteristics of 
BBB endothelial cells after a few passages in culture [22], which 
produces variability depending on the passage BCECs regarding 
phenotypic, permeability properties and cell contaminants (pericytes, 
leptomeningeal cells, smooth muscle cells) [22] [23]. The monitoring 
criteria to guarantee the quality of monolayers in transport studies 
include TEER and permeability to hydrophilic markers such as 14C-
sucrose, which reflect the degree of tight junction formation. However, 
BCECs are still not able to reach the in vivo conditions (TEER in the 
range >2 k·Ω·cm2 ≤8 k·Ω·cm2 [24] and sucrose permeability of 
approximately 0.3·10-7cm·s-1) [25].  
One of the most relevant application of this model has been the 
use of cultures of primary cells isolated from mice to examine 
mechanistic aspects of neurological diseases. For example, Miller and 
coworkers [26] developed a system consists of a coculture with primary 
cells isolated from mice to study inflammatory events in cerebral 
endothelium.  
 
Immortalized brain endothelial cells  
Due to the disadvantages of primary BCECs described above, 
different immortalized BCECs have been used to assess endothelial cell 
uptake of compounds and to perform mechanistic and biochemical 
studies [23, 27, 28]. Table 2 summarizes the most important 
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immortalized BCECs and their TEER (transendothelial electrical 
resistance) values. The development of immortalized BCECs has 
resulted in more reproducible results with less variation between studies 
compared to primary BCECs, due to the ease of culture, less 
contamination and no isolation process and a slower dedifferentiation. 
However, though immortalized cells lines are useful to overcome the 
limitations of the primary cultures, they are still limited by the loss of 
brain barrier phenotype, compared to in vivo. The generation of 
incomplete tight junctions restricts its use for BBB permeability 
screening. Most of the cell lines have been obtained by transfection of 
primary rat brain endothelial cells (RBE), including RBE4 cell line, 
RBEC1 cell line [29] and TR-BBB13 cell line [30]. In order to increase 
their barrier properties and improve their predictive capacity several 
different strategies have been used, including addition of 
phosphodiesterase inhibitors, glucocorticoids or interferons to the 
media [31, 32]. Due to the increasing number of immortalized RBE cell 
lines appearing, Roux et al. [22, 33] published a criteria in order to better 
characterize immortalized BCECs. They consider that the most 
important characteristics that have to be present in cell lines to better 
mimic BBB conditions are non-transformed phenotype, the expression 
of endothelial cell markers and the presence of BBB specific transport 
proteins.    
In contrast to RBEC, a human brain immortalized endothelial 
(hCMEC/D3) cell line was generated by transfection of the human 
telomerase or SV40 T antigen. The result is a stable, well characterized 
and cell differentiated human brain endothelial cell line [34], exhibiting 
unlimited and robust cell proliferation, tight junctions and efflux 
transporters expression. Recent proteomic studies demonstrated that 
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hCMEC/D3 cells retain the expression of most transporters, thus this 
cell line is useful for examining drug transport across the BBB. 
However, some differences have been observed compared with isolated 
human brain microvessels [35]. 
Table 2 Most important immortalized BCECs lines and TEER values. Adapted from Tetsuya 
et al, 2003 [36]. 
Source Cell line name 
TEER 
value 
(kΩcm2) 
Reference 
Rat RBE4 <30 Roux F. et al. [80] 
Rat RBEC1  Kido et al. [81] 
Rat TRBBB 99-109 Hosoya et al. [82] 
Rat GPNT <30 Weksler B. et al [83] 
Mouse TM-BBBs 105-118 Hosoya et al [84] 
Mouse MBEC4 40-50 Garberg P et al. [14] 
Pig PBMEC 300-550 Zhang et al. [85] 
Human ECV 30 Garberg P et al. [14] 
Human ECV-C6 100 Garberg P et al. [14] 
Human hCMEC/D3 30-40 Weksler B. et al [83] 
Human - 300-400 Stins M.F. et al [86] 
Human TY08 35-43 Sano Y. et al [87] 
Dog MDCK 130-150 Garberg P et al. [14] 
Dog MDCK-MDR1 120-140 Garberg P et al. [14] 
 
Cells of non-cerebral origin  
One of the most characterized and used cell line is the Madin-
Darby Canine Kidney (MDCK) cell line, which is easy to grow, achieves 
a reproducible TEER value and can be transfected with the MDR1 
gene, resulting in the polarized expression of P-gp [4]. MDR1- 
transfected MDCK cells have also shown high absorptive transport for 
CNS(+) drugs and low absorptive transport for CNS(-) drugs [7] and, 
consequently, may be a suitable model for BBB permeation due to the 
overexpression of P-gp. This cell line is characterized by a high 
restrictive paracellular transport [44]. Nevertheless its epithelial origin 
results in significant differences in morphology metabolic and transport 
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parameters. Despite these shortcomings a recent study based on a 
modified set up for MDCK cell experiments has demonstrated its ability 
to predict fu, plasma, Vu, brain  and Kp,uu, brain (the most relevant parameters 
for rate and extend of CNS access) which make this model an useful 
tool at the screening stage [45].  
 
Binding studies in brain slices  
Becker and Liu [46] and Friden [47] have proposed a method to 
estimate free fraction in brain (fu, brain) in which they used brain slices 
instead of brain homogenate. This modification of the technique retains 
the cellular structure of the brain and, in con¬sequence, any differences 
between ISF and ICF can be captured in the obtained fu, brain values. This 
methodology may be applied as a high throughput, evaluating different 
compounds in the same buffer, which allows to a high screening in the 
early phases of drug development [47]. However, because the brain 
slices should be kept in the best possible physiological conditions, it 
requires controlled experimental conditions and only small brain areas 
are used in the experimental setup. On the other hand, only when 
equilibrium between buffer and slices has been achieved, it is possible 
to measure fu, brain and Vu, brain.  
 
Endothelial cells derived from pluripotent stem cells 
Due to the limitations of the in vitro models described above 
there is still not a fully validated and human-origin in vitro model for 
high-throughput screening of potential CNS candidates. Lippmann and 
coworkers have developed recently a promising model based on human 
pluripotent stem cells (hPSCs). They describe how some neural 
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progenitor cells differentiated to mature neurons and astrocytes that can 
be used in co-culture to modeling a robust BBB model with excellent 
barrier properties, expression of transport systems and cells of adequate 
size. Permeability values obtained from co-cultures of endothelial cells 
obtained from hPSCs and astrocytes correlate well with in vivo brain 
uptake. Moreover, the versatility of the system to generate barrier 
models from modified material opens the possibility of investigating the 
development, regulation and drug access in disease conditions [48].  
 
Tridimensional hollow-fiber BBB model  
Traditional techniques for mimicking the BBB described above 
are based on static two chamber systems separated by a cell monolayer 
grown on a polycarbonate membrane that represents the barrier. These 
static models have limitations mainly because they do not reproduce the 
anatomical and physiological features of the blood-brain-barrier and, 
most of them, provide poor correlations with in vivo data. In order to 
address these limitations, dynamic in vitro models with tridimensional 
architecture were developed to reproduce more accurately the 
physiological features of the brain vascular segments and to take into 
account the blood flow in the prediction of brain permeation.  In these 
systems, cell lines are cultured in the lumen of the tridimensional hollow 
fibers and exposed to flow and in the second compartment astrocytes 
are seeded providing a strong BBB model. This approach, used 
successfully by different research groups with different cell lines, has 
allowed an increase of the knowledge and predictability in CNS drug 
development [49, 50]. Studies carried out by Cucullo et al. have 
confirmed by genomic and proteomic analysis that physiological 
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environment (included mechanical stimuli) is crucial for the 
differentiation of endothelial cells [51]. Their research has provided 
evidence of the importance of the shear stress in the formation and 
maintenance of BBB features, suggesting that changes in the flow could 
play a role in neurological diseases. Subsequently, this system has been 
refined in order to establish a dynamic capillary-venule system capable 
of reproducing more accurately different vascular segments of the brain 
vascular network [52]. The main goal of this model is to explore the 
cerebrovascular response to pathophysiological stimuli and develop 
therapeutic strategies for neurological pathologies including epilepsy 
[53]. Moreover, this technical approach could be combined with the 
hPSC-derived BMECs to better mimic physiological conditions and 
improve the relevance and predictive power of the preclinical screens 
[54]. 
 
Microfluidic blood brain barrier model 
Despite their many advantages conventional dynamic in vitro 
BBB models lack a thin dual cell layer interface. To overcome this 
limitation microfluidic in vitro models have been recently designed and 
developed. They are constituted by a microfluidic chip with 
microcirculation sized two-compartment chamber. Endothelial cells are 
seeded in the apical compartment and media or support neuronal cells 
are placed in the basolateral one. The devices have sufficient key 
characteristics to be considered a good model useful for studies of BBB 
function or drug delivery. It has many advantages such as low cost, 
controlled growth conditions and dynamic microenvironment with 
shear stress stimulation.  Effectively, this method mimics the 
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cerebrovascular environment and thinner culture membrane even 
better than tridimensional models. Booth and Kim [55] developed a 
microfluidic BBB in where cultured b.End3 endothelial cells with and 
without co-cultured C6-D1A astrocytes in order to reproduce the BBB 
microenvironment. Prabhakarpandian et al [56] designed a similar 
system called “Synthetic Microvasculature Model of the blood-Brain-
Barrier” which used the rat brain endothelial cell line (RBE4) and a 
perfusate of astrocyte conditioned media. Griep et al [57] have reported 
a promising microfluidic chip with immortalized human brain 
endothelial cell line hCMEC/D3. These realistic models are versatile 
and, for this reason, suitable to study barrier function and dysfunction 
and evaluate drug delivery in pathological and non-pathological 
conditions  
 
CONCLUSIONS 
In the CNS drug development, the main objective is to achieve 
free drug concentrations sufficient to obtain the desired therapeutic 
effect. According to the free (or unbound) drug hypothesis, unbound 
drug plasma concentration is directly related to unbound drug brain 
concentration and in consequence high plasma protein binding can 
reduce unbound concentration in the brain [1]. On the other hand, if 
there is any active process involved in the drug permeation across the 
BBB this relationship is no longer direct. Therefore, the three major 
factors governing free concentrations in brain are: BBB permeability, P-
gp efflux transport, and plasma protein and brain tissue binding [1]. 
These characteristics must be represented in the model selected in vitro, 
in order to predict more accurately the drug access to the CNS.  
Chapter 3 
 
  159 
 
 High BBB permeability is important in achieving rapid onset. 
But there is also a practical upper limit of convenient or adequate BBB 
permeability (e.g., > 15 cm/s in MDCK). Extremely high permeability 
can be counterproductive owing to increased non-specific binding and, 
consequently, lower unbound drug concentration in the brain. BBB 
permeability for screening purposes can be measured by in vitro methods 
such as PAMPA-BBB or MDCK assays.  
 P-gp efflux is a major obstacle for brain penetration. 
Compounds with a high P-gp efflux ratio have low chance to become 
successful CNS agents. Conversely, P-gp efflux characteristics are 
beneficial for non-CNS therapies to limit CNS side effects. Saturation 
of P-gp at the BBB is unlikely. P-gp efflux is mostly species independent 
with some exceptions. MDR1-MDCKII and MDR1a/1b double 
knockout mouse models are effective tools to detect P-gp efflux 
mechanisms.  
 Tissue binding studies (to estimate the distribution volume in 
brain Vu) need in vivo methods or in vitro models as brain slices but there 
are preliminary promising results with some cell culture studies [45]. 
 On the other hand some new approaches as cultures based on 
pluripotent stem cells or three-dimension models could add the 
advantage of rendering kinetic parameters (as permeability values) while 
also informing about the effect of pathological and physiological 
changes as transporters expression levels, alteration of the barrier 
properties or blood flow changes. Ultimately there will not be a single 
in vitro model but their selections have to be based on the final purpose, 
either screening of candidates or a mechanistic study for new drug 
design. 
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FUTURE PERSPECTIVES  
In the early phases of CNS drug development, still many 
questions have to be answered using different methodologies thus 
making complicate the high throughput screening of candidates.  In vitro 
methods have been recognized in their capability to predict the drug 
access rate into the brain, the role of different transporters in drug 
permeation and the relevance of some biomarkers in the signal 
transduction but the measurement of the extent and the drug brain 
distribution require separate experimental systems. A whole in vitro 
single system able to provide a complete characterization of the relevant 
drug parameters would be a relevant improvement for accelerating 
candidate screening. On the other hand, more research is necessary to 
obtain more reliable and stable in vitro cell lines reflecting either the 
healthy and ill brain conditions. These new in vitro systems have to be 
able to test the efficacy of the new technologies to cross the BBB thus, 
it would be desirable a flexible system with a tunable enzymatic and 
transporter expression levels. Finally, to fully exploit the in vitro results 
their integration in physiology-based pharmacokinetic-
pharmacodynamic models would lead to obtain clinically relevant 
outputs (i.e. plasma and brain time profiles and concentration effect 
relationships) and to reduce the attrition rate. 
 
EXECUTIVE SUMMARY 
• There are no fully accepted criteria about what in vitro methods 
are the most convenient for predicting rate and extend of drug access 
to the brain. 
• Simple methods based on the physicochemical properties as 
Immobilized artificial membrane chromatography, parallel artificial 
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permeability assays and lipophilicity measurements are the most 
commonly used in early screening but are mainly useful for compounds 
transported by passive diffusion. 
• Isolated microvessels have three dimensional structure, 
differentiation and availability. They are useful to study morphological 
aspects, the expression and activity of transporters and carry out drug 
delivery assays. 
• Primary or low passage brain capillary endothelial cell cultures 
are not able to retain blood brain barrier properties. Co cultures with 
astrocytes and pericytes are time consuming and still do not fully 
reproduce in vivo conditions. 
• Immortalized brain endothelial cells of animal and human origin 
have been developed, resulting in easy culture cell lines, no isolation 
needed and less contamination observed. However, low tight junctions 
were obtained which limits its application in permeability studies.  
• Among the cultures with cells of non-cerebral origin, MDCK 
and MDCK-MDR1 are the most promising cell lines thanks to their 
high TEER values and the possibility of obtaining stably transfected 
clones with the transporter of interest. 
• Controlled and standardized Brain slices experiments allow the 
measurement of fu, brain and Vu ,brain. This model may be used in a high 
throughput mode and has the advantage of capturing the differences 
between ISF and ICF. 
• Endothelial cells derived from pluripotent stem cells constitute 
a promising approach of human origin. Co-cultures of mature neurons 
and astrocytes provide a robust BBB model useful to study 
physiological and pathological aspects of the BBB and drug access in 
disease conditions. 
Chapter 3 
 
  162 
 
• Tridimensional hollow-fiber models reproduce more accurately 
the physiological features of the brain vascular segments and allow 
exploring the response to pathophysiological stimuli. 
• Microfluidic blood brain barrier models are realistic and 
versatile devices suitable to mimic the cerebrovascular environment. 
They are promising models to study barrier function and dysfunction 
and evaluate drug delivery in pathological and non-pathological 
conditions. 
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INTRODUCTION 
The relevance of cell culture permeation assays in drug 
development 
Drug development can be evaluated in terms of success rate and 
time to market of new drug products. Obtaining molecules with high 
activity does not warrant their effectiveness in vivo because the drug 
must achieve therapeutic concentrations at the sites of action. The 
access to the therapeutic targets implies crossing biological barriers. 
This question is of great relevance especially in two groups of drug 
products: 1) Oral drug products in which the drug must be absorbed 
through the intestinal barrier to reach the systemic circulation and 2) 
those drugs whose sites of action are located in the so-called “drug 
sanctuaries” as the Central Nervous System (CNS) that must cross a 
blood-brain tight barrier.  
Oral route is the preferred one in terms of patient compliance 
[1]. However, not all the drugs are suitable for oral administration. Drug 
dissolution and permeation through the intestinal membrane are the 
essential steps to reach the systemic circulation, consequently solubility 
and permeability are two of the key biopharmaceutical properties that 
determines drug product “developability”. In 1995, Amidon et al. 
developed the Biopharmaceutics Classification System (BCS) [2] as a 
framework to classify drugs and to forecast in vivo drug product 
performance from in vitro data (i.e. permeability solubility and 
dissolution rate). The FDA in 2000 presented the guideline for waiver 
of in vivo bioavailability and bioequivalence studies for immediate-
release solid oral dosage forms based on the Biopharmaceutics 
Classification System (BCS) [3] in which an exemption of in vivo 
bioequivalence studies (“biowaiver”) can be requested for comparison 
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of drug products containing class 1 drugs. Class 1 drugs are those 
exhibiting high permeability (defined as an oral fraction absorbed 
>90%) and high solubility.  EMA [4] and WHO [5] established the cut 
off for drug high permeability when the oral fraction absorbed is ≥85%. 
FDA accepts in vitro estimation of permeability using assays in cell 
monolayers as a method for permeability classification under certain 
conditions, i.e., passively absorbed drugs, epithelial cell monolayers, and 
the demonstrated suitability of the assay [3]. However EMA and WHO 
consider in vitro permeability estimations only as supportive data [4, 5].  
On the other hand CNS drugs have in general lower success 
rates and longer development times (10.5 years) [6-9] than in other 
therapeutic areas because of the complexity of the brain, the blood brain 
barrier and the low predictability of CNS animal models.6 For these 
reasons many groups are working on the development of predictive 
preclinical models [10-26]. 
Recently an innovative in vitro method to predict rate and extent 
of drug delivery to the brain across the Blood-Brain Barrier has been 
published by our group [27]. The system permits the estimation of fu, 
plasma, Vu ,brain and Kp,uu, brain in a single experimental system, using in vitro 
cell monolayers in different conditions.  
In summary, cell culture permeability experiments are very 
valuable tools in drug development and candidate selection in the 
preclinical stage and also in clinical phases and generic development. A 
cell monolayer permeability assay consists of two chambers separated 
by a porous support material in which a single cell thickness layer of 
cells grows until confluence is attained and sufficient cell differentiation 
is reached. The drug solution is placed in one of the chambers and 
samples are taken in the opposite chamber at different times in order to 
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estimate permeability. The monolayer preparation protocols (seeding 
density, growth time, media composition and change frequency), the 
experimental conditions (apical and basolateral media composition, 
filter porosity, agitation conditions, temperature etc.) and the 
calculations procedures can affect the permeability estimation. Hence, 
standardization and method suitability demonstration are necessary 
steps for using permeability data for regulatory purposes. 
 
Permeability estimation methods 
 The permeability is calculated from the drug concentrations and 
accumulated amounts in acceptor chamber using either linear or 
nonlinear regression models, depending of the assumption about sink 
conditions on the receptor side [28, 29]. Tavelin et al. [29] described the 
different profiles that are usually observed between accumulated 
amounts of drug in the acceptor side versus time. Three examples of 
these profiles are represented in Figure 1. 
 
Figure 1. Profiles of accumulated amounts of drug in acceptor chamber versus time in 
permeability experiments in cell monolayers. Profile A: Drug is transported during the first 
sampling interval at a lower rate than expected; Profile B: Drug is transported linearly with a 
constant rate; Profile C: Drug is transported at a higher rate during the first sampling interval. 
 
Tavelin et al. [28] highlighted the existence of atypical profiles 
(Profiles A and C on Figure 1) and explained the possible reasons to 
these profiles. Profile A may be caused by poor temperature control at 
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the beginning of the experiment, or by the fact that partitioning of the 
drug into the cell monolayer is the rate-limiting step. Profile C is 
sometimes observed when the transport of radiolabeled drugs is 
studied. The reason may be that radiolabeled low molecular weight 
impurities (such as 3H-water) are present in the drug solution and are 
transported at a higher rate than the drug. Another reason may be that 
the cell monolayer is affected by a too harsh application of the drug 
solution. In such cases, the estimation of the permeability by the 
standard linear regression methods or even non-linear regression 
methods may not be correct. Therefore, a good estimation of 
permeability is needed to correctly classify drugs under BCS criteria. 
Simulation is an important tool for the evaluation of 
pharmacokinetic models that allows analyzing different scenarios and a 
more efficient decision making during drug development [30-38]. 
Regulatory agencies, FDA and EMA, encourage model simulation as a 
tool to increase predictability and efficiency in preclinical and clinical 
phases [39-41].  
The aim of this study was to use a simulation strategy to explore 
the performance of a Modified Non-Sink equation, MNS; (in terms of 
precision and accuracy) for permeability estimation in different types of 
profiles and scenarios of variability, to compare the new proposed 
model with the classical sink and non-sink approaches and to explore 
its usefulness for BCS classification. Data from cell culture experiments 
representing the different experimental profiles have been analyzed 
with all the equations to validate the new approach. The limitations ad 
advantages of the MNS equation are discussed. 
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MATERIAL AND METHODS 
Permeability calculations 
Sink (S) equation 
Permeability values in sink conditions are estimated from the 
first Fick’s law equation under the assumption of sink condition (i.e. 
negligible drug concentration in acceptor versus donor or in 
mathematical terms acceptor concentration<10% of donor 
concentration), no change of drug donor concentration during the assay 
and under a linear approximation of the appearance rates. 
𝑃𝑒𝑓𝑓 = (
𝑑𝑄
𝑑𝑡⁄ )/𝑆 · 𝐶0      (1) 
where dQ/dt is the apparent appearance rate of drug in the 
receiver side, calculated using linear regression of amounts in the 
receiver chamber versus time, S is the surface area of the monolayer C0 
is the drug concentration in the donor chamber and Peff is the 
permeability value. When the transport rate is low, neither the donor 
nor the receiver concentrations will change significantly with time, and 
sink conditions are assumed as a reasonable approximation.  
Sink Corrected (SC) equation 
Artursson et al. proposed a modified equation, in order to avoid 
the limitations of classical equation of sink conditions because even 
under sink conditions the change in donor concentration affects to the 
driving force and may not be negligible. In this new equation the 
concentration in the donor chamber changes in each sample interval 
[28].  
𝑃𝑒𝑓𝑓 = (
𝑑𝑄
𝑑𝑡⁄ )/𝑆 · 𝐶𝐷      (2) 
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where CD is the concentration in the donor chamber at each 
sample interval. 
Non-sink (NS) equation 
Under non sink conditions, the apparent permeability 
coefficient was calculated according the following equation: 
𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟,𝑡 =
𝑄𝑡𝑜𝑡𝑎𝑙
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟+𝑉𝑑𝑜𝑛𝑜𝑟
+ ((𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟,𝑡−1 · 𝑓) −
𝑄𝑡𝑜𝑡𝑎𝑙
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟+𝑉𝑑𝑜𝑛𝑜𝑟
) ·
𝑒
−𝑃𝑒𝑓𝑓·𝑆·(
1
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟
+
1
𝑉𝑑𝑜𝑛𝑜𝑟
)·∆𝑡
     (3) 
where Creceiver,t is the drug concentration in the receiver chamber 
at time t, Qtotal is the total amount of drug in both chambers, Vreceiver and 
Vdonor are the volumes of each chamber, Creceiver,t−1  is the drug 
concentration in receiver chamber at previous time, f is the sample 
replacement dilution factor, S is the surface area of  the monolayer, Δt 
is the time interval and Peff is the permeability coefficient. This equation 
considers a continuous change of the donor and receiver 
concentrations, and it is valid in either sink or non-sink conditions. The 
curve-fitting is performed by nonlinear regression, by minimization of 
the Sum of Squared Residuals (SSR), where:  
𝑆𝑆𝑅 = ∑[𝐶𝑟,𝑖,𝑜𝑏𝑠 − 𝐶𝑟,𝑖(𝑡𝑒𝑛𝑑,𝑖)]
2
     (4) 
Cr,i,obs is the observed receiver concentration at the end of 
interval i, and Cr,i(tend,i) is the corresponding concentration at the same 
time calculated according to Eq. 3 [42]. 
New proposed equation: Modified Non-Sink (MNS) 
𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟,𝑡 =
𝑄𝑡𝑜𝑡𝑎𝑙
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟+𝑉𝑑𝑜𝑛𝑜𝑟
+ ((𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟,𝑡−1 · 𝑓) −
𝑄𝑡𝑜𝑡𝑎𝑙
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟+𝑉𝑑𝑜𝑛𝑜𝑟
) ·
𝑒
−𝑷𝒆𝒇𝒇 𝟎,𝟏·𝑆·(
1
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟
+
1
𝑉𝑑𝑜𝑛𝑜𝑟
)·∆𝑡
      (5) 
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where all the terms are defined in the previous equation and Peff 
is the permeability coefficient, which might be Peff 0 or Peff 1. This 
equation, as equation 3 considers a continuous change of the donor and 
receiver concentrations, and it is valid in either sink or non-sink 
conditions. The new feature is the option to estimate two permeability 
coefficients (Peff 0 and Peff 1) to account for the atypical profiles A and C 
in which the initial rate is different.  
The non-linear regressions to fit equation 3 (NS) and 5 (MNS) 
to data can be performed in Excel using Solver tool for minimization 
of the Sum of Squared Residuals. Equation 1 (S) and equation 2 (SC) 
are linear regression models that can be also executed in Excel.  
 
Model Validation 
Simulation step 
In order to validate the modification in the Non-sink equation, 
different scenarios were simulated. 1000 experiments, 3 wells per 
experiment were generated combining different initial setups. Simulated 
data were obtained using Modified Non-sink (MNS) equation 5. 
Simulations have been performed with MSN equation that is the more 
general case but when Peff 0 = Peff 1 it matches the Non-sink equation. 
Moreover when Peff 0 (= Peff 1) is small, sink conditions prevails, then 
sink experiments have been also simulated. In other words, changing 
the parameters in the MSN model, that is a generalized model is 
equivalent to performing simulations with non-sink model (when Peff 0 
= Peff 1), sink model (when permeability is small) and MSN.  Simulated 
data analysis in this case, permits evaluate which of the equations is able 
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to grasp the atypical profiles and to render a permeability estimation 
closer to the “real or true” one. 
Preset conditions during the simulation step are the user-
defined parameters values. All values are summarized in Table 1-2. Data 
were simulated either in sink (Table 1) or non-sink (Table 2) conditions. 
Samples times were established to be 900, 1800, 3600 and 5400 sec. 
Inter-individual (inter-well) variability was added to the set permeability 
value and residual variability was added to the simulated concentrations. 
Variability in both cases followed an exponential error model (equation 
6-7). For each well, an individual permeability was assigned, depending 
on the coefficient of variation (CV) defined in each scenario of 
variability. A combination of high (H=20% CV) or low (L=5% CV) 
interindividual and residual variability were selected in order to evaluate 
four different variability combinations. 
𝜃𝑖 = 𝜃𝑝 · 𝑒
𝜂     𝜂 𝜖 𝑁(0, 𝜔2)     (6) 
𝑦𝑖 = 𝑦𝑝 · 𝑒
𝜀       𝜀 𝜖 𝑁(0, 𝜎2)     (7) 
 
Peff 0 (cm/s) 10
-8
 10
-6
 5·10
-6
 
Peff 1 (cm/s) 10
-6
 10
-6
 10
-6
 
C
0 
(µM) 100 
V
D
 (mL) 2 
V
R
 (mL) 3 
V
S
 (mL) 0.2 
Table 1. Parameter values of the preset conditions in Sink conditions. 
 
 
 
Chapter 4 
 
 
  179 
 
 
Peff 0 (cm/s) 10
-8
 5·10
-5
 10
-4
 
Peff 1 (cm/s) 5·10
-5
 5·10
-5
 5·10
-5
 
C
0 
(µM) 100 
V
D
 (mL) 2 
V
R
 (mL) 3 
V
S
 (mL) 0.2 
Table 2. Parameter values of the preset conditions in Non-sink conditions. 
 
Permeability estimation 
Permeability values were estimated from simulated 
concentrations in the receiver chamber, obtained in the previous step, 
using four different equations: Modified Non-sink (MNS) (equation 5), 
Non-sink (NS) (equation 3), Sink (S) (equation 1) and Corrected Sink 
(SC) (equation 2). The permeability coefficient estimations in sink and 
non-sink conditions were carried out in an Excel® worksheet. 
Validation of model with experimental data. 
MDCKII cells were grown in Dubelcco’s Modified Eagle’s 
Media containing L-glutamine, fetal bovine serum and penicillin-
streptomycin. Each two days the media was replaced. Cells monolayers 
were prepared by seeding 400000 cells/cm2 on a polycarbonate 
membrane which surface area was 4.2 cm2. They were maintained at 
37°C temperature, 90% humidity and 5% CO2 and medium was 
replaced each two days until confluence (7-9 days). Afterwards, the 
integrity of the each cell monolayer was evaluated by measuring the 
trans-epithelial electrical resistance (TEER). In experiment Hank’s 
balanced salt solution (HBSS) supplemented with HEPES was used to 
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fill the receiver chamber and to prepare the drug solution that was 
placed in the donor chamber after adjusting pH to 7.   
Transport studies were conducted in an orbital environmental 
shaker at constant temperature (37°C) and agitation rate (50 rpm). In 
vitro studies were performed in both directions, from apical-to-basal 
(AB) and from basal-to-apical (BA) sides. The volume was 2 mL and 3 
mL in apical and basolateral chamber respectively. Four samples of 200 
µL each one were taken, and replaced each time with HBSS 
supplemented with HEPES from the receiver side at 15, 30, 45 and 90 
minutes. Samples of the donor side were taken at the beginning and the 
end of the experiment. Moreover, the amount of compound in cell 
membranes and inside the cells was determined at the end of 
experiments in order to check the mass balance and the percentage of 
compound retained in the cell compartment (always less than 5%.)  
Drugs used were Metoprolol, Caffeine, Verapamil, Zidovudine 
Atenolol and Norfloxacin. They were selected for having high or 
moderate permeability values (Metoprolol, Caffeine and Verapamil) or 
low ones (Zidovudine Atenolol and Norfloxacin) to obtain sink and 
non-sink conditions on the experimental system. Samples were analyzed 
by a validated HPLC procedure previously described [43]. 
Individual profiles of amounts or concentrations in acceptor 
chamber were carefully examined to identify atypical ones. 
Approximately 10% of the wells presented some degree of deviation 
from linearity (amount/concentration versus time profiles). Some 
examples and the result of their analysis are shown in Figure 2. 
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Figure 2.  Concentrations in acceptor chamber versus time on individual wells for the following 
compounds Metoprolol, Caffeine, Verapamil, (no sink 1; no sink 2 and no sink 3 respectively) 
Zidovudine, Atenolol and Norfloxacin (sink 1; sink 2 and sink 3). Red line corresponds to the 
fit of the non-sink equation and the blue one is the fit of the MNS model to the data. 
 
Graphical analysis 
Receiver simulated concentrations are plotted versus population 
predicted concentrations obtained by NS and MNS equations. Plots 
were obtained using S-Plus 6.0 and RStudio using R version 2.14. 
Estimation error 
Once permeability coefficients were estimated for each well 
with the different methods, the average permeability of the experiment 
was calculated as the arithmetic mean of the three individual well 
permeability values. Then, mean estimation error, intra-assay estimation 
error and individual estimation error were determined as follow: 
𝑀𝑒𝑎𝑛 𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑖𝑜𝑛 𝐸𝑟𝑟𝑜𝑟 =
𝑃𝑒𝑓𝑓 𝐸𝑆𝑇𝐼𝑀𝐴𝑇𝐸𝐷−𝑃𝑒𝑓𝑓
𝑃𝑒𝑓𝑓
   (6) 
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where Peff ESTIMATED is the mean estimated permeability of each 
experiment and Peff is the simulated permeability in the preset 
conditions (without variability). Mean estimation error, evaluates the 
capacity of each model to replicate the three observed scenarios. 
𝐼𝑛𝑡𝑟𝑎𝑎𝑠𝑠𝑎𝑦 𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑖𝑜𝑛 𝐸𝑟𝑟𝑜𝑟 =
𝑃𝑒𝑓𝑓 𝐸𝑆𝑇𝐼𝑀𝐴𝑇𝐸𝐷−𝑃𝑒𝑓𝑓 𝑊𝐸𝐿𝐿
𝑃𝑒𝑓𝑓 𝑊𝐸𝐿𝐿
  (7) 
where Peff WELL is the mean value of the three individual 
permeability values assigned in the simulation step to the wells. Intra-
assay estimation error, evaluates the performance of each method to 
predict the mean permeability of the well in different variability 
scenarios 
𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝐸𝑠𝑡𝑖𝑚𝑎𝑡𝑖𝑜𝑛 𝐸𝑟𝑟𝑜𝑟 =
𝑃𝑒𝑓𝑓 𝐸𝑆𝑇𝐼𝑀𝐴𝑇𝐸𝐷 𝐴−𝑃𝑒𝑓𝑓 𝐴
𝑃𝑒𝑓𝑓 𝐴
  (8) 
where Peff ESTIMATED A is the estimated permeability in well A and 
Peff A is the individual permeability of well A assigned in the simulation 
step. Error estimations were carried out in an Excel® worksheet. 
Statistical analysis 
Analysis of variance (ANOVA) was performed in order to 
detect statistical differences in the mean estimation error in each 
scenario of variability.  Scheffe test was selected as a post-hoc analysis 
to detect differences between equations with α=0.05. All statistical 
procedures were performed using SPSS 20.0.  
 
Model Comparison 
Simulation step 
At this point, in order to evaluate the performance of 
permeability estimation by each method to classify drugs in the BCS 
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framework, simulations were performed in a set of borderline scenarios 
regarding BCS. The question to be answered in this exercise was the 
following: in a borderline situation for BCS classification as high 
permeability compound i.e. test permeability closer to the high 
permeability cutoff, could the estimation method of test or reference 
permeability bias the classification result? Or in another words, which 
method would give a more accurate classification?  
The high permeability cutoff was set at 2.0·10-5 cm·sec-1 [44, 45]. 
To perform the simulations, test and reference permeability values were 
set at three levels of 2.0·10-5 cm·sec-1, (average value), 1.8·10-5 cm·sec-1 
(80% or lower limit) and 2.5·10-5 cm·sec-1 (125% or upper limit). These 
levels were set to use a bioequivalence-like approach in the permeability 
classification [46]. 108 scenarios were generated combining 3 levels of 
permeability (upper limit, average or lower limit) for test * 3 levels of 
permeability for reference * 4 variability scenarios (as in the model 
validation step) * 3 profiles types (A, B or C).  
Simulated data were obtained using Modified Non-sink (MNS) 
equation (3). Preset simulation conditions were fixed to a donor volume 
of 0.5 mL, receptor volume of 1.2 mL and sample volume of 0.2 mL; 
initial concentration in the donor chamber of 100 µM; and surface area 
of the monolayer of 0.9 cm2. Samples times considered were 900, 1800, 
3600 and 5400 sec. Initial permeability (Peff 0) and final permeability (Peff 
1) were used to simulate different profiles, both in the reference as in 
the test compound. In order to be able to detect the effect in the 
permeability estimation, profiles simulated for reference and test 
compounds were Profile A, where less drug is transported during the 
first sampling interval (Peff 0 = 10
-8 cm·sec-1); Profile B, where there is a 
constant permeation during the first sampling interval (Peff 0 = Peff 1); and 
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Profile C, where more drug is transported during the first sampling 
interval (Peff 0 = 5·10
-5 cm·sec-1). In each profile, different scenarios of 
variability were simulated considering an exponential model with high 
(20% CV) or low (5% CV) interindividual variability (IIV)  high or low 
residual variability (RSV) i.e. each profile was simulated in four different 
scenarios of variability (2 interindividual*2 residual). Each scenario 
contained 1000 simulated experiments (500 simulated test experiments 
and 500 simulated reference experiments). Considering 3 wells per 
experiment it gives a total of 3000 wells per scenario. 
Permeability estimation  
 Permeability values were estimated from simulated 
concentrations in the receiver chamber obtained in the previous step 
using four different equations: Modified Non-sink (MNS) (equation 5), 
Non-sink (NS) (equation 3), Sink (S) (equation 1) and Corrected Sink 
(SC) (equation 2). From the permeability coefficients obtained for each 
well the average permeability of the experiment was calculated as the 
arithmetic mean of the three wells. The permeability coefficient 
estimations in sink and non-sink conditions were carried out in an 
Excel® worksheet.   
In order to evaluate the performance for classification of each 
estimation method the results were evaluated and labeled as following: 
Label OK; label ERROR and label VARIABILITY. 
The OK result was established when the relationship between 
the preset simulation conditions  (without variability) with simulation 
conditions specifically assigned to the well (IIV and RSV variability) and 
the result of the estimated permeability coefficient by each method were 
the same. 
Chapter 4 
 
 
  185 
 
ERROR result was established when preset simulation 
conditions (without variability) matched with simulation conditions 
specifically assigned to the well (IIV and RSV variability), but not with 
the result of the permeability coefficient estimated by each method. 
This label means that the estimation method was not able to estimate 
correctly the rank order of the test regarding the reference (higher, 
similar or lower). ERROR label was also assigned when preset 
simulation conditions (without variability) did not match with 
simulation conditions specifically assigned to the well (IIV and RSV 
variability) and the estimated permeability value did not match the 
permeability assigned to that well. 
VARIABILITY result was established when preset simulation 
conditions (without variability) did not match with simulation 
conditions specifically assigned to the well (IIV and RSV variability), 
but the result of the estimated permeability coefficient matched to the 
simulation conditions specifically assigned to the well. In another words 
the label VARIABILITY represents the situation in which the 
theoretical permeability value used for data simulation and the rank 
order of test and reference did not correspond to the particular 
permeability (and rank order) assigned to a particular well of the 
experiments, even if the estimation method was able to correctly 
estimate the well permeability. 
An example of labeling results for one scenario is represented 
in Table 3 in order to clarify the label meaning. 
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PRESET SIMULATION 
CONDITIONS 
SIMULATIONS 
CONDITIONS WITH 
VARIABILITY 
ESTIMATION RESULT 
AND LABEL 
1500 SIMULATED TEST COMPOUND 
T > R PSIM-T ≥ R PEST ≥ R OK 
T > R PSIM-T ≥ R PEST < R ERROR 
T > R PSIM-T < R PEST ≥ R ERROR 
T > R PSIM-T< R PEST < R VARIABILITY 
1500 SIMULATED REFERENCE COMPOUND 
R < T PSIM-R < T PEST < T OK 
R < T PSIM-R< T PEST ≥ T ERROR 
R < T PSIM-R≥ T PEST < T ERROR 
R < T PSIM-R ≥ T PEST ≥ T VARIABILITY 
Table 3. Example of a scenario with the possible results obtained regarding the simulation and 
estimation process. T is referred to Test compound, R is reference compound. In the preset 
simulation conditions a particular rank order is selected, for instance theoretical permeability 
value of test T is higher than the reference one (T>R). PSIM is the permeability value assigned 
to the well (due to the interindividual variability) and PEST is the estimated permeability value 
by any of the used methods. 
 
Statistical analysis 
Results from each model were analyzed using a crosstab and 
chi-square test to detect statistical differences between methods used 
(MNS, NS, S, SC) and results obtained. A statistical p-value of 0.05 was 
established. All statistical procedures were executed using SPSS 20.0.  
 
RESULTS 
Model Validation 
Graphical analysis 
Simulated concentration in the receiver chamber was plotted 
versus time by each profile and scenario of variability generated (high 
(H) and low (L) interindividual variability (IIV) and residual variability 
(RSV)) are represented in Figure 3. 
  
 
 
 
Figure 3. Profile A, B and C (left, middle and right groups) by scenarios of variability in sink conditions are represented in the upper line and non-sink conditions 
are plotted in the lower line. Blue dots are simulated concentrations (ng/mL) in 3000 wells, solid line is the population predicted values obtained by MNS equation 
and dotted line is the population predicted value by NS. 
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Validation of model with experimental data. 
Results of permeability experiments in MDCKII cells were 
selected for model validation. Figure 2 represents the concentrations in 
acceptor chamber versus time on individual wells for the following 
compounds Metoprolol, Caffeine, Verapamil, ( non-sink 1 ; non-sink 2 
and non-sink 3) Zidovudine Atenolol and Norfloxacin (sink 1; sink 2 
and sink 3). Red line corresponds to the fit of the non-sink equation 
and the blue one is the fit of the MNS model to the data. Fits of the 
non-sink and MNS models were compared with Snedecor’s F test. F 
calculated and tabulated values are summarized in Table 4. 
PROFILE A 
 
SINK NON SINK 
H IIV 
H RSV 
H IIV 
L RSV 
L IIV 
H RSV 
L IIV 
L RSV 
H IIV 
H RSV 
H IIV 
L RSV 
L IIV 
H RSV 
L IIV 
L RSV 
MNS MNS MNS MNS MNS MNS MNS MNS 
NS Sig Sig Sig Sig Sig Sig Sig Sig 
S NS NS NS NS Sig Sig Sig Sig 
SC NS NS Sig Sig Sig Sig Sig Sig 
Table 4. ANOVA results of Profile A data sets in each scenario of variability between methods 
of estimation (MSN, NS, S and SC). Sig means statistical differences and NS no statistical 
differences were observed. 
Estimation error 
Results from mean, intra-assay and individual estimation error 
are shown on Figures 4, 5 and 6. Red dots are the mean values of 
estimation error of each method (MNS, NS, S, SC), grey box is one 
standard deviation (SD) of the mean and lines are two SD of the mean 
value.  
  
 
Figure 4. Estimation errors of Profile A in sink and non-sink conditions, by each scenario of variability and by each method of estimation.  
   
 
 
Figure 5. Estimation errors of Profile B in sink and non-sink conditions, by each scenario of variability and by each method of estimation. 
  
 
Figure 6. Estimation errors of Profile C in sink and non-sink conditions, by each scenario of variability and by each method of estimation. 
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Statistical analysis 
 ANOVA of the mean estimation errors was performed 
with Scheffe as post-hoc test. Results are summarized in Table 5-7.  
PROFILE A 
 
SINK NON SINK 
H IIV 
H RSV 
H IIV 
L RSV 
L IIV 
H RSV 
L IIV 
L RSV 
H IIV 
H RSV 
H IIV 
L RSV 
L IIV 
H RSV 
L IIV 
L RSV 
MNS MNS MNS MNS MNS MNS MNS MNS 
NS Sig Sig Sig Sig Sig Sig Sig Sig 
S NS NS NS NS Sig Sig Sig Sig 
SC NS NS Sig Sig Sig Sig Sig Sig 
Table 5. ANOVA results of Profile A data sets in each scenario of variability between methods 
of estimation (MSN, NS, S and SC). Sig means statistical differences and NS no statistical 
differences were observed. 
 
PROFILE B 
 
SINK NON SINK 
H IIV 
H RSV 
H IIV  
L RSV 
L IIV  
H RSV 
L IIV  
L RSV 
H IIV 
 H RSV 
H IIV  
L RSV 
L IIV  
H RSV 
L IIV  
L RSV 
MNS MNS MNS MNS MNS MNS MNS MNS 
NS NS NS NS NS NS NS NS NS 
S NS NS NS Sig Sig Sig Sig Sig 
SC NS NS NS NS Sig Sig Sig Sig 
Table 6. ANOVA results of Profile B data sets in each scenario of variability between methods 
of estimation (MSN, NS, S and SC). Sig means statistical differences and NS no statistical 
differences were observed. 
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PROFILE C 
 
SINK NON SINK 
H IIV  
H RSV 
H IIV  
L RSV 
L IIV  
H RSV 
L IIV   
L RSV 
H IIV  
H RSV 
H IIV  
L RSV 
L IIV  
H RSV 
L IIV   
L RSV 
MNS MNS MNS MNS MNS MNS MNS MNS 
NS Sig Sig Sig Sig Sig Sig Sig Sig 
S NS S NS Sig Sig Sig Sig Sig 
SC NS NS NS Sig Sig Sig Sig Sig 
Table 7. ANOVA results of Profile C data sets in each scenario of variability between methods 
of estimation (MSN, NS, S and SC). Sig means statistical differences and NS no statistical 
differences were observed. 
 
Model comparison 
Permeability estimation 
Results of the classification from 108 scenarios with each 
method of estimation are summarized in Table 8. (Chi-square results 
are in Tables 1 to 3 in supporting information file).  
Results were classified in OK, ERROR or VARIABILITY.  
Considering the meaning of these labels (as the examples presented in 
Table 3) the objective would be finding which method is able to obtain 
the higher number of OK results, the lower number of ERROR labels 
and it is not biased by the variability of the experiment.  After 
performing the chi-square test, the number of occasions that the MNS 
method produced better results than the others was computed and 
these results are displayed in Table 8. For instance, MNS estimation 
method obtained a statistically higher number of OK results in 59 
scenarios compared with NS method, the same number in 12 and less 
OK results than NS in 37 scenarios (108 total scenarios). Regarding the 
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ERROR results, MNS method produced less times ERROR results in 
75 scenarios compared with NS method, the same number in 12 
scenarios and more ERROR results in 21 scenarios. In VARIABILITY 
results, MNS method led to a higher number of VARIABILITY results 
compared with NS in 40 scenarios, a similar number in 49 scenarios and 
less number of VARIABILITY results in 19 scenarios. 
 OK ERROR VARIABILITY 
 NS S SC NS S SC NS S SC 
BETTER 59 83 24 75 90 44 40 42 4 
SIMILAR 12 25 82 12 15 62 49 66 104 
WORSE 37 0 2 21 3 2 19 0 0 
Table 8. Comparison of statistically significant differences between MNS and NS, MNS and S 
and MNS versus SC. In the Columns OK and VARIABILITY, BETTER is considered when 
the number of results, either OK or VARIABILITY was significantly higher in MNS than the 
other methods; SIMILAR is when the differences were not significant; WORSE when the 
number of results (OK or VARIABILITY) was significantly lower in MNS than the other 
methods. In the Column ERROR, BETTER corresponds to a significant lower number of 
ERROR results, SIMILAR means a non-significant difference and WORSE implies a 
significantly higher number of ERROR results. 
 
DISCUSSION 
Drugs for oral administration and CNS drugs are two 
therapeutic groups which need to cross biological barriers; in 
consequence, to increase the success rate during development a good 
preclinical screening system of the membrane permeability of the 
candidates is essential.  
The in vitro permeability studies are a fundamental tool in the 
preclinical development of new drugs [28, 47-51]. Permeability is the 
ability of a molecule to cross biological barriers and several cell 
monolayers are used in the in vitro permeation studies [49, 52-54]. On 
top of that, an accurate estimation of permeability is relevant for correct 
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classification and selection of optimal candidates for further preclinical 
and clinical evaluation. For this reason, in this work we have evaluated 
the standard procedures for permeability estimation from experimental 
data and we have compared them with a modified equation in order to 
accommodate all the experimental profiles that are usually obtained in 
these in vitro permeability experiments. 
 
Model Performance with Simulated data 
As published by Tavelin et al. [28] the profiles of accumulated 
amount of drug versus time are not always perfectly linear but might 
have initial atypical behaviors (called Profile A and C). Figures 1 shows 
the prediction of MNS and NS methods for a simulated database in 
different initial conditions of permeation and different scenarios of 
variability, both in low permeability (sink) and high permeability (non-
sink) conditions. When there is no alteration in the initial permeation of 
the drug across the cell monolayer, NS and MNS predicted equally well 
the simulated concentrations in the receiver chamber. But if there is any 
initial alteration (Profile A and C), only MNS is able to estimate 
accurately the “true” permeability due its ability to discriminate the 
initial permeability until the first sampling interval (Peff 0) and the final 
(or “true”) permeability (Peff 1), i.e. this method takes into account the 
behavior in the initial phase and it avoids that this initial alteration 
affects the estimation of the permeability. Therefore, NS method 
underestimates in Profile A and overestimates in Profile C the 
permeability value in all scenarios of variability and sink and non-sink 
conditions.  
When comparing the results of the estimation errors (Figure 3-
5), no significant differences are observed between the behavior of the 
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mean, intra-assay and individual estimation errors. In all the profiles (A, 
B and C), under sink conditions linear regression models (S and SC) 
achieved similar estimation errors compared with MNS method. These 
results are expected because the linear sink and sink corrected models 
allow the intercept of the regression to be different from 0. However, 
when conditions are non-sink and linearity is affected, S and SC 
underestimate in Profile A and overestimate in Profile C across all 
variability scenarios.  
On the other hand, NS method produces estimation errors 
different from 0 when the initial permeation across the monolayer is 
affected (in all scenarios of variability) and under sink and non-sink 
conditions (Figures 3-5). The single permeability parameter in the 
equation is not able to satisfy, by nonlinear regression, all experimental 
concentrations in the receiver chamber. However, when there is no 
alteration in the initial phase (Figure 2) NS method is able to predict an 
accurate permeability value under sink and non-sink conditions in all 
scenarios of variability.  
NS presents statistically significant differences in average 
estimation error compared to MNS, under sink and non-sink, in the 
Profile A and C in all variability scenarios proposed. Therefore NS 
method underestimates or overestimates statistically the permeability. 
There were no significant differences in Profile B between NS and MNS 
method.  
Linear regression models (S and SC) showed statistically 
significant differences when non-sink conditions existed in each of the 
profiles and scenarios of variability proposed. In some cases, under sink 
conditions, significant differences were observed between S and SC and 
MNS, usually when IIV and RSV variability was low. This could be 
Chapter 4 
 
 
197 
 
explained because as the variance of the mean estimation errors is small, 
small differences in the mean error between methods could be 
significant in Scheffe test. 
Therefore, these differences observed in Figures 3 to 6 and the 
statistical differences in estimation errors evidenced in the ANOVA 
(Tables 5-7) demonstrated that linear regression models are not valid at 
any level of variability under non-sink, and even in scenarios with low 
variability under sink conditions. Likewise, NS method is not useful for 
calculating the permeability when there is an alteration of the 
permeation through the cell monolayer in the initial stages in all 
scenarios of variability and under sink and non-sink conditions. 
 
Model validation with experimental data 
As it can be observed in Figure 2  and Table 4 MNS method 
provided a better fit  with atypical values (Metoprolol and Verapamil) 
under non sink conditions and as well under sink conditions 
(Zidovudine and Norfloxacin). In other words the more complex model 
offers a statistically significant better fit when in those cases with an 
apparent lag time for permeation or a higher transport in the earlier 
times either in sink and non-sink conditions. In profiles without these 
problems non sink equation performs well and it is not necessary to 
include a new parameter to describe the data. 
 
Model Comparison 
The importance of a correct estimation of the permeability of 
new drugs in development lies in an efficient selection of the candidates 
to ensure a greater chance of reaching the market. This fact is, in 
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particular, relevant when the classification of the candidate by 
comparison with a reference could be biased if the estimation is not 
accurate. 
The designed scenarios to perform the simulations are focused 
on a borderline situation for classification as high permeability 
compound (in BCS framework) that is test and reference permeability 
values very similar. This particular case was selected because, obviously, 
when the classification is clear, or in other words, with a test 
permeability value much higher or lower than the reference one, the 
bias due to the estimation method could be neglected, as it could affect 
test or reference in a different magnitude but it would never mask the 
existing differences. Thus, actually a biased permeability estimates 
would not affect the comparison. The problem of the estimation 
method could arise when the candidate compound is near the cutoff 
value. In this situation, a bioequivalence-like approach could be useful 
to ensure the statistical significance of the test-reference difference but 
it should not be forgotten that if the average value for 90% confidence 
interval construction is biased the comparison would be also erroneous.  
The main objective in this section is to compare the number of 
satisfactory estimation results i.e. correct classification (OK and 
VARIABILITY) (given a particular scenario) produced by each 
estimation method. Results summarized in Table 7 demonstrated that 
the MNS method would conclude a correct classification in more 
potential scenarios even when the designed scenarios were borderline 
situations. Given a theoretical difference of 20% in test and reference 
compound, when the experimental variability is added to the system, 
the MNS equation led to a correct rank order, matching the “true” 
parameters in a higher number of occasions, including those with 
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“atypical” profiles of cumulative amounts versus time. It is important 
to point out that the so called atypical profiles are actually not unusual 
but often neglected and then, the standard calculation methods are used 
without considering their influence in the estimation error.  In the 
present simulation it is demonstrated that when these profiles arise the 
new Modified Non Sink equation gives the most accurate estimate. 
Therefore, the main conclusion of this section is that the MNS method 
is able to correctly estimate the permeability in a larger number of cases 
compared to the proposed models and it has fewer errors in the 
classification of the compound. This is essential for a more efficient 
candidate selection. 
Regarding of the limitation of the present approach it is 
necessary to point out the three tested models (Sink, Non-sink and 
MNS) include the assumption that permeability is equal in both 
directions and, thus, they would predict equal concentration in apical 
and basolateral compartments at equilibrium. However, oftentimes this 
assumption does not hold. For instance, active transport and pH 
gradient for ionizable compounds, lead to direction dependent 
permeability. Even in these cases the new MNS model would capture 
the loss of sink condition or would describe the altered initial rate.  
In order to accommodate for non-equal concentration in both 
chambers at equilibrium and then estimate in a single step the different 
apical to basal and basal to apical permeability a differential equation 
model have to be used as it has been already proposed [55, 56]. On the 
other hand the simplest approach to detect direction dependent 
phenomena is to estimate the unidirectional permeability and evaluate 
the basal to apical and apical to basal ratios. The new proposed method 
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is intended for this purpose and has demonstrated its better 
performance. 
 
CONCLUSION 
Modified Non Sink equation (Mangas-Casabó method) is a 
precise and accurate equation for calculating the apparent unidirectional 
permeability in any type of profile and under different scenarios of 
variability, as well as sink and non-sink conditions, while the NS method 
fails in obtaining good permeability estimates in those situations in 
which the initial permeation rate is altered.  
Linear regression models (S and SC), are not valid under strong 
non-sink conditions as expected as the underlying assumptions (sink 
conditions) do not hold but also in situations in which sink conditions 
are fulfilled but the system variability is high.  
MSN method would be the recommended one as it 
accommodates not only sink and non-sink conditions but also all type 
of profiles with altered initial rates. Sink corrected could be a good 
approximation (in slightly non sink conditions) even better than Non 
Sink method because NS does not fit well the atypical profiles. 
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INTRODUCTION 
In vitro models with high predictive ability have been revealed as 
strong tools for pharmaceutical industry. The use of validated in vitro 
models also means lower development cost and less time-consuming 
processes. Moreover, the use of a good predictive model in the early 
phases of drug discovery could prevent sub-optimal drug candidates 
from reaching clinical development with the associated waste of time, 
resources and money. Current in vitro models for the predictions of drug 
transport across biological membranes include cell cultures that 
reproduce physiological characteristics of different barriers, such as the 
intestine, the blood-brain barrier or the kidney and liver. However, it 
has been reported that in vitro models have some limitations. For 
instance, the variability in permeability estimations complicates the 
comparison and combination of data from different laboratories and it 
makes necessary the careful validation of the model and the continuous 
suitability demonstration.  Permeability values and their associated 
variability from cell culture transport experiments is influenced by 
several factors that can be classified in three groups, pre-experimental, 
experimental and post-experimental factors. The adequate 
standardization of these factors can help to reduce the inter- and intra-
laboratory variability in permeability values.  
Among the pre-experimental factors the most relevant are the 
cell type and source and passage number which could affect the 
monolayer differentiation, membrane composition, transporter 
expression and tight junction resistance (1-2). In fact, some research 
works describe differences in cell shape and size, multilayer formation 
and actin staining between the same cell sources (3). Several cellular 
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lines have been traditionally used in order to determine the in vitro 
permeability values. Caco-2, MDCK or MDCK-MDR1 cell lines are the 
most commonly used for this purpose. Caco-2 cells are the most widely 
used model for estimation of drug intestinal permeability despite its 
colonic origin (4-5). On the other hand MDCK epithelial cells despite 
of its non-human and non-intestinal origin have demonstrated a good 
correlation with Caco-2 cells results and good predictive performance 
of human oral fraction absorbed (6-7). MDCK-Mdr1 cells correspond 
to the P-gp transfected clone from MDCK and are used for the study 
of P-gp substrates (8-9). MDCK and MDCK-Mdr1 lines with low 
values of trans-epithelial resistance (TEER) are used also as blood brain 
barrier model (10-12). These three cell lines have been included in this 
study as the most representative barrier models to compare its intrinsic 
variability when used with the same protocol. The culture conditions, 
such as the components of the culture medium or the cell density, the 
pH or the temperature also affect the final characteristics of the 
monolayer (13-14). Subculture details such as the frequency of culture 
media renewal affect the expression of several enzymes and the kinetic 
parameters of the transport substrates (15-16).  
Regarding the passage number, many researchers have 
demonstrated that changes in TEER, cell growth, mannitol flux and 
active transport are observed with passage number (17-19). However, 
there is no consensus regarding the optimal interval of passages for 
conducting assays in order to obtain adequate and reproducible 
permeability values.  
The experimental factors can also affect the monolayer 
absorption and metabolic properties. The literature describe parameters 
involved in monolayer permeability such as media composition and pH 
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of both chambers, seeding density, system shaking, plastic support 
material type, solute concentration, temperature, etc. which also affect 
the barrier properties (integrity, permeability and transporter 
expression) and the thickness of the unstirred water layer (2-20). 
Differentiation period after confluence is a crucial parameter in order 
to obtain reproducible results as the cells suffer important changes in 
morphology, barrier properties and expression of transporters with time 
(17-19-21-22). With increasing age, changes in cell height and shape, cell 
junction formation, TEER values, metabolic activity, P-gp, MRP2, 
OATB OCTN2 and PePT1 transporters expression and brush border 
microvilli were observed (23). The challenge is to determine the 
optimum culture period for performing transport assays. Moreover, 
features such as the sampling schedule (only acceptor chamber or both, 
number of samples, media replacement), the maintenance or not of sink 
conditions are determinant of the calculation method and thus influence 
the permeability estimate obtained.   
Among the post experimental factors, the variability associated 
with the analytical method is an important aspect to take into account 
as well as the estimation method (and its underlying mathematical 
assumptions) that it is an aspect often neglected (24).  
The objective of this paper is the evaluation of the effect of 
passage number, experimental protocol, maturation time after seeding 
and calculation method on the permeability values and their associated 
variability in cell culture transport experiments conducted in our 
laboratory using three cell lines, Caco-2, MDCK and MDCK-Mdr1. 
The final goal is to select the best experimental conditions for further 
method validation and to determine the sample size for detecting a 
given difference in permeability values. Three compound markers of 
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transcellular permeability (Metoprolol), paracellular permeability 
(Lucifer Yellow) and P-gp functionality (Rhodamine-123) were used to 
check the performance of the cell lines and their ability to reach pre-
established specifications. 
 
MATERIALS AND METHODS 
Compounds assayed and cell lines 
Metoprolol, Rhodamine and Lucifer Yellow were purchased 
from Sigma (Barcelona, Spain. Compounds transport was studied at 100 
µM for Metoprolol, at 5.5 µM for Rhodamine and at 2 mM for Lucifer 
Yellow. 
Samples were analyzed by HPLC using a 5 μm, 3.9 x 150 mm 
Novapack C18 column.  
Metoprolol samples were analyzed with fluorescence detection 
(λexcitation=231 nm and λemission=307 nm). The mobile phase was 
60:20:20, water: methanol: acetonitrile, with a flow rate of 1 mL/min 
and the injected volume was 20 μL. In these conditions, the retention 
time of Metoprolol was around 2.5 min. Rhodamine samples were 
analyzed with fluorescence detection (λexcitation=485 nm and 
λemission=546 nm). The mobile phase was 60:40, water: acetonitrile, 
with a flow rate of 1 mL/min and the injected volume was 20 μL. In 
these conditions, the retention time of Rhodamine was around 4.5 min. 
Lucifer Yellow samples were analyzed with fluorescence detection 
(λexcitation=430 nm and λemission=530 nm). The mobile phase was 
80:20, water: acetonitrile, with a flow rate of 1 mL/min and the injected 
volume was 20 μL. In these conditions, the retention time of Lucifer 
Yellow was around 3 min. 
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Caco-2 cell lines were provided by Dr. Hu (Washington State 
University, Pullman). MDCK and MDCK-MDR1 cell lines were 
provided by Dr. Gottesman, MM. (National Institutes of Health, 
Bethesda). 
 
Cell culture and transport studies  
Pre-experimental factors:  
Passage number  
The passage numbers used were between 10 to 80 post 
defrosting cell lines. Cell monolayers were grown in Dulbecco’s 
modified Eagle’s media as described previously (Hu M et al. 1994; Hu 
M et al. 1994). Cell cultures were maintained at 37ºC under 90% 
humidity and 5% CO2.  
SOPs 
Two different experimental protocols have been used to grow 
the cells and perform the experiments. Protocols for transport 
experiment differ mainly in the filter support coating and the medium 
and plastic ware brands and in the batch homogenization of some 
medium components (as the serum growth factor). Both protocols used 
tissue culture flasks 25 cm2 (T-25) or 75 cm2 (T-75) (Falcon, Beckton 
Dickinson). DMEM (Dulbecco’s Modified Eagle’s Medium With 4500 
mg/L glucose, L-glutamine sodium bicarbonate, without sodium 
pyruvate from Sigma D5796) (89%) was adding by Gentamicin G1272 
from Sigma (0.25%), MEM Non-Essential Aminoacid from Gibco 
11140-035 (1%), Foetal Bovine Serum F7524 from Sigma (10%) and 
HEPES 1M 15630-056 by Gibco.  
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Solutions for cell trypsinization were done with PBS-CMF 
(Phosphate-buffered saline PBS, Calcium and Magnesium Free from 
Gibco 10010-015, 12 ml during 10 minutes and 0.25% Trypsin, 1mM 
EDTA.4Na in HBSS-CMF (2.5 g/L trypsin; 0.38 g/L EDTA.4Na) 
from Gibco 25200-056. 
In the first protocol cells grew in a collagen coated 
polycarbonate membrane (Costar inserts, surface area 0.9 cm2, 0.4 µm 
pore size) (SOP 1) and, in the second one cells grew in a polycarbonate 
membrane without collagen coated. (MILLICEL-PCF, surface area 0.9 
cm2, 0.4 µm pore size) (SOP 2). 
Experimental factors:   
Days between seeding  
Experiments in Caco-2 cell monolayers were developed at 4, 15 
or 21 days and in MDCK /MDCK-MDR1 at 4 or 9 days. 
Experiment 
All experimental conditions below explained were the same for 
all experiments. The integrity of each cell monolayer was checked by 
measuring its transepithelial electrical resistance (TEER) value before 
an experiment.  Normal TEER values were typically 250 Ω·cm2 for 
Caco-2 cells (21) and 190 Ω·cm2 for MDCK or MDCK-MDR1 (25). 
Cell monolayers with TEER values less than 180 Ω·cm2 or 150 Ω·cm2 
respectively were not used. Hank’s balanced salt solution (HBSS) (9.8 
g/L) supplemented with NaHCO3 (0.37 g/L), HEPES (5.96 g/L) and 
glucose (3.5 g/L) 14025-050 form Gibco was used for all the 
experiments after adjusting pH to the desired value in both protocols 
(26-27). 
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Transport studies were conducted in an orbital environmental 
shaker at constant temperature (37ºC) and agitation rate (100 rpm). 
Four samples of 200 µL each one were taken, and replaced with fresh 
buffer, from the receiver side at 30, 60, 90 and 120 minutes. Samples of 
the donor side were taken at the beginning and the end of the 
experiment. Moreover, the amount of compound in cell membranes 
and inside the cells was determined at the end of experiments in order 
to check the mass balance. The percentage of compound retained in the 
cell compartment was always less than 5%. 
Transport studies were performed in both directions, from 
apical-to-basal (A-to-B) and from basal-to-apical (B-to-A) sides. The 
volume of donor compartment was 0.5 mL in A-to-B direction and 1.2 
mL in B-to-A direction.  
Post-experimental factor 
Data analysis 
The permeability was calculated from the drug concentrations 
and accumulated amounts in acceptor chamber using either linear or 
nonlinear regression models, depending of the assumption about sink 
conditions on the receptor side (28). The permeability calculation can 
be done according Sink (S) equation, Sink Corrected (SC) equation, 
Non-sink (NS) equation, Modified Non-Sink (MNS) equation (a 
recently developed modification of the non-sink analysis to 
accommodate lag times and higher permeability in the initial times). 
 
Sink (S) equation 
Permeability values in sink conditions are estimated from the 
first Fick’s law equation under the assumption of sink condition (i.e. 
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negligible drug concentration in acceptor versus donor or in 
mathematical terms acceptor concentration<10% of donor 
concentration), no change of drug donor concentration during the assay 
and under a linear approximation of the appearance rates. 
𝑃𝑒𝑓𝑓 = (
𝑑𝑄
𝑑𝑡⁄ )/𝑆 · 𝐶0      (1) 
where dQ/dt is the apparent appearance rate of drug in the receiver 
side, calculated using linear regression of amounts in the receiver 
chamber versus time, S is the surface area of the monolayer C0 is the 
drug concentration in the donor chamber and Peff is the permeability 
value. When the transport rate is low, neither the donor nor the receiver 
concentrations will change significantly with time, and sink conditions 
are assumed as a reasonable approximation.  
 
Sink Corrected (SC) equation 
Artursson et al. proposed a modified equation, in order to avoid 
the limitations of classical equation of sink conditions because even 
under sink conditions the change in donor concentration affects to the 
driving force and may not be negligible. In this new equation the 
concentration in the donor chamber changes in each sample interval 
(28).  
𝑃𝑒𝑓𝑓 = (
𝑑𝑄
𝑑𝑡⁄ )/𝑆 · 𝐶𝐷      (2) 
where CD is the concentration in the donor chamber at each 
sample interval. 
 
Non-sink (NS) equation 
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Under non sink conditions, the apparent permeability 
coefficient is calculated according the following equation: 
𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟,𝑡 =
𝑄𝑡𝑜𝑡𝑎𝑙
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟+𝑉𝑑𝑜𝑛𝑜𝑟
+ ((𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟,𝑡−1 · 𝑓) −
𝑄𝑡𝑜𝑡𝑎𝑙
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟+𝑉𝑑𝑜𝑛𝑜𝑟
) ·
𝑒
−𝑃𝑒𝑓𝑓·𝑆·(
1
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟
+
1
𝑉𝑑𝑜𝑛𝑜𝑟
)·∆𝑡
     (3) 
where Creceiver,t is the drug concentration in the receiver chamber 
at time t, Qtotal is the total amount of drug in both chambers, Vreceiver and 
Vdonor are the volumes of each chamber, Creceiver,t−1 is the drug 
concentration in receiver chamber at previous time, f is the sample 
replacement dilution factor, S is the surface area of the monolayer, Δt is 
the time interval and Peff is the permeability coefficient. This equation 
considers a continuous change of the donor and receiver 
concentrations, and it is valid in either sink or non-sink conditions.  
 
Modified Non-Sink (MNS) equation 
𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟,𝑡 =
𝑄𝑡𝑜𝑡𝑎𝑙
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟+𝑉𝑑𝑜𝑛𝑜𝑟
+ ((𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟,𝑡−1 · 𝑓) −
𝑄𝑡𝑜𝑡𝑎𝑙
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟+𝑉𝑑𝑜𝑛𝑜𝑟
) ·
𝑒
−𝑷𝒆𝒇𝒇 𝟎,𝟏·𝑆·(
1
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟
+
1
𝑉𝑑𝑜𝑛𝑜𝑟
)·∆𝑡
      (4) 
All the terms are defined in the previous equation and Peff is 
the permeability coefficient, which might be Peff 0 or Peff 1. This 
equation, as equation 3 considers a continuous change of the donor and 
receiver concentrations, and it is valid in either sink or non-sink 
conditions. The new feature is the option to estimate two permeability 
coefficients (Peff 0 and Peff 1) to account for atypical profiles in which 
the initial rate is different (24).   
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The non-linear regressions to fit equation 3 (NS) and 4 (MNS) 
to data can be performed in Excel using Solver tool for minimization 
of the Sum of Squared Residuals. Equation 1 (S) and equation 2 (SC) 
are linear regression models that can be also executed in Excel.  
Studies were performed by triplicate and the data were 
presented as mean ± standard deviation (SD). ANOVA and Scheffe 
post hoc tests and Student’s t-test were performed with PASW Statistics 
17 (SPSS Inc.) in order to determine statistically significant differences 
between A-to-B and B-to-A permeability values, as well as the influence 
of factors than can affect permeability values.   
Akaike criterion (AIC), weighted sum of squared residuals 
(SSR), were used to evaluate the goodness of fit and to select the best 
data analysis. The improvement of the sum of squared residuals value 
by a more complex model was statistically assessed with a Snedecor’s F 
test. The more complex model was accepted at a significance value 
p<0.05. 
 
RESULTS 
Post-experimental factors 
Data analysis 
The selection of the best permeability estimation model is 
required in order to obtain less biased values ant to compare 
experimental conditions and protocols. Table 1 summarizes the analysis 
of the modelling strategies for permeability estimation. In the first place 
it was determined if sink conditions prevailed or not in each well before 
selecting the equation to estimate the permeability. In “sink conditions” 
wells the linear approximations were used and the best fit models were 
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selected. In non-sink conditions, non-sink equation and the modified 
non sink equation were used. Table 1 reflects the percentage of wells 
accomplishing sink or not sink conditions and the best fit model for 
each situation. 
Table 5. Comparison of models for permeability estimation under sink and non-sink conditions. 
*Model comparison by AIC value. **Models compared by Snedecor’s F test over the sum of 
squared residuals corrected by the degrees of freedom. 
Conditions prevailing in the 
experiment 
Best fit model 
Sink (47% of wells) * 
Sink Model  0 % 
Sink corrected model 100% 
Non-Sink (53 % of wells)** 
Non sink 12% 
Modified Non sink 88% 
 
Consequently the permeability estimation was performed with 
Sink corrected approach when sink conditions prevailed and Modified 
non-sink model in all the non-sink conditions. 
 
Pre-experimental factors 
Passage number 
Figures 1 and 3 represent permeability values of Metoprolol 
obtained at different passage number after thawing the three cell lines 
Caco-2, MDCK and MDCK-MDR1 using both protocols (SOP). 
Figure 2 and 4 represent the variability (expressed as coefficient of 
variation) in each passage number and cell line. In this set of 
experiments SOP 1 experiments were performed 21 days after seeding 
while SOP 2 maturation time after seeding was 15 days. 
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Figure 1. Permeability values of Metoprolol (100 µM) obtained at different passage number 
after thawing process in 3 cell lines. (SOP1) 
 
Figure 2. Variability in the estimation of permeability values obtained with SOP 1, expressed as 
coefficient of variation in both directions and in the three cell lines  
 
Chapter 5 
 
 
223 
 
 
Figure 3. Permeability values of Metoprolol (100 µM) obtained at different passage number 
after defrost process in 3 cell lines. (SOP2) 
 
 
Figure 4. Variability in the estimation of permeability values obtained with SOP 2, expressed as 
coefficient of variation in both directions and in the three cell lines  
 
In SOP 1 the one-way analysis of variance detected differences 
in permeability values with passage number only in Caco-2 cells. Post 
hoc Scheffe test concluded statistical significant differences among all 
passages versus passage 10 in Caco-2 cells (in AB and BA directions). 
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No differences in permeability values with passage number were 
detected in MDCK and MDR cell lines 
In SOP 2 the one-way analysis of variance detected differences 
in permeability values in each direction with passage number in the 
three cell lines. Post hoc Scheffe test concluded statistical significant 
differences among all passages versus passage 10 in MDR cells (in AB 
and BA directions). Differences are detected (with passage 10) after 
passage 60 in MDCK and after passage 20 in Caco-2 cells (in both 
directions).  
Protocol (SOP) 
Both SOPs were compared in 3 cell lines and using early (10 
passages after defrost), intermediate (40 passages after defrost) or late 
(80 passages after defrosting) passages. Permeability values of typical 
marker compounds as LY (paracellular marker), Metoprolol 
(transcellular marker) and Rhodamine 123 (secretion marker due to P-
pg) were investigated. Results are summarized in Figures 5 to 7. The 
coefficients of variation of permeability values of each compound in 
each cell line and protocol are represented in Tables 2 to 4. 
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Figure 5. Permeability values of LY (2mM) obtained with both harvesting protocols (SOPs) at 
different passage number after defrosting process in 3 cell lines. 
 
Table 2. Variability in Lucifer Yellow permeability values in both protocols, in different passage 
numbers and cell lines. 
Lucifer 
Yellow 
Passage CV% SOP1 CV% SOP2 
Caco2 Early 7.3 3.0 
Caco2 Intermediate 11.8 90.8 
Caco2 Late 5.1 23.2 
MDCK Early 15.6 15.2 
MDCK Intermediate 10.3 9.7 
MDCK Late 4.8 18.7 
MDR Early 7.1 9.6 
MDR Intermediate 2.8 38.3 
MDR Late 16.1 28.0 
Average  9.0 26.3 
 
Anova analysis and Scheffe post-hoc comparison showed 
differences in both SOP’s in LY permeability values among all passages 
(in both directions). 
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Figure 6. Permeability values of Metoprolol (100 µM) obtained with both harvesting protocols 
(SOPs) at different passage number after defrosting process in 3 cell lines. 
 
Table 3. Variability in Metoprolol permeability values in both protocols, in different passage 
numbers and cell lines. 
Metoprolol Passage CV% SOP1 CV% SOP2 
Caco2 Early 4.1 5.4 
Caco2 Intermediate 8.8 9.4 
Caco2 Late 7.4 4.5 
MDCK Early 8.6 6.6 
MDCK Intermediate 3.5 4.2 
MDCK Late 2.2 8.0 
MDR Early 3.1 6.3 
MDR Intermediate 4.0 17.5 
MDR Late 2.5 7.1 
Average  4.9 7.7 
 
Anova analysis and Scheffe post-hoc comparison showed 
differences in both SOP’s in Metoprolol permeability values in early 
passage compared with late (in both directions and all cell lines) 
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Figure 7. Permeability values of Rhodamine (5.5 µM) obtained with both harvesting protocols 
(SOPs) at different passage number after defrosting process in 3 cell lines. 
 
Table 4.  Variability in Rhodamine permeability values in both protocols, in different passage 
numbers and cell lines 
Rhodamine Passage CV% SOP1 CV% SOP2 
Caco2 Early 4.6 6.2 
Caco2 Intermediate 36.5 5.7 
Caco2 Late 145.7 27.2 
MDCK Early 4.0 16.5 
MDCK Intermediate 5.5 4.9 
MDCK Late 47.1 7.6 
MDR Early 29.0 7.5 
MDR Intermediate 8.4 4.0 
MDR Late 2.3 0.5 
Average  31.5 8.9 
 
Anova analysis and Scheffe post-hoc comparison showed 
differences in both SOP’s in Rhodamine permeability values in early 
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passage compared with late in BA direction in MDCK and MDR but 
not in Caco-2 cells.  
 
Experimental factors 
Days between seeding and experiment 
One of the factors affecting permeability values is the time 
between seeding cells and performing the experiment as it could affect 
to the transporter expression and cell maturation. The usual maturation 
time depends on the kind of cells and it used to be from 4 to 21 days in 
Caco2 cell line and from 4 to 9 in MDCK and MDR1. Our aim was to 
confirm the influence of the maturation time in SOP1 in order to select 
the best option for further experiments. For this reason, transport 
experiments were performed at different time post seeding according 
to the cell line assayed. For Metoprolol and Lucifer Yellow an 
intermediate passage number was used while for Rhodamine it has also 
been checked the relevance of the passage number as from the previous 
experiments it was shown that for a carrier mediated compound the 
influence of the passage number was a relevant factor on the transporter 
expression. 
Figures 8, 9 and 10 show the permeability values of Lucifer 
Yellow, Metoprolol and Rhodamine respectively obtained at different 
times post seeding and passages in the three cell lines. 
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Figure 8. Permeability values of LY (2mM) obtained at different times post seeding and passages 
in the three cell lines.  
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Figure 9. Permeability values of Metoprolol (100 µM) obtained at different times post seeding 
and passages in the three cell lines.  
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Figure 10. Permeability values of Rhodamine (5.5 µM) obtained at different times post seeding 
and passages in the three cell lines.  
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The two-way analysis of variance and scheffe post hoc analysis 
demonstrated statistical significant differences in permeability values 
with the time after seeding in the three cell lines and for all the 
compounds.  
Tables 5 to 7 summarized the average coefficient of variation in 
AB and BA permeability values in the different conditions (passage and 
time after seeding) for all cell lines and compounds. 
Table 5. Variability in permeability values of Rhodamine obtained in different cell lines and 
passages with different maturation days after seeding. 
Rhodamine       
Line Passage Days Mean CV% 
Caco2 Early 4 7.1 
    15 3.5 
    21 5.0 
  Intermediate 4 10.4 
    15 11.6 
    21 4.9 
  Late 4 46.6 
    15 9.7 
    21 6.4 
MDCK Early 4 5.9 
    9 4.9 
  Intermediate 4 4.0 
    9 21.6 
  Late 4 3.7 
    9 21.2 
MDR Early 4 21.2 
    9 15.5 
  Intermediate 4 2.4 
    9 2.6 
  Late 4 3.6 
    9 149.5 
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Table 6. Variability in permeability values of Lucifer Yellow obtained in different cell lines and 
passages with different maturation days after seeding 
Lucifer Yellow   
Line Days Mean CV% 
Caco 2 4 5.1 
  15 7.0 
  21 11.8 
MDCK 4 5.8 
  9 10.3 
MDR 4 7.3 
  9 6.2 
 
Table 7. Variability in permeability values of Metoprolol obtained in different cell lines and 
passages with different maturation days after seeding 
Metoprolol     
Line Days Mean CV% 
Caco 2 4 3.8 
  15 8.4 
  21 8.5 
MDCK 4 3.6 
  9 3.0 
MDR 4 1.4 
  9 3.0 
 
DISCUSSION 
Pre-experimental factors 
Passage number 
The effect of passage number was studies in both protocols with 
Metoprolol. The effect of passage number was different in SOP 1 
versus SOP 2. In SOP 1 with Caco-2 cells after passage 10 the 
permeability values decreased and remained fairly constant in the 
subsequent passages. In MDCK and MDR1 passage number does not 
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seem to affect to the permeability values at least in the range of passages 
assayed (Figure 1). 
In SOP 2 on the contrary the passage number had a marked 
effect on Metoprolol permeability in particular in Caco-2 cells where 
there is a trend with higher permeability values of Metoprolol with 
higher passages (Figure 2). This result is in contradiction with other 
studies in which lower permeability values are found with higher 
passages due to tighter paracellular space [88]. In order to explain these 
differences further experiments with Lucifer Yellow and Rhodamine 
were performed to compare both protocols. (See next section) 
On the other hand the variability in permeability estimation 
showed a trend to decrease in MDCK and Caco-2 cells with SOP1 but 
a tendency to increase in SOP 2. MDCK-Mdr1 showed the lower 
variability in both protocols (ranged between 5 and 7% as average 
values), without any relevant change with passage number. 
Considering these results, SOP 1 at intermediate passage 
number seems to be the best experimental conditions to compare drugs 
absorbed by passive diffusion by transcellular route. 
Protocol 
Coating with collagen is the main difference between both 
protocols and it has been show that rat collagen type I coating leads to 
a quicker confluence and higher cell density in caco-2 cells compared 
with filters without coating. Collagen coating also affect to transport 
expression and enzyme activity (2).  
A more detailed comparison between protocols was done using 
three model compounds to check changes in paracellular, transcellular 
and P-gp expression. With SOP 1 as well as SOP 2 Lucifer Yellow 
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permeability decreased with higher passages in all cell lines, but 
Metoprolol permeability values decreased with higher passages in SOP 
1 but increased in SOP 2 in Caco- 2 cells. These differences were lower 
in MDCK and MDR lines. For both compounds variability in average 
CV was lower for SOP 1 (see Tables 2 and 3). It seems that with both 
protocols in all cell lines the paracellular route becomes more restricted 
with higher passage numbers. The increase in Metoprolol permeability 
in SOP 2 with higher passage numbers is difficult to explain but it 
reflects a loss of the trans-cellular barrier properties with higher 
passages.  
These results confirm the conclusion of the previous 
experiments, indicating that coating in SOP 1 helps to cell 
differentiation in a more stable manner compared to SOP 2 which 
showed permeability changes with passage and also more variable 
values 
Regarding Rhodamine permeability, it was not affected by 
passage number in Caco-2 cells with any of the protocols, but variability 
increased with higher passage numbers. This result is in contradiction 
with the observed by Siisalo et al. (29) who observe a clear effect of 
passage number in P-gp and other transporters expression in Caco-2 
cell. In accordance with Siisalo et al in MDCK and MDR P-gp 
functionality is increased at higher passage numbers in both protocols. 
In this compound variability is lower with SOP 2. 
The differences in SOP 1 and 2 regarding the effect of passage 
number on the different permeation routes show the complexity of the 
involved mechanisms. For P-gp interaction studies in this case would 
be more convenient SOP 2 at intermediate or late passage numbers.  
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Experimental factors 
Days between seeding and experiment 
The time post seeding had the expected effect in particular in 
Rhodamine permeability for which higher maturation times lead to a 
higher expression of the transporter (see Figure 7). The influence on 
Metoprolol and Lucifer Yellow is less clear and even if statistical 
differences are detected there is not a clear trend neither in permeability 
values nor in variability. These results support the idea of developing 
“fast maturation” models that can be useful for screening compounds 
absorbed by passive mechanism (30). 
 
Post-experimental factors 
Data analysis 
The analysis of permeability data was performed with the four 
possible approximations but the final model was selected based on 
goodness of fit criteria (AIC and Snedecor’s F test). The selection of the 
analysis method is a relevant aspect to reduce inter- and intra-laboratory 
variability as the estimated permeability value can change up to a 100% 
in value with different methods. On the other hand in order to obtain 
the most accurate estimate it is necessary to use a calculation method 
with accurate implicit assumptions. Even when sink conditions prevail, 
the donor concentration changes with time thus sink corrected equation 
gave better fit in 100% of the linear cases. For non-sink conditions the 
percent of wells with some deviation in the first data point (lag time or 
higher permeation rate) is about 30% thus making necessary to include 
a second parameter in the model to account for the deviation and avoid 
Chapter 5 
 
 
237 
 
the bias in slope estimation. Our new approach gave a better fit to 
experimental data in most non-sink wells.  
 
CONCLUSIONS 
The results obtained in this study confirm the complexity of the 
interaction between cell culturing protocols and cell lines and the need 
for standardization and characterization of the culture properties to 
optimize the conditions depending on the study objectives. In our 
study, the average variability observed in permeability values in all cell 
lines is around 10%-15% that means that for detecting a 15% difference 
in permeability values the required number of individual estimations 
would be between 8 and 12, i.e. one plate of 12 wells. The variability is 
lower in intermediate passages in Caco-2 cells supporting the 
recommendation of use a short range of passages to a particular study. 
MDCK was more influenced by the passage number, with less CV in 
lower passages. MDCK-MDR1 showed constant CV among passages, 
protocols and experimental conditions but permeability values were 
affected by all the studied conditions, indicating that for this cell line 
standardization of experimental conditions is in particular relevant to 
obtain comparable results between different laboratories.   
As conclusion, we have confirmed the influence of maturation 
conditions, passage number in permeability values and in their 
variability. Based in our results protocol with coating would be more 
adequate for studies of compounds absorbed by passive diffusion but 
the protocol without coating gave us better results for studies about P-
gp interactions. A similar study should be done in each laboratory to 
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understand the influence of their protocols in the monolayer properties 
in order to standardizing conditions and setting the acceptance criteria. 
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INTRODUCTION 
 The prevalence of central nervous system (CNS) disorders 
worldwide is around 30% and it is estimated that 65% of CNS patients 
do not receive any or correct treatment [1]. For instance, the health 
costs related to stroke, depression, schizophrenia and Alzheimer’s 
disease patients in United States are estimated to be over US$250 
billion. This tendency is expected to raise [2] because most of the CNS 
drugs are used to treat symptoms rather than the etiology [3] and due to 
other factors like ageing society and unhealthy life styles [4]. 
 The drug development process has shown its sub-optimal 
efficiency on the light of the increasing cost and time to reach the 
market and the decreasing number of drugs approved in the last years 
[5]. In the CNS related drugs, the probability of success in obtaining a 
marketing authorization is less than 7% [6] and the time needed, 
considering clinical and regulatory phases, is around 10.5 years, the 
longest compared to other therapeutic areas [7]. Thereby, reliable 
methods for selecting the best candidates in the early preclinical phases 
are urgently needed in order to reduce the risk of costly later failures in 
clinical phases [3, 8]. 
Blood-brain barrier (BBB) controls the access of endogenous 
substances and xenobiotics to the extracellular fluid (ECF) and 
intracellular cerebral fluid (ICF). BBB is an active barrier with important 
functions for brain homeostasis and protection, formed by endothelial 
cells with high expression of tight junctions and transporters. Only the 
unbound fraction of drug in plasma can permeate through the BBB and 
interact with the target in the brain [4, 9-11]. The most important 
parameters that govern the pharmacokinetics of drug in the CNS are fu, 
plasma, Kp,uu, brain and Vu, brain. fu, plasma is the unbound fraction of drug in 
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plasma, Kp,uu, brain represents the ratio between unbound drug 
concentrations in brain and in blood and Vu, brain is the apparent 
distribution volume in brain. ECF concentrations could only be 
obtained using microdialysis. For ethical reasons, human cerebrospinal 
fluid concentrations (CSF) have been used as a surrogate measure of 
the ECF concentrations. De Lange et al. has recently published the 
utility of human Kp,uu, CSF as reference of the ECF concentrations in 
brain [4].  
In silico, in vitro, in situ or in vivo methodologies have been 
employed to evaluate the pharmacokinetic of new drug candidates in 
the CNS [12]. In vitro cell culture experiments are used as a high 
throughput method to select best candidates for further stages of the 
drug development process, however permeability coefficients (Papp) are 
relevant only for the rate of access and the onset of action but do not 
determine the extent as in a steady state drug administration there is not 
a limited time for the permeation process. Consequently the range of 
adequate permeability values for BBB barrier is wider than that used for 
intestinal permeability screening [10, 13]. Different in vitro cell models 
have been used to mimic the blood-brain barrier (BBB) [14-18]. Madin-
Darby canine kidney II (MDCKII) cells and MDCKII transfected with 
the human multidrug resistance gene 1 (encoding P- glycoprotein, P-gp) 
(MDCKII-MDR1) are commonly used to evaluate the blood–brain 
barrier permeability of drugs [16, 19, 20] MDCK I cells show much 
higher transepithelial electric resistance (TEER) than MDCK II cells, 
although they bear similar numbers of tight junction (TJ) strands [21]. 
These cells display morphological, enzymatic, and antigenic cell 
markers, also found in cerebral endothelial cells and have been reported 
as a suitable model for this barrier. The MDCKII-MDR1 cell line was 
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identified as the most promising cell line among several cell lines, for 
qualitative predictions of brain distribution, and to distinguish between 
compounds that pass the blood–brain barrier by passive diffusion and 
those that are substrates for active efflux by P-glycoprotein, P-gp [22-
24]. The P-gp transporter and other membrane transporters belonging 
to the ATP-binding cassette family of transporters have been 
extensively described to regulate intracellular concentrations of 
different compounds [25-27].  
The in vivo microdialysis is the gold standard technique, allowing 
continuous monitoring with high-resolution concentration profiles of 
drugs and metabolites from (freely moving) individual subjects. 
Measurements are obtained from brain extracellular fluid, inserting one 
probe into the brain tissue and from peripheral blood stream. Then, 
unbound brain and plasma concentrations are estimated as the best 
reference to explore drug permeation and distribution across the BBB 
[9, 10, 28-30]. However, the main disadvantage of this technique is the 
high time-consuming, which reduces its application as a high screening 
method for new drug candidates. 
The aim of the present work was to develop a new whole in vitro 
high throughput method to predict drug rate and extent of access across 
the BBB. The system permits using apparent permeability values (Papp) 
from in vitro cell monolayers experiments in different conditions to 
estimate fu, plasma, Vu, brain, and Kpuu, brain.  
In order to explore the feasibility of the in vitro system as a 
screening method for CNS compounds the predicted in vitro values have 
been correlated to in vivo fu, plasma, Kpuu, brain, human Kpuu, CSF and Vu, brain 
values obtained by microdialysis by Friden et al. [31] (Table 1). Cell 
cultures of MDCKII and MDCKII-MDR1 have been used to compare 
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its prediction performance and to determine the transport mechanism 
for each compound tested.  
 
  
 
                      
            RAT HUMAN 
COMPOUND MW (g/mol) log P HBA P-gp CNS Cu (µM) Vu,brain (ml/g brain) fup Kpuu,brain Kpuu,csf 
Amitriptyline 277.39 4.41 1 + + 0.022 310 0.09 0.73 0.18 
Atenolol 266 0.335 5 - - 1.5 2.5 1 0.026 0.54 
Diphenhydramine 291.82 2.997 2 - + 0.051 32 0.48 1.05   
Ethyl-phenyl malonamide 206.24 0.348 4 - + 4.3 0.9 0.55 1.25   
Levofloxacin 361.37 1.855 7 + + 0.59 1.7 0.82 0.12 0.18 
Metoprolol 267.38 1.632 4 - - 0.75 5.5 0.9 0.64 0.93 
Norfloxacin 319.13 1.744 6 + - 0.7 2.9 0.87 0.028 0.11 
Propranolol 259.4 2.9 3 + + 0.051 118 0.09 0.61 0.42 
Verapamil 454.6 3.899 6 + - 0.075 54 0.12 0.053 1.13 
Zidovudine 267.24 0.052 9 - + 1.2 1.1 0.64 0.09 1.04 
 
Table 1. In vivo data for each compound tested.[89] MW means molecular weight, HBA is hydrogen bond acceptor. Cu is the unbound plasma concentration in rat, 
Vu,brain refers to apparent volume of distribution in brain, fu,p is the unbound fraction in plasma, Kp,uu,brain is the unbound relationship between brain and 
plasma in rat and Kp,uu,CSF is the unbound relationship between cerebrospinal fluid in human 
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EXPERIMENTAL SECTION 
Chemicals. Amitriptyline, Atenolol, Diphenhydramine, Ethyl-
Phenyl Malonamide, Levofloxacin, Metoprolol, Norfloxacin, 
Propranolol, Verapamil and Zidovudine were purchased by Sigma 
Aldrich. Sodium azide (Az) as inhibitor was purchased from Sigma 
(Barcelona, Spain). All other reactives were HPLC grade. Experiments 
were conducted in four different concentrations and in the presence of 
sodium azide (1 mM) to detect and eliminate carrier mediated processes 
in order to estimate the passive diffusion component of the transport 
(Table 2). All concentrations were assayed in all types of experiments 
and both cell cultures 
. 
  
 
 
COMPOUND CONCENTRATION (µM) ACID WATER METHANOL ACETONITRILE λ RETENTION TIME (min) DETECTOR 
Amitriptyline 
1500 
40   60 240 1.36 UV 
1000 
500 
100 
100 + 1 mM Azide 
Atenolol 
1000 
90 5 5 
231-
307 
3.51 FLUO 
500 
100 
50 
100 + 1 mM Azide 
Diphenhydramine 
1500 
70   30 245 2.88 UV 
1000 
500 
100 
100 + 1 mM Azide 
Ethyl-phenyl malonamide 
1500 
40 60   205 1.59 UV 1000 
750 
  
 
500 
500 + 1 mM Azide 
Levofloxacin 
1000 
60 40   
282-
450 
1.75 UV 
500 
100 
50 
100 + 1 mM Azide 
Metoprolol 
1000 
60 20 20 
231-
307 
1.38 FLUO 
500 
100 
50 
100 + 1 mM Azide 
Norfloxacin 
1000 
60 20 20 
300-
500 
1.16 FLUO 
500 
100 
50 
100 + 1 mM Azide 
Propranolol 
1000 
50 30 20 
254-
350 
1.6 FLUO 
500 
100 
50 
100 + 1 mM Azide 
  
 
Verapamil 
1000 
62   38 
275-
350 
3.17 FLUO 
500 
100 
50 
100 + 1 mM Azide 
Zidovudine 
1000 
70 30   276 2 UV 
500 
100 
50 
100 + 1 mM Azide 
 
Table 2. Drug concentrations and analytical methods used in HPLC. Acid water was prepared with 0.5 mL Trifuoroacetic acid in 1 L water. Water, Methanol and 
Acetonitrile were purchased by Sigma, HPLC grade. Novapack C18 3.9x150mmm was used. 
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Cell culture and transport studies.  
MDCKII and MDCKII-MDR1 cells were grown in Dubelcco’s 
Modified Eagle’s Media containing L-glutamine, fetal bovine serum and 
penicillin-streptomycin. Each two days the media was replaced. Cells 
monolayers were prepared by seeding 400000 cells/cm2 for MDCKII 
and 20000 cells/cm2 for MDCKII-MDR1 on a polycarbonate 
membrane which surface area was 4.2 cm2. They were maintained at 
37°C temperature, 90% humidity and 5% CO2 and medium was 
replaced each two days until confluence (7-9 days). Afterwards, the 
integrity of the each cell monolayer was evaluated by measuring the 
trans-epithelial electrical resistance (TEER). In experiment Hank’s 
balanced salt solution (HBSS) supplemented with HEPES was used to 
fill the receiver chamber and to prepare the drug solution that was 
placed in the donor chamber after adjusting pH to 7.   
 Transport studies were conducted in an orbital environmental 
shaker at constant temperature (37°C) and agitation rate (50 rpm). Four 
samples of 200 µL each one were taken, and replaced each time with 
HBSS supplemented with HEPES from the receiver side at 15, 30, 45 
and 90 minutes. Samples of the donor side were taken at the beginning 
and the end of the experiment. Moreover, the amount of compound in 
cell membranes and inside the cells was determined at the end of 
experiments in order to check the mass balance and the percentage of 
compound retained in the cell compartment (always less than 5%.) 
standard one with the same buffer for apical and basolateral 
compartment were conducted in apical to basolateral (AB) and 
basolateral to apical (BA) direction, the albumin experiments with 
presence of albumin in apical compartment were performed in AB 
direction (mimicking blood compartment) and the homogenate 
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experiments with brain homogenate in basolateral compartment were 
conducted in BA direction (mimicking brain compartment). Solutions 
were prepared 24h before the experiment and stored at 4°C. Drug 
concentrations assayed are summarized in Table 2.  Samples were stored 
at -20ºC until analyzed.  A scheme of the three different experimental 
settings is represented in Figure 1. 
 
Figure 1. Scheme of the system based in three experimental settings to obtain permeability 
values used to estimate extent and rate of brain access. Two cell lines, MDCK and MDCK-
MDR1 were checked to establish their predictive performance in this new experimental system 
by comparison with in vivo data. 
 
Standard Experiments 
In vitro studies were performed in both directions, from apical-
to-basal (AB) and from basal-to-apical (BA) sides. The volume was 2 
mL and 3 mL in apical and basolateral chamber respectively.  
 
Albumin Experiments  
The concentration of albumin used was 4%, in similar 
percentage to human blood. Drug solution with albumin was placed in 
the apical chamber (blood compartment). Albumin transport 
experiments were performed in MDCKII and MDCKII-MDR1 cells in 
AB direction. 
Chapter 6 
 
256 
 
Homogenate Experiments 
Animals: Male Landrace-Large White pigs weighing 15-20 kg were 
purchased from Animal house at University of Valencia. All animals 
were pair-housed at 18–22°C under a 12-h light/dark cycle with free 
access to food and water. The pre-anesthesia was composed by 
ketamine, medetomidine and azaperone by intramuscular injection. 
Animals were intubated and moved to the operation room with 
intravenous anesthesia and spontaneous ventilation. All procedures 
were performed by responsible veterinarian.  The animal study was 
approved by the Scientific Committee of the Faculty of Pharmacy and 
followed the guidelines described in the EC Directive 86/609, the 
Council of the Europe Convention ETS 123 and Spanish national laws 
governing the use of animals in research (Real Decreto 223/1988, BOE 
67, 18-3-98: 8509-8511). 
Homogenate brain dilution: Drug-naive pigs were sacrificed under 
overdose of anesthesia, the brain was removed and homogenized as 
described by Friden et al. [31]. Brain homogenate was mixed with 
phosphate buffer (180 mM pH 7.4) in 1:3 ratio to obtain the brain 
homogenate dilution. The same amount of each drug than in the 
standard experiments were dissolved in 3mL of brain homogenate 
dilution to be placed in the basolateral chamber in MDCKII and 
MDCKII-MDR1 cell monolayers. 
 
Drug analysis 
 Analytical methods for each drug are described in Table 2. All 
samples were analyzed using Waters 2695 separations module, Waters 
2487 ultraviolet and Waters 2475 Fluorescence detector. The standard 
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calibration curves were prepared by dilution from the drug solution 
assayed. Acid water was prepared with 0.5 mL Trifluoroacetic acid in 1 
L water. Water, Methanol and Acetonitrile were purchased by Sigma, 
HPLC grade. A Novapack C18 3.9x150mmm cartridge was used.  
The concentration of all the samples was within the linear range 
of quantitation for all the assays. Analytical methods were validated with 
regard to specificity, selectivity, linearity, precision and accuracy. 
Albumin samples (200 µL) were diluted in 400 µL acetonitrile to 
precipitate albumin. Afterwards, all samples from standard transport 
experiment, albumin and homogenate samples were centrifuged at 6150 
G for 10 minutes and aliquots of supernatant were transferred to vials 
and analyzed using HPLC.  
 
Data analysis 
 The apparent permeability coefficient was calculated according 
to the following equation: 
𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟,𝑡 =
𝑄𝑡𝑜𝑡𝑎𝑙
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟+𝑉𝑑𝑜𝑛𝑜𝑟
+ ((𝐶𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟,𝑡 · 𝑓) −
𝑄𝑡𝑜𝑡𝑎𝑙
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟+𝑉𝑑𝑜𝑛𝑜𝑟
) ·
𝑒
−𝑃·𝑆·(
1
𝑉𝑟𝑒𝑐𝑒𝑖𝑣𝑒𝑟
+
1
𝑉𝑑𝑜𝑛𝑜𝑟
)·∆𝑡
      (1) 
where Creceiver, t is concentration of drug in the receiver chamber 
at time t, Qtotal is the total amount of drug in both chambers, Vreceiver and 
Vdonor are the volumes of each chamber, Creceiver, t-1 is drug concentration 
in receiver chamber at previous time, f is the sample replacement 
dilution factor, S is the surface area of the monolayer, Δt is the time 
interval and P is the permeability coefficient. This equation considers a 
continuous change of the donor and receiver concentrations, and it is 
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valid in either sink or non-sink conditions [32, 33]. The permeability 
coefficient estimations in sink and non-sink conditions were carried out 
in an Excel® worksheet. When the experiments are performed at the 
same pH in donor and acceptor chambers the ratio of the basal to apical 
(PBA) and apical to basal (PAB) permeability values can be used to detect 
the presence of secretion (PBA/PAB>2) or absorption carrier mediated 
transport mechanisms (PBA/PAB<0.8).  
In vitro BBB parameters were derived as explained below. In vitro 
fu, plasma is obtained from the ratio of the permeability obtained in the AB 
direction in the albumin experiments, Papp ALB, and the permeability in 
the AB direction in the standard experiment, Papp A→B, the rational is the 
following. In the absence of albumin (as in the standard experiments) 
the flux of drug from apical to basolateral chamber is expressed by this 
equation based on Fick’s first law, assuming sink conditions (i.e. 
negligible drug concentration at the receiver chamber): 
𝑑𝑄
𝑑𝑡
= 𝑃𝑎𝑝𝑝 𝐴→𝐵 · 𝐶𝐴        (2) 
where Q is the amount of drug, S the surface of the membrane, 
CA the drug concentration in the apical chamber and Papp A→B the 
intrinsic permeability of the drug in the membrane. 
In the presence of albumin in the apical chamber (plasma), only 
the unbound drug is available for permeation, then the unbound drug 
concentration, Cu, plasma is the responsible of the concentration gradient 
driving the diffusion step. Unbound drug concentration can be 
estimated from the total drug concentration in apical chamber CA as: 
𝐶𝑢,𝑝𝑙𝑎𝑠𝑚𝑎 = 𝑓𝑢,𝑝𝑙𝑎𝑠𝑚𝑎 · 𝐶𝐴      (3) 
The drug flux in AB direction in presence of albumin is then: 
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𝑑𝑄
𝑆·𝑑𝑡
= 𝑃𝑎𝑝𝑝 𝐴→𝐵 · 𝐶𝑢,𝑝𝑙𝑎𝑠𝑚𝑎     (4) 
𝑑𝑄
𝑆·𝑑𝑡
= 𝑃𝑎𝑝𝑝 𝐴→𝐵 · 𝑓𝑢,𝑝𝑙𝑎𝑠𝑚𝑎 · 𝐶𝐴    (5) 
As in the permeability calculations the total drug concentration 
in apical chamber CA is used (because fu is unknown) actually the 
permeability value obtained in presence of albumin is an “apparent 
value”, Papp ALB, 
𝑑𝑄
𝑆·𝑑𝑡
= 𝑃𝑎𝑝𝑝 𝐴𝐿𝐵 · 𝐶𝐴      (6) 
Dividing equation 5 and 6 it is easy to obtain the relationship 
between the permeability in presence and in absence of albumin that 
corresponds to in vitro fu, plasma 
𝑃𝑎𝑝𝑝 𝐴𝐿𝐵 = 𝑃𝑎𝑝𝑝 𝐴→𝐵 · 𝑓𝑢,𝑝𝑙𝑎𝑠𝑚𝑎    (7) 
  If the in vitro unbound fraction in plasma is close to 1 (no drug 
is bound to albumin), both permeability values should be equal at the 
same concentration. If in vitro unbound fraction in plasma is lower than 
1 (drug is bounded to albumin), Papp ALB should be lower than Papp A→B, 
as less free drug is available for diffusion. 
 In vivo fu, brain is related to the unbound concentration in brain and 
the total concentration in brain.   
𝐶𝑢,𝑏𝑟𝑎𝑖𝑛 = 𝐶𝑡𝑜𝑡𝑎𝑙,𝑏𝑟𝑎𝑖𝑛 · 𝑓𝑢,𝑏𝑟𝑎𝑖𝑛    (8)  
 Following the same rational that that used for albumin 
experiments , in vitro fu, brain may be obtained from the ratio between the 
BA apparent permeability values obtained in presence of homogenate, 
Papp HOM and Papp B→A the permeability in the basal-to-apical direction of 
the standard experiments.  
Chapter 6 
 
260 
 
𝑃𝑎𝑝𝑝 𝐻𝑂𝑀 = 𝑃𝑎𝑝𝑝 𝐵→𝐴 · 𝑓𝑢,𝑏𝑟𝑎𝑖𝑛    (9) 
𝑓𝑢,𝑏𝑟𝑎𝑖𝑛 = 𝑃𝑎𝑝𝑝 𝐻𝑂𝑀/𝑃𝑎𝑝𝑝 𝐵→𝐴    (10) 
 In vivo Kpuu, brain is defined as the relation between unbound 
concentration in brain and unbound concentration in plasma at steady 
state. These concentrations are the driving forces to achieve a 
pharmacological effect. This ratio describes quantitatively how the BBB 
controls the drug permeation by passive diffusion or active 
influx/efflux transport. Kpuu, brain is determined by the relationship 
between the influx and efflux clearances.10  
𝐾𝑝,𝑢𝑢,𝑏𝑟𝑎𝑖𝑛 = 𝐶𝑙𝑖𝑛 𝐶𝑙𝑜𝑢𝑡⁄      (11) 
If passive diffusion is the only mechanism involved in the 
transport of the drug across BBB, Kpuu, brain is equal to 1. If Kpuu, brain is 
lower than 1, it means there is efflux transport (out from the brain) 
whereas if Kpuu, brain is higher than 1, an influx transport mechanism is 
present. 
 Taking into account that clearance is defined as: 
𝐶𝐿 = 𝑃𝑎𝑝𝑝 · 𝑆       (12) 
in vitro Kpuu, brain may be defined as the ratio between apical-to-
basolateral and basolateral-to-apical apparent permeability values 
obtained in the standard experiments.  
𝐾𝑝,𝑢𝑢,𝑏𝑟𝑎𝑖𝑛 = 𝑃𝑎𝑝𝑝 𝐴→𝐵 𝑃𝑎𝑝𝑝 𝐵→𝐴⁄     (13) 
 In vivo Vu, brain is defined as [10]  
𝑉𝑢,𝑏𝑟𝑎𝑖𝑛 = 𝐴𝑡𝑜𝑡𝑎𝑙,𝑏𝑟𝑎𝑖𝑛 𝐶𝑢,𝑏𝑟𝑎𝑖𝑛⁄     (14) 
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 Where Atotal, brain represents total amount of drug in brain and Cu, 
brain is the unbound concentration in brain.  In vivo apparent volume in 
brain can be also estimated with the following equation10 
𝑉𝑢,𝑏𝑟𝑎𝑖𝑛 = 𝑉𝐸𝐶𝐹 + (1 𝑓𝑢,𝑏𝑟𝑎𝑖𝑛⁄ ) · 𝑉𝐼𝐶𝐹   (15) 
where VECF is the volume of the extracellular fluid (brain 
interstitial fluid) and VICF is the brain intracellular volume. If there is no 
binding in brain parenchyma (i.e. drug does bind to any cell 
component), fu, brain is almost one, and Vu, brain is equal to VECF +VICF, 
which is typically around 0.8 ml·g brain-1 )( 0.2 ml·g brain-1 +0.6 ml·g 
brain-1 )[10]. Likewise, Vu, brain is larger than 0.8 ml·g brain
-1 when fu, brain 
is small. 
 
Methods of in vitro in vivo correlation 
In order to estimate the in vivo relevance of this in vitro method, 
in vivo rat fu, plasma, Kpuu, brain, Vu, brain and human Kpuu, CSF  data were 
obtained from Friden et al. [31].  The next step is to calculate from the 
above equations all the in vitro parameters and for these purpose there 
are three possible alternatives considering that Papp values have been 
obtained at different initial concentrations. 
First option is to estimate in vitro parameters using the Papp 
obtained at the lowest assayed concentrations (at which supposedly the 
saturable transport processes are not saturated. The second option is to 
estimate the in vitro parameters from each Papp and averaging the in vitro 
parameters obtained and, finally, using and extrapolation strategy to 
take into account the transport mechanism and the differences between 
the in vivo human concentrations (i.e. steady state concentrations) and 
the in vitro concentrations used. 
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Extrapolation: For some of the assayed compounds, apparent 
permeability values were concentration dependent due to the existence 
of carrier mediated influx or efflux processes. As the in vitro values are 
obtained from the apparent permeability values it is necessary to use 
those apparent permeability values obtained at the same unbound 
plasma concentrations reported by Friden et al. [34]. For this reason an 
extrapolation procedure was used in order to compare in vitro and in vivo 
BBB parameters at the same concentration.  
Permeability as a function of concentration models were fitted 
using linear or nonlinear regression in Excel® with Solver tool. The best 
model was selected by comparing the residual variances with an F-
Snedecor’s test at α=0.05 significance level. 
Extrapolation models: Passive diffusion model assumed that 
permeability is not concentration dependent thus the effective 
permeability is the average of the experimental values at all the 
concentrations assayed: 
𝑃𝑎𝑝𝑝,𝑒𝑥𝑡𝑟𝑎𝑝𝑜𝑙𝑎𝑡𝑒𝑑 = 𝑃𝑎𝑝𝑝̅̅ ̅̅ ̅̅      (16) 
where Papp is the mean apparent permeability value obtained by Solver 
minimization of the sum of squares residuals (SSR). Consequently the 
extrapolated value corresponds to the mean value.  
Linear model was also fitted to the Papp values for each cell line 
versus the assayed concentrations: 
𝑃𝑎𝑝𝑝 = 𝑆𝑙𝑜𝑝𝑒 · 𝐶 + 𝑏      (17)  
where C is the concentration and b represents the intercept of the model 
obtained by Solver minimization of the SSR. With the parameter values 
b and slope the Papp, extrapolated was estimated at the in vivo 
concentration. 
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Influx model parameters were estimated by fitting this equation 
to the Papp versus concentration data 
𝑃𝑎𝑝𝑝 = 𝑃𝑑𝑖𝑓 + 𝑉𝑚𝑎𝑥/(𝐾𝑀 + 𝐶)    (18) 
where VMAX represents de maximal rate of transport, KM is the 
concentration at the half VMAX and Pdif represents the diffusion 
permeability obtained by Solver minimization of the SSR. Pdif, VMAX 
and KM were then used to estimate Papp, extrapolated. 
Finally, the efflux model is represented by the following 
equation: 
𝑃𝑎𝑝𝑝 = 𝑃𝑑𝑖𝑓 − 𝑉𝑚𝑎𝑥/(𝐾𝑀 + 𝐶)    (19) 
where VMAX represents de maximal rate of transport, KM is the 
concentration at the half VMAX and Pdif represents the diffusion 
permeability obtained by Solver minimization of the SSR.  
For each drug the best model was selected and used for 
obtaining by extrapolation the apparent permeability value, Papp, 
extrapolated, at the in vivo concentration in each experimental setting. 
Papp, extrapolated values were used for the calculation of the in vitro fu, 
plasma , Kpuu, brain, Vu, brain  as described previously and correlated with the 
in vivo values. The linear regression plots and the 95% confidence 
prediction intervals were estimated using S-Plus 6.1 
 
RESULTS 
Permeability values 
In Table 3 the extrapolated permeability values at the in vivo 
concentrations for all the compounds, cell line and type of experiment 
are shown. 
 
  
COMPOUND 
CONCENTRATION 
(µM) 
MDCKII Papp (x10-6 cm/sec) MDCKII-MDR1 Papp (x10-6 cm/sec) 
A→B   B→A   ALB   HOM    PB→A/PA→B A→B   B→A   ALB   HOM    PB→A/PA→B 
Amitriptyline 0.022 74.77 
P 178.48 P 6.02 P 6.54 P 2.39 17.95 P 16.91 P 3.45 P 1.76 P 0.94 
Atenolol 1.5 1.32 
P 1.49 P 1.12 P 1.59 P 1.13 0.49 P 0.88 P 0.42 P 0.74 P 1.80 
Diphenhydramine 0.051 91.72 
P 79.62 P 13.12 P 25.31 P 0.87 99.97 P 58.40 P 15.42 P 11.75 P 0.58 
Ethyl-phenyl 
malonamide 4.3 
18.11 P 19.73 P 9.40 P 17.43 P 1.09 5.80 P 11.28 P 6.38 P 9.42 P 1.94 
Levofloxacin 0.59 3.90 
L 6.67 P 3.47 P 5.84 P 1.71 1.83 P 25.00 P 0.92 P 21.61 P 13.67 
Metoprolol 0.75 94.66 
P 112.07 P 78.33 P 35.91 P 1.18 57.30 P 52.09 P 27.51 P 21.22 P 0.91 
Norfloxacin 0.7 2.51 
P 8.16 P 1.84 P 5.79 P 3.25 0.94 P 2.15 P 0.63 P 1.93 P 2.28 
Propranolol 0.051 68.37 
P 89.08 P 7.24 P 8.18 P 1.30 110.65 P 52.75 P 13.29 P 7.38 P 0.48 
Verapamil 0.075 58.29 
P 49.22 P 15.54 P 15.83 P 0.84 82.73 P 51.66 P 8.66 P 17.89 P 0.62 
Zidovudine 1.2 11.39 
P 14.03 P 7.74 P 14.50 P 1.23 2.73 P 28.41 P 1.98 P 28.84 P 10.41 
 
Table 3. Extrapolated permeability values, Papp,extrapolated  at the in vivo relevant concentration in MDCKII and MDCKII-MDR1 cell lines and in the different 
experimental settings (standard, albumin and brain homogenate presence). P(passive), L (lineal), I (influx) and E (efflux) are the model used for extrapolation.  
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In vitro BBB parameters 
The in vitro estimated fu, plasma, Kpuu, CSF, Vu, brain  in MDCKII are 
summarized in table 4. In vivo data were obtained from Friden et al. [34] 
and in vitro data were calculated according to equations described above.  
 In Table 5 in vitro estimated of fu, plasma , Kpuu, brain, Vu, brain  in 
MDCKII-MDR1 are reported. In vivo data were obtained from Friden 
et al. [34] and in vitro data were calculated according to equations 
described above.  
 
Correlations 
 
MDCKII 
Figure 2 shows the correlation obtained between in vivo fu, plasma 
and in vitro fu, plasma values obtained with MDCK cells.  The in vitro values 
of Kpuu, brain predicted with MDCK cells and the correlation with in vivo 
values is represented in Figure 3. Figure 4 shows the correlation 
obtained between in vivo Vu, brain and in vitro Vu, brain from MDCK cells. 
Parameters of the linear correlations, Pearson coefficient and squared 
Pearson correlation coefficients are displayed in the figures.  
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Figure 2. Correlation obtained between in vivo fu,p and in vitro fu,p in MDCKII cell line  for 
ten compounds. The solid line represents the linear regression, and the dotted line represents 
the 95% confidence interval of the predictions. R is Pearson correlation coefficient and R2 is 
the square of Pearson correlation coefficient that reflects the percent of total variance of the 
dependent variable that is explained by the independent one.  
 
 
 
Figure 3. Correlation obtained between rat in vivo Kp,uu,brain and in vitro Kp,uu,brain (left) 
and between human in vivo Kp,uu,CSF  and in vitro Kp,uu,brain (right) in MDCKII cell line. 
The solid line represents the linear regression, and the dotted line represents the 95% 
confidence interval of the predictions. R is Pearson correlation coefficient and R2 is the square 
of Pearson correlation coefficient reflecting the percent of total variance of dependent variable 
explained by the independent one. 
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Figure 4. Correlation obtained between in vivo Vu,brain and in vitro Vu,brain in MDCKII cell line for 
the ten assayed drugs. The solid line represents the linear regression, and the dotted line 
represents the 95% confidence interval of the predictions. R is Pearson correlation coefficient 
and R2 is the square of Pearson correlation coefficient. 
 
MDCKII-MDR1 
The correlation obtained between in vivo fu, plasma and in vitro fu, 
plasma values obtained with MDCK-MDR1 cells is represented in Figure 
5. The in vitro values of Kpuu, brain predicted with MDCK-MDR1 cells 
versus the in vivo values is represented in Figure 6. Figure 7 shows the 
correlation obtained between in vivo Vu, brain and in vitro Vu, brain from 
MDCK-MDR1 cells. Parameters of the linear correlations, Pearson 
coefficient and squared Pearson correlation coefficients are displayed in 
the figures.  
 
Chapter 6 
 
268 
 
 
Figure 5. Correlation obtained between in vivo fu,p and in vitro fu,p in MDCKII-MDR1 cell line 
for ten compounds. The solid line represents the linear regression, and the dotted line represents 
the 95% confidence interval of the predictions. R is Pearson correlation coefficient and R2 is 
the square of Pearson correlation coefficient. 
 
 
 
Figure 6. Correlation obtained between rat in vivo Kp,uu,brain and in vitro Kp,uu,brain (left) and 
between human in vivo Kp,uu,CSF  and in vitro Kp,uu,brain (right) in MDCKII-MDR1 cell line for 
nine compounds (Ethyl-phenyl malonamide was not considered). The solid line represents the 
linear regression, and the dotted line represents the 95% confidence interval of the predictions. 
R is Pearson correlation coefficient and R2 is the square of Pearson correlation coefficient. 
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Figure 7. Correlation obtained between in vivo Vu,brain and in vitro Vu,brain in MDCKII-MDR1 cell 
line for ten compounds. The solid line represents the linear regression, and the dotted line 
represents the 95% confidence interval of the predictions. R is Pearson correlation coefficient 
and R2 is the square of Pearson correlation coefficient. 
 
DISCUSSION 
 The Blood-Brain barrier is a restrictive membrane which limits 
the access and distribution into the brain to many different molecules. 
It preserves the brain environment due to tight junctions between 
endothelial cells and transport mechanisms. The rate of success of CNS 
drugs in drug development is limited by a lack of reliable screening 
methods which may select the most valuables candidates for further 
analysis. Therefore, in this article a new in vitro methodology to predict 
the access and distribution of drugs into the brain is proposed and its 
predictive performance is evaluated. The method is developed in 
MDCKII and MDCKII-MDR1 cell lines because they closely reflect 
the tightness and transporters expression of the blood brain barrier in a 
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more reliable and constant manner than non-immortalized cell lines [19, 
20]. 
 The relevant BBB parameters for predicting rate and extent of 
access are: fu, plasma, Vu, brain, and Kpuu, brain. fu, plasma explains the drug’s 
affinity to blood proteins and this parameter quantify the free 
concentration that is able to cross the BBB and reach the target. 
However, the amount of drug that is able to reach the target depends 
also on the free drug concentration in brain.  Therefore, Kpuu, brain is a 
measurement in equilibrium of the relationship between free brain 
concentrations and free plasma concentrations. The value of Kpuu, brain 
indicates the extent of the drug that crossed the blood-brain barrier and 
is highly related to the effect. When Kpuu, brain is greater than 1, an influx 
transporter is involved in the permeation of the drug (i.e. drug transport 
into the brain is favored); passive diffusion occurs when Kp,uu, brain is 
equal to 1 and when Kp,uu,brain is less than 1, the drug is transported by 
an efflux mechanism (i.e. is permeation into the brain is interfered by 
the transporter). The parameter that describes the distribution of the 
drug in brain is Vu, brain. The brain may be divided in two different 
compartments, extracellular fluid (ECF) and intracellular fluid (ICF). 
The ECF+ICF real volume is the minimum volume in which the drug 
may be distributed if it does not bind to the cells components. If the 
drug is accumulated in cells, then Vu, brain is greater than (ECF+ICF) 
volume.  
The experimental determination of these three parameters 
required different and independent experimental setups. fu, plasma is 
determined in vitro, Kpuu, brain requires in vivo microdialysis studies to 
estimate the ECF and plasma concentrations and Vu, brain may also be 
obtained using in vitro methods [9]. A reliable and easy experimental 
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system, which allows the screening of CNS compounds, is needed to 
select the best candidates for future in vivo analysis [3, 8]. It could 
redirect the expensive and time consuming drug development to a more 
efficient process. The ideal situation would be having a single system 
able to predict the three relevant parameters and amenable to be 
miniaturized and robotized for high throughput screening. With this 
aim a new in vitro model is proposed, based on cell monolayer 
permeability experiments, in order to allow the simultaneous 
determination of fu, plasma, Vu, brain, and Kpuu, brain thanks to the modification 
of the experimental standard setting and to the adequate mathematical 
modeling.  
 
Model compounds 
Model compounds were selected to include CNS and non-CNS 
drugs, as well as considering their affinity to P-gp transporter [35-41]. 
Drugs with high and low degree of plasma protein binding were 
included as well as having a wide span of lipophilicity -values from 
clearly hydrophilic (Atenolol, Ethyl-phenyl Malonamide and 
Zidovudine) to highly lipophilic (Amitriptyline, Diphenhydramine and 
Verapamil). The molecular weight range was not as wide as it goes from 
250 to 450. The final set of ten compounds fulfilling these 
characteristics was selected based on the in vivo data availability as the 
final purpose was checking the predictability of the in vitro model (Table 
1).  
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Experimental setting 
The use of in vitro cells monolayers with albumin in the acceptor 
(basolateral) chamber has been proposed in models of the intestinal 
membrane in order to mimic the blood side after drug intestinal 
permeation [42]. On the other hand, the estimation of the unbound 
drug fraction in plasma based in the ratio of the permeability values in 
the absence and in the presence of albumin in the basolateral chamber 
has been also explored [42]. Based on this idea, an experimental setting 
with albumin in donor chamber to mimic the blood side is proposed in 
the BBB model. The derivation of the fu, plasma calculation follows the 
same rational that the previously reported. The albumin concentration 
was fixed to the average albumin concentration in human plasma [42]. 
The inclusion of brain homogenate in the basolateral chamber, 
following the same rational, should allow the estimation of fu, brain by 
comparison of the permeability values obtained with and without brain 
homogenate in the system. Different buffer/brain homogenate ratios 
were examined to select the most adequate ratio in terms of adherence, 
sampling feasibility and physiological resemblance. A 3:1 ratio of 
buffer/brain homogenate was selected as it was reported by Friden et 
al. [31].  
 
Correlations 
All the correlations in vitro versus in vivo parameters were done 
using the three proposed correlation methods, i.e. from the Papp at the 
lowest concentrations, by averaging the in vitro estimates at all the 
concentrations and from the extrapolation strategy. The last method 
produced the best correlations (higher correlation coefficients) in both 
cell lines. 
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MDCKII 
 In this cell line In vitro fu,p calculated from permeability values 
and  in vivo fu,p presented a good correlation (Figure  1) in ten 
compounds tested (R=0.93).  In vitro Kpuu, brain and in vivo human Kpuu, 
CSF correlation (Figure 2) was obtained with an R=0.85.  Human Kpuu, 
CSF data were better correlated than rat Kpuu, brain values (R=0.25), 
probably due to the less transporter expression in MDCKII and human 
Blood-cerebrospinal fluid barrier (BCSFB). Good Vu, brain correlation 
(Figure 3) was observed between in vitro Vu, brain and in vivo Vu, brain 
(R=0.99). Amitriptyline, Diphenhydramine, Propranolol and Verapamil 
showed 15-fold rank order, whereas Atenolol 3-fold, Levofloxacin, 
Metoprolol and Norfloxacin 2-fold and Ethyl-phenyl malonamide and 
Zidovudine close to 1-fold rank order (Table 4).   
MDCKII 
COMPOUND Vu,brain (ml/g brain) Kpuu,CSF fu,plasma 
  In vitro In vivo In vitro In vivo In vitro In vivo 
Amitriptyline 16.58 310.00 0.42 0.18 0.08 0.09 
Atenolol 0.76 2.50 0.88 0.54 0.85 1.00 
Diphenhydramine 2.09 32.00 1.15 1.05 0.14 0.48 
Ethyl-phenyl malonamide 0.88 0.90 0.92 1.25 0.52 0.55 
Levofloxacin 0.89 1.70 0.58 0.18 0.89 0.82 
Metoprolol 2.07 5.50 0.84 0.93 0.83 0.90 
Norfloxacin 1.05 2.90 0.31 0.11 0.73 0.87 
Propranolol 6.74 118.00 0.77 0.42 0.11 0.09 
Verapamil 2.07 54.00 1.18 1.13 0.27 0.20 
Zidovudine 0.78 1.10 0.81 1.04 0.68 0.64 
Table 4. In vitro parameters in MDCKII cell line calculated from equations 4, 7, 9 and 11 and in 
vivo parameters published by Friden et al. [[89]]. 
 
MDCKII-MDR1 
 In the MDR1 transfected cell line, in vitro and in vivo fu, p 
correlation (Figure 4) was less accurate and precise. A Pearson 
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correlation coefficient of 0.66 is lower than observed than in MDCKII 
cell line (R=0.93). In vitro Kpuu, brain and in vivo Kpuu, brain correlation 
(Figure 5) was obtained with an R=0.66, removing Ethyl-phenyl 
malonamide data. Rat Kpuu, brain data were better correlated than human 
Kpuu, CSF values (R=0.30), but a good correlation was not achieved with 
any of the in vivo Kpuu values. The higher expression level of P-gp in this 
cell line might not reflect the in vivo expression levels in BBB. Good Vu, 
brain correlation (Figure 6) was observed between in vitro Vu, brain and in vivo 
Vu, brain (R=0.92). Similar behavior in rank order was observed as 
explained in MDCKII. Amitriptyline showed a 51-fold rank order, 
Propranolol and Verapamil showed 25-fold rank order, 
diphenhydramine 10-fold rank order, whereas Atenolol, Metoprolol, 
Norfloxacin 3-fold, Levofloxacin 2-fold and Ethyl-phenyl malonamide 
and Zidovudine close to 1-fold rank order (Table 5). 
 
MDCKII-MDR1 
COMPOUND Vu,brain (ml/g brain) Kpuu,brain fu,plasma 
  In vitro In vivo In vitro In vivo In vitro In vivo 
Amitriptyline 5.97 310.00 1.06 0.73 0.19 0.09 
Atenolol 0.91 2.50 0.55 0.03 0.87 1.00 
Diphenhydramine 3.18 32.00 1.71 1.05 0.14 0.48 
Ethyl-phenyl malonamide 0.92 0.90 0.00 1.25 1.10 0.55 
Levofloxacin 0.89 1.70 0.07 0.12 0.50 0.82 
Metoprolol 1.67 5.50 1.10 0.64 0.48 0.90 
Norfloxacin 0.87 2.90 0.44 0.03 0.67 0.87 
Propranolol 4.49 118.00 2.10 0.61 0.12 0.09 
Verapamil 1.93 54.00 1.60 0.05 0.10 0.20 
Zidovudine 0.79 1.10 0.10 0.09 0.73 0.64 
Table 5. In vitro parameters in MDCKII-MDR1 cell line calculated from equations 4, 7, 9 and 
11 and in vivo parameters published by Friden et al. [89] 
Comparing both cell lines, in general the prediction 
performance of MDCKII cell lines is better than the MDCK-MDR1. 
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Nevertheless the worst predicted compounds are the same in both cell 
lines at least for Kpuu and for fu. For instance Zidovudine and Ethyl-
phenylmalonamide in vivo Kpuu are underestimated in both cell lines 
while Propranolol and atenolol are over estimated. Diphenhydramine fu 
is underestimated in both cell lines. The reason for the deviation is not 
clear but it does not seem to be related with the different expression 
level of P-gp that is the most relevant difference between both cell lines. 
 
CONCLUSION 
The BBB parameters obtained with our new method were 
predictive of the in vivo behavior of candidates. in vitro fu, plasma, Kpuu ,brain 
and Vu, brain calculated with Papp from MDCKII cell line presented a good 
correlation with in vivo fu, plasma, Kpuu, brain and Vu, brain published values 
(r=0.93; r=0.85 and r=0.99 respectively). Despite its simplicity the 
predictive performance is fairly good considering the reduced number 
of tested compounds with different physicochemical and transport 
properties. Further experimental modifications could be checked to 
optimize the method but the present data support its feasibility. As 
other in vitro cell culture models the system is suitable for 
miniaturization and robotization to allow high throughput 
performance. 
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PERMEABILITY ESTIMATION  
Model Validation 
Cell culture permeability experiments are valuable tools in drug 
development and candidate selection but the monolayer preparation 
protocols and the calculations procedures can affect the permeability 
estimation.  
Calculations 
There are different profiles that are usually observed between 
accumulated amounts of drug in the acceptor side versus time. Three 
examples of these profiles are represented in Figure 3. 
 
 
Figure 3. Profiles of accumulated amounts of drug in acceptor chamber versus time in 
permeability experiments in cell monolayers. Profile A: Drug is transported during the first 
sampling interval at a lower rate than expected; Profile B: Drug is transported linearly with a 
constant rate; Profile C: Drug is transported at a higher rate during the first sampling interval. 
 
Tavelin et al. [24] highlighted the existence of these atypical 
profiles (Profiles A and C on Figure 3) that could be caused by poor 
control of temperature, partitioning of the drug into the cell monolayer, 
low molecular weight impurities (such as 3H-water) that are transported 
at a higher rate than the drug or harsh application of the drug solution 
leading to the disturbance of the monolayer.  
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An objective of this work was to use a simulation strategy to 
explore the performance of a new proposed Modified Non-Sink 
equation (MNS) for permeability estimation in different types of 
profiles, considering several levels of experimental variability and to 
compare MNS method with the classical sink and non-sink approaches 
and finally to explore its usefulness for BCS classification. 
 Simulated concentrations in the receiver chamber were plotted 
versus time by each profile and scenario of variability (high (H) and low 
(L) interindividual variability (IIV) and residual variability (RSV)) in 
Figure 4.  
 
  
 
Figure 4. Profile A, B and C (left, middle and right groups) by scenarios of variability in sink conditions are represented in the upper line and non-sink conditions 
are plotted in the lower line. Blue dots are simulated concentrations (ng/mL) in 3000 wells, solid line is the population predicted values obtained by MNS equation 
and dotted line is the population predicted value by NS. 
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Estimation error 
 Results from mean, intra-assay and individual estimation error 
of Permeability values are calculated and depicted on Figures 5-7. Dots 
are the mean values of estimation error of each method (MNS, NS, S, 
SC), grey box is one standard deviation (SD) of the mean and lines are 
two SD of the mean value. 
 
  
 
 
Figure 5. Estimation errors of Profile A in sink and non-sink conditions, by each scenario of variability and by each method of estimation. 
  
 
Figure 6. Estimation errors of Profile B in sink and non-sink conditions, by each scenario of variability and by each method of estimation. 
  
 
 
Figure 7. Estimation errors of Profile C in sink and non-sink conditions, by each scenario of variability and by each method of estimation. 
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Statistical analysis 
 ANOVA of the mean estimation errors was performed with 
Scheffe as post-hoc test. Results are summarized in Table 1-3.  
PROFILE A 
 
SINK NON SINK 
H IIV 
H RSV 
H IIV 
L RSV 
L IIV 
H RSV 
L IIV 
L RSV 
H IIV 
H RSV 
H IIV 
L RSV 
L IIV 
H RSV 
L IIV 
L RSV 
MNS MNS MNS MNS MNS MNS MNS MNS 
NS Sig Sig Sig Sig Sig Sig Sig Sig 
S NS NS NS NS Sig Sig Sig Sig 
SC NS NS Sig Sig Sig Sig Sig Sig 
Table 1. ANOVA results of Profile A data sets in each scenario of variability between methods 
of estimation (MSN, NS, S and SC). Sig means statistical differences and NS no statistical 
differences were observed. 
PROFILE B 
 
SINK NON SINK 
H IIV 
H RSV 
H IIV  
L RSV 
L IIV  
H RSV 
L IIV  
L RSV 
H IIV 
 H RSV 
H IIV  
L RSV 
L IIV  
H RSV 
L IIV  
L RSV 
MNS MNS MNS MNS MNS MNS MNS MNS 
NS NS NS NS NS NS NS NS NS 
S NS NS NS Sig Sig Sig Sig Sig 
SC NS NS NS NS Sig Sig Sig Sig 
Table 2. ANOVA results of Profile B data sets in each scenario of variability between methods 
of estimation (MSN, NS, S and SC). Sig means statistical differences and NS no statistical 
differences were observed. 
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PROFILE C 
 
SINK NON SINK 
H IIV  
H RSV 
H IIV  
L RSV 
L IIV  
H RSV 
L IIV   
L RSV 
H IIV  
H RSV 
H IIV  
L RSV 
L IIV  
H RSV 
L IIV   
L RSV 
MNS MNS MNS MNS MNS MNS MNS MNS 
NS Sig Sig Sig Sig Sig Sig Sig Sig 
S NS S NS Sig Sig Sig Sig Sig 
SC NS NS NS Sig Sig Sig Sig Sig 
Table 3. ANOVA results of Profile C data sets in each scenario of variability between methods 
of estimation (MSN, NS, S and SC). Sig means statistical differences and NS no statistical 
differences were observed. 
 
Model comparison 
Permeability estimation 
 Results of the classification from 108 scenarios with each 
method of estimation are summarized in Table 4. Results were classified 
in OK, ERROR or VARIABILITY.  Considering the meaning of these 
labels (as the examples presented in Table 3) the objective would be 
finding which method is able to obtain the higher number of OK 
results, the lower number of ERROR labels and it is not biased by the 
variability of the experiment.  After performing the chi-square test, the 
number of occasions that the MNS method produced better results 
than the others was computed and these results are displayed in Table 
4. For instance, MNS estimation method obtained a statistically higher 
number of OK results in 59 scenarios compared with NS method, the 
same number in 12 and less OK results than NS in 37 scenarios (108 
total scenarios). Regarding the ERROR results, MNS method produced 
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less times ERROR results in 75 scenarios compared with NS method, 
the same number in 12 scenarios and more ERROR results in 21 
scenarios. In VARIABILITY results, MNS method led to a higher 
number of VARIABILITY results compared with NS in 40 scenarios, 
a similar number in 49 scenarios and less number of VARIABILITY 
results in 19 scenarios. 
 
 OK ERROR VARIABILITY 
 NS S SC NS S SC NS S SC 
BETTER 59 83 24 75 90 44 40 42 4 
SIMILAR 12 25 82 12 15 62 49 66 104 
WORSE 37 0 2 21 3 2 19 0 0 
Table 4. Comparison of statistically significant differences between MNS and NS, MNS and S 
and MNS versus SC. In the Columns OK and VARIABILITY, BETTER is considered when 
the number of results, either OK or VARIABILITY was significantly higher in MNS than the 
other methods; SIMILAR is when the differences were not significant; WORSE when the 
number of results (OK or VARIABILITY) was significantly lower in MNS than the other 
methods. In the Column ERROR, BETTER corresponds to a significant lower number of 
ERROR results, SIMILAR means a non-significant difference and WORSE implies a 
significantly higher number of ERROR results. 
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VARIABILITY OF PERMEABILITY ESTIMATION FROM 
DIFFERENT PROTOCOLS OF SUBCULTURE AND 
TRANSPORT EXPERIMENTS IN CELL MONOLAYERS 
Protocol characterization and optimization 
Other factor that can affect permeability values is the protocol 
for sub-culturing cell monolayers and performing transport 
experiments. In this work, insert type (polycarbonate membrane with 
or without collagen coating), passage number (10 40 and 80 after 
defrost) and time after seeding (4, 15, 21 days after seeding) were 
considered to evaluate the permeability values and their variability. 
Metoprolol (Passive transport marker), Lucifer Yellow 
(paracelular transport markers) and Rhodamine-123 (P-gp substrate) 
were used to check the performance of the cell lines. Results are 
summarized in Figures 8 to 10. The coefficients of variation of 
permeability values of each compound in each cell line and protocol are 
represented in Tables 5 to 7. 
Two different experimental protocols have been used to grow 
the cells and perform the experiments. Protocols for transport 
experiment differ mainly in the filter support coating and the medium 
and plastic ware brands and in the batch homogenization of some 
medium components (as the serum growth factor). In the first protocol 
cells grew in a collagen coated polycarbonate membrane (Costar inserts, 
surface area 0.9 cm2, 0.4 µm pore size) (SOP 1) and, in the second one 
cells grew in a polycarbonate membrane without collagen coated. 
(MILLICEL-PCF, surface area 0.9 cm2, 0.4 µm pore size) (SOP 2) 
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Figure 8. Permeability values of LY (2mM) obtained with both harvesting protocols (SOPs) at 
different passage number after defrosting process in 3 cell lines. 
 
Lucifer 
Yellow 
Passage CV% SOP1 CV% SOP2 
Caco2 Early 7.3 3.0 
Caco2 Intermediate 11.8 90.8 
Caco2 Late 5.1 23.2 
MDCK Early 15.6 15.2 
MDCK Intermediate 10.3 9.7 
MDCK Late 4.8 18.7 
MDR Early 7.1 9.6 
MDR Intermediate 2.8 38.3 
MDR Late 16.1 28.0 
Average  9.0 26.3 
Table 5. Variability in Lucifer Yellow permeability values in both protocols, in different passage 
numbers and cell lines. 
 
Anova analysis and Scheffe post-hoc comparison showed 
differences in both SOP’s in LY permeability values among all passages 
(in both directions). 
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Figure 9. Permeability values of Metoprolol (100 µM) obtained with both harvesting protocols 
(SOPs) at different passage number after defrosting process in 3 cell lines. 
 
Metoprolol Passage CV% SOP1 CV% SOP2 
Caco2 Early 4.1 5.4 
Caco2 Intermediate 8.8 9.4 
Caco2 Late 7.4 4.5 
MDCK Early 8.6 6.6 
MDCK Intermediate 3.5 4.2 
MDCK Late 2.2 8.0 
MDR Early 3.1 6.3 
MDR Intermediate 4.0 17.5 
MDR Late 2.5 7.1 
Average  4.9 7.7 
Table 6. Variability in Metoprolol permeability values in both protocols, in different passage 
numbers and cell lines. 
 
Anova analysis and Scheffe post-hoc comparison showed 
differences in both SOP’s in Metoprolol permeability values in early 
passage compared with late (in both directions and all cell lines). 
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Figure 10. Permeability values of Rhodamine (5.5 µM) obtained with both harvesting protocols 
(SOPs) at different passage number after defrosting process in 3 cell lines. 
 
Rhodamine Passage CV% SOP1 CV% SOP2 
Caco2 Early 4.6 6.2 
Caco2 Intermediate 36.5 5.7 
Caco2 Late 145.7 27.2 
MDCK Early 4.0 16.5 
MDCK Intermediate 5.5 4.9 
MDCK Late 47.1 7.6 
MDR Early 29.0 7.5 
MDR Intermediate 8.4 4.0 
MDR Late 2.3 0.5 
Average  31.5 8.9 
Table 7. Variability in Rhodamine permeability values in both protocols, in different passage 
numbers and cell lines 
Anova analysis and Scheffe post-hoc comparison showed 
differences in both SOP’s in Rhodamine permeability values in early 
passage compared with late in BA direction in MDCK and MDCK-
MDR1 but not in Caco-2 cells.  
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One of the factors affecting permeability values is the time 
between seeding cells and performing the experiment as it could affect 
to the transporter expression and cell maturation. The usual maturation 
time depends on the kind of cells and it used to be from 4 to 21 days in 
Caco2 cell line and from 4 to 9 in MDCK and MDCK-MDR1.  
Figures 11, 12 and 13 show the permeability values of Lucifer 
Yellow, Metoprolol and Rhodamine respectively obtained at different 
times post seeding and passages in the three cell lines. 
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Figure 11. Permeability values of LY (2mM) obtained at different times post seeding and 
passages in the three cell lines.  
 
General Results 
 
301 
 
 
Figure 12. Permeability values of Metoprolol (100 µM) obtained at different times post seeding 
and passages in the three cell lines.  
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Figure 13. Permeability values of Rhodamine (5.5 µM) obtained at different times post seeding 
and passages in the three cell lines.  
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The analysis of variance test and scheffe post hoc analysis 
demonstrated statistical significant differences in permeabilities with the 
time after seeding in the three cell lines and for all the compounds.  
Tables 8 to 10 summarized the average coefficient of variation in AB 
and BA permeability values in the different conditions (passage and 
time after seeding) for all cell lines and compounds. 
 
Rhodamine       
Line Passage Days Mean CV% 
Caco2 Early 4 7.1 
    15 3.5 
    21 5.0 
  Intermediate 4 10.4 
    15 11.6 
    21 4.9 
  Late 4 46.6 
    15 9.7 
    21 6.4 
MDCK Early 4 5.9 
    9 4.9 
  Intermediate 4 4.0 
    9 21.6 
  Late 4 3.7 
    9 21.2 
MDCK 
MDR1 
  
Early 4 21.2 
9 15.5 
Intermediate 4 2.4 
    9 2.6 
  Late 4 3.6 
    9 149.5 
Table 8. Variability in permeability values of Rhodamine obtained in different cell lines and 
passages with different maturation days after seeding. 
 
 
General Results 
 
304 
 
 
Lucifer Yellow   
Line Days Mean CV% 
Caco 2 4 5.1 
  15 7.0 
  21 11.8 
MDCK 4 5.8 
  9 10.3 
MDCK-
MDR1 
4 7.3 
9 6.2 
Table 9. Variability in permeability values of Lucifer Yellow obtained in different cell lines and 
passages with different maturation days after seeding 
 
Metoprolol     
Line Days Mean CV% 
Caco 2 4 3.8 
  15 8.4 
  21 8.5 
MDCK 4 3.6 
  9 3.0 
MDCK-
MDR1 
4 1.4 
9 3.0 
Table 10. Variability in permeability values of Metoprolol obtained in different cell lines and 
passages with different maturation days after seeding. 
 
The results obtained in this study confirmed the complexity of 
the interaction between cell culturing protocols and the need for 
standardization and characterization of the culture properties to 
optimize the conditions. These results allowed developing a new whole 
in vitro high throughput method to predict drug rate and extent of access 
across the BBB. The system permitted to estimate fu, brain, Vu, brain and 
Kpuu, brain in a single experimental system, using in vitro cell monolayers 
in different conditions. 
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In this work it was necessary to validate the prediction ability of 
the new in vitro models by comparison of the in vitro parameters with in 
vivo data.  
 
INNOVATIVE IN VITRO METHOD TO PREDICT DRUG 
PERMEATION ACROSS THE BBB 
Permeability Values of In Vitro BBB Experiments 
In Table 11-12 the extrapolated permeability values at the in vivo 
concentrations for all the compounds, cell line and type of experiment 
are shown. 
 
COMPOUND 
CONCENTRATION 
(µM) 
MDCKII Papp (x10-6 cm/sec) 
A→B   B→A   ALB   HOM    PB→A/PA→B 
Amitriptyline 0.022 74.77 P 178.48 P 6.02 P 6.54 P 2.39 
Atenolol 1.5 1.32 P 1.49 P 1.12 P 1.59 P 1.13 
Diphenhydramine 0.051 91.72 P 79.62 P 13.12 P 25.31 P 0.87 
Ethyl-phenyl 
malonamide 4.3 
18.11 P 19.73 P 9.40 P 17.43 P 1.09 
Levofloxacin 0.59 3.90 L 6.67 P 3.47 P 5.84 P 1.71 
Metoprolol 0.75 94.66 P 112.07 P 78.33 P 35.91 P 1.18 
Norfloxacin 0.7 2.51 P 8.16 P 1.84 P 5.79 P 3.25 
Propranolol 0.051 68.37 P 89.08 P 7.24 P 8.18 P 1.30 
Verapamil 0.075 58.29 P 49.22 P 15.54 P 15.83 P 0.84 
Zidovudine 1.2 11.39 P 14.03 P 7.74 P 14.50 P 1.23 
Table 61. Extrapolated permeability values, Papp,extrapolated  at the in vivo relevant 
concentration in MDCKII and MDCKII-MDR1 cell lines and in the different experimental 
settings (standard, albumin and brain homogenate presence). P(passive), L (lineal), I (influx) and 
E (efflux) are the model used for extrapolation.   
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COMPOUND 
CONCENTRATION 
(µM) 
MDCKII-MDR1 Papp (x10-6 cm/sec) 
A→B   B→A   ALB   HOM    PB→A/PA→B 
Amitriptyline 0.022 17.95 P 16.91 P 3.45 P 1.76 P 0.94 
Atenolol 1.5 0.49 P 0.88 P 0.42 P 0.74 P 1.80 
Diphenhydramine 0.051 99.97 P 58.40 P 15.42 P 11.75 P 0.58 
Ethyl-phenyl 
malonamide 4.3 
5.80 P 11.28 P 6.38 P 9.42 P 1.94 
Levofloxacin 0.59 1.83 P 25.00 P 0.92 P 21.61 P 13.67 
Metoprolol 0.75 57.30 P 52.09 P 27.51 P 21.22 P 0.91 
Norfloxacin 0.7 0.94 P 2.15 P 0.63 P 1.93 P 2.28 
Propranolol 0.051 110.65 P 52.75 P 13.29 P 7.38 P 0.48 
Verapamil 0.075 82.73 P 51.66 P 8.66 P 17.89 P 0.62 
Zidovudine 1.2 2.73 P 28.41 P 1.98 P 28.84 P 10.41 
Table 72. Extrapolated permeability values, Papp,extrapolated  at the in vivo relevant 
concentration in MDCKII and MDCKII-MDR1 cell lines and in the different experimental 
settings (standard, albumin and brain homogenate presence). P(passive), L (lineal), I (influx) and 
E (efflux) are the model used for extrapolation.   
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In Vitro BBB parameters 
The in vitro estimated fu, plasma, Kpuu, CSF, Vu, brain in MDCKII are 
summarized in Table 13. In vivo data were obtained from Friden et al. 
[89] and in vitro data were calculated according to equations described in 
Chapter 6.  
 
MDCKII 
COMPOUND Vu,brain (ml/g brain) Kpuu,CSF fu,plasma 
  In vitro In vivo In vitro In vivo In vitro In vivo 
Amitriptyline 16.58 310.00 0.42 0.18 0.08 0.09 
Atenolol 0.76 2.50 0.88 0.54 0.85 1.00 
Diphenhydramine 2.09 32.00 1.15 1.05 0.14 0.48 
Ethyl-phenyl malonamide 0.88 0.90 0.92 1.25 0.52 0.55 
Levofloxacin 0.89 1.70 0.58 0.18 0.89 0.82 
Metoprolol 2.07 5.50 0.84 0.93 0.83 0.90 
Norfloxacin 1.05 2.90 0.31 0.11 0.73 0.87 
Propranolol 6.74 118.00 0.77 0.42 0.11 0.09 
Verapamil 2.07 54.00 1.18 1.13 0.27 0.20 
Zidovudine 0.78 1.10 0.81 1.04 0.68 0.64 
Table 83. In vitro parameters in MDCKII cell line calculated from equations 4, 7, 9 and 11 and 
in vivo parameters published by Friden et al. [89]. 
In Table 14 in vitro estimated of fu,plasma , Kp,uu,brain, Vu,brain  in 
MDCKII-MDR1 are reported. In vivo data were obtained from Friden 
et al. [89] and in vitro data were calculated according to equations 
described above.  
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MDCKII-MDR1 
COMPOUND Vu,brain (ml/g brain) Kpuu,brain fu,plasma 
  In vitro In vivo In vitro In vivo In vitro In vivo 
Amitriptyline 5.97 310.00 1.06 0.73 0.19 0.09 
Atenolol 0.91 2.50 0.55 0.03 0.87 1.00 
Diphenhydramine 3.18 32.00 1.71 1.05 0.14 0.48 
Ethyl-phenyl malonamide 0.92 0.90 0.00 1.25 1.10 0.55 
Levofloxacin 0.89 1.70 0.07 0.12 0.50 0.82 
Metoprolol 1.67 5.50 1.10 0.64 0.48 0.90 
Norfloxacin 0.87 2.90 0.44 0.03 0.67 0.87 
Propranolol 4.49 118.00 2.10 0.61 0.12 0.09 
Verapamil 1.93 54.00 1.60 0.05 0.10 0.20 
Zidovudine 0.79 1.10 0.10 0.09 0.73 0.64 
Table 94. In vitro parameters in MDCKII-MDR1 cell line calculated from equations 4, 7, 9 and 
11 and in vivo parameters published by Friden et al. [89]. 
 
Correlations 
To validate the reliability of the new method it was necessary to 
correlate in vitro vs in vivo BBB parameters. 
MDCKII 
Figure 14 shows the correlation obtained between in vivo fu,plasma 
and in vitro fu,plasma. values obtained with MDCK cells.  The in vitro values 
of  Kp,uu,brain predicted with MDCK cells and the correlation with in vivo 
values is represented in Figure 15. Figure 16 shows the correlation 
obtained between in vivo Vu,brain and in vitro Vu,brain from MDCK cells. 
Parameters of the linear correlations, Pearson coefficient and squared 
Pearson correlation coefficients are displayed in the figures.  
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Figure 14. Correlation obtained between in vivo fu,p and in vitro fu,p in MDCKII cell line  for 
ten compounds. The solid line represents the linear regression, and the dotted line represents 
the 95% confidence interval of the predictions. R is Pearson correlation coefficient and R2 is 
the square of Pearson correlation coefficient that reflects the percent of total variance of the 
dependent variable that is explained by the independent one. 
 
Figure 15. Correlation obtained between rat in vivo Kp,uu,brain and in vitro Kp,uu,brain (left) and 
between human in vivo Kp,uu,CSF  and in vitro Kp,uu,brain (right) in MDCKII cell line. The solid line 
represents the linear regression, and the dotted line represents the 95% confidence interval of 
the predictions. R is Pearson correlation coefficient and R2 is the square of Pearson correlation 
coefficient reflecting the percent of total variance of dependent variable explained by the 
independent one. 
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Figure 16. Correlation obtained between in vivo Vu,brain and in vitro Vu,brain in MDCKII cell line 
for the ten assayed drugs. The solid line represents the linear regression, and the dotted line 
represents the 95% confidence interval of the predictions. R is Pearson correlation coefficient 
and R2 is the square of Pearson correlation coefficient. 
 
MDCKII-MDR1 
The correlation obtained between in vivo fu, plasma and in vitro fu, 
plasma values obtained with MDCK-MDR1 cells is represented in Figure 
17. The in vitro values of Kpuu, brain predicted with MDCK-MDR1 cells 
versus the in vivo values are represented in Figure 18. Figure 19 shows 
the correlation obtained between in vivo Vu, brain and in vitro Vu, brain from 
MDCK-MDR1 cells. Parameters of the linear correlations, Pearson 
coefficient and squared Pearson correlation coefficients are displayed in 
the figures.  
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Figure 17. Correlation obtained between in vivo fu,p and in vitro fu,p in MDCKII-MDR1 cell line 
for ten compounds. The solid line represents the linear regression, and the dotted line represents 
the 95% confidence interval of the predictions. R is Pearson correlation coefficient and R2 is 
the square of Pearson correlation coefficient. 
 
Figure 18. Correlation obtained between rat in vivo Kp,uu,brain and in vitro Kp,uu,brain (left) and 
between human in vivo Kp,uu,CSF  and in vitro Kp,uu,brain (right) in MDCKII-MDR1 cell line for 
nine compounds (Ethyl-phenyl malonamide was not considered). The solid line represents the 
linear regression, and the dotted line represents the 95% confidence interval of the predictions. 
R is Pearson correlation coefficient and R2 is the square of Pearson correlation coefficient. 
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Figure 19. Correlation obtained between in vivo Vu,brain and in vitro Vu,brain in MDCKII-MDR1 
cell line for ten compounds. The solid line represents the linear regression, and the dotted line 
represents the 95% confidence interval of the predictions. R is Pearson correlation coefficient 
and R2 is the square of Pearson correlation coefficient. 
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PERMEABILITY ESTIMATION 
The in vitro permeability studies are a fundamental tool in the 
preclinical development of new drugs [24, 90-94].Permeability is the 
ability of a molecule to cross biological barriers and several cell 
monolayers are used in the in vitro permeation studies [54, 92, 95, 96]. 
The importance of a correct estimation of the permeability of new drugs 
in development lies in an efficient selection of the candidates to ensure 
a greater chance of reaching the market. This fact is, in particular, 
relevant when the classification of the candidate by comparison with a 
reference could be biased if the estimation is not accurate. 
 
Model Validation 
 NS and MNS predicted equally well the simulated 
concentrations in the receiver chamber when there is no alteration in 
the initial phases of drug permeation. But if there is any initial alteration 
(Profile A and C Figure 2, only MNS is able to estimate accurately the 
“true” permeability due its ability to discriminate the initial permeability 
until the first sampling interval (Peff 0) and the final (or “true”) 
permeability (Peff 1), i.e. this method takes into account the behavior in 
the initial phase and it avoids that this initial alteration affects the 
estimation of the permeability. Therefore, NS method underestimates 
in Profile A and overestimates in Profile C the permeability value in all 
scenarios of variability and sink and non-sink conditions. 
 When comparing the results of the estimation errors (Figure 8-
10), no significant differences are observed between the behavior of the 
mean, intra-assay and individual estimation errors. In all the profiles (A, 
B and C), under sink conditions linear regression models (S and SC) 
achieved similar estimation errors compared with MNS method. These 
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results are expected because the linear sink and sink corrected models 
allow the intercept of the regression to be different from 0. 
 On the other hand, NS method produces estimation errors 
different from 0 when the initial permeation across the monolayer is 
affected (in all scenarios of variability) and under sink and non-sink 
conditions (Figures 8-10). The single permeability parameter in the 
equation is not able to satisfy, by nonlinear regression, all experimental 
concentrations in the receiver chamber. However, when there is no 
alteration in the initial phase (Figure 2) NS method is able to predict an 
accurate permeability value under sink and non-sink conditions in all 
scenarios of variability. NS presents statistically significant differences 
in average estimation error compared to MNS, under sink and non-sink, 
in the Profile A and C in all variability scenarios proposed. 
 Linear regression models (S and SC) showed statistically 
significant differences when non-sink conditions existed in each of the 
profiles and scenarios of variability proposed. In some cases, under sink 
conditions, significant differences were observed between S and SC and 
MNS, usually when IIV and RSV variability was low. This could be 
explained because as the variance of the mean estimation errors is small, 
small differences in the mean error between methods could be 
significant in Scheffe test. 
Therefore, these differences observed in Figures 7 to 10 and the 
statistical differences in estimation errors evidenced in the ANOVA 
(Tables 1-3) demonstrated that linear regression models are not valid at 
any level of variability under non-sink, and even in scenarios with low 
variability under sink conditions. Likewise, NS method is not useful for 
calculating the permeability when there is an alteration of the 
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permeation through the cell monolayer in the initial stages in all 
scenarios of variability and under sink and non-sink conditions. 
 
Model Comparison 
 The designed scenarios to perform the simulations are focused 
on a borderline situation for classification as high permeability 
compound (in BCS framework) that is test and reference permeability 
values very similar. This particular case was selected because, obviously, 
when the classification is clear, or in other words, with a test 
permeability value much higher or lower than the reference one, the 
bias due to the estimation method could be neglected, as it could affect 
test or reference in a different magnitude but it would never mask the 
existing differences. Thus, actually a biased permeability estimates 
would not affect the comparison. The problem of the estimation 
method could arise when the candidate compound is near the cutoff 
value. 
 Results from Chapter 4 demonstrated that the MNS method 
would conclude a correct classification in more potential scenarios even 
when the designed scenarios were borderline situations. Given a 
theoretical difference of 20% in test and reference compound, when the 
experimental variability is added to the system, the MNS equation led 
to a correct rank order, matching the “true” parameters in a higher 
number of occasions, including those with “atypical” profiles of 
cumulative amounts versus time. It is important to point out that the so 
called atypical profiles are actually not unusual but often neglected and 
then, the standard calculation methods are used without considering 
their influence in the estimation error.  In the present simulation it is 
demonstrated that when these profiles arise the new Modified Non Sink 
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equation gives the most accurate estimate. Therefore, the main 
conclusion of this section is that the MNS method is able to correctly 
estimate the permeability in a larger number of cases compared to the 
proposed models and it has fewer errors in the classification of the 
compound. This is essential for a more efficient candidate selection. 
 
VARIABILITY OF PERMEABILITY ESTIMATION FROM 
DIFFERENT PROTOCOLS OF SUBCULTURE AND 
TRANSPORT EXPERIMENTS IN CELL MONOLAYERS 
In SOP 1 with Caco-2 cells after passage 10 the permeability 
values decreased and remained fairly constant in the subsequent 
passages. In MDCK and MDCK-Mdr1 passage number does not seem 
to affect to the permeability values at least in the range of passages 
assayed (Figure 1). In SOP 2 on the contrary the passage number had a 
marked effect on Metoprolol permeability in particular in Caco-2 cells 
where there is a trend with higher permeability values of Metoprolol 
with higher passages (Figure 2). 
On the other hand the variability in permeability estimation 
showed a trend to decrease in MDCK and Caco-2 cells with SOP1 but 
a tendency to increase in SOP 2. MDCK-MDR1 showed the lower 
variability in both protocols (ranged between 5 and 7% as average 
values), without any relevant change with passage number. 
Considering these results, SOP 1 at intermediate passage 
number seems to be the best experimental conditions to compare drugs 
absorbed by passive diffusion by transcellular route. 
SOP 1 helps to cell differentiation in a more stable manner 
compared to SOP 2 which showed permeability changes with passage 
and also more variable values. 
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The differences in SOP 1 and 2 regarding the effect of passage 
number on the different permeation routes show the complexity of the 
involved mechanisms. For P-gp interaction studies in this case would 
be more convenient SOP 2 at intermediate or late passage numbers.  
The results obtained in this study confirm the complexity of the 
interaction between cell culturing protocols and cell lines and the need 
for standardization and characterization of the culture properties to 
optimize the conditions depending on the study objectives. In our 
study, the average variability observed in permeability values in all cell 
lines is around 10%-15% that means that for detecting a 15% difference 
in permeability values the required number of individual estimations 
would be between 8 and 12, i.e. one plate of 12 wells. The variability is 
lower in intermediate passages in Caco-2 cells supporting the 
recommendation of use a short range of passages to a particular study. 
MDCK was more influenced by the passage number, with less CV in 
lower passages. MDCK-MDR1 showed constant CV among passages, 
protocols and experimental conditions but permeability values were 
affected by all the studied conditions, indicating that for this cell line 
standardization of experimental conditions is in particular relevant to 
obtain comparable results between different laboratories.   
As conclusion, we have confirmed the influence of maturation 
conditions, passage number in permeability values and in their 
variability. Based in our results protocol with coating would be more 
adequate for studies of compounds absorbed by passive diffusion but 
the protocol without coating gave us better results for studies about P-
gp interactions. A similar study should be done in each laboratory to 
understand the influence of their protocols in the monolayer properties 
in order to standardizing conditions and setting the acceptance criteria. 
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INNOVATIVE IN VITRO METHOD TO PREDICT DRUG 
PERMEATION ACROSS THE BBB 
In vitro methods have been recognized in their capability to 
predict the drug access rate into the brain, the role of different 
transporters in drug permeation and the relevance of some biomarkers 
in the signal transduction, but the measurement of the extent and the 
drug brain distribution require separate experimental systems. A whole 
in vitro single system has been proposed using MDCKII and MDCKII-
MDR1 cell lines because they closely reflect the tightness and 
transporters expression of the blood brain barrier in a more reliable and 
constant manner than non-immortalized cell lines [14, 15] and it 
provides a well characterization of the relevant drug parameters in order 
to improve candidate selection in the preclinical stages for further in vivo 
analysis [97, 98].  
 The relevant BBB parameters for predicting rate and extent of 
access are: fu, plasma, Vu, brain, and Kp,uu, brain. fu, plasma explains the drug’s 
affinity to blood proteins and this parameter quantify the free 
concentration that is able to cross the BBB and reach the target. 
However, the amount of drug that is able to reach the target depends 
also on the free drug concentration in brain.  Therefore, Kp,uu, brain is a 
measurement in equilibrium of the relationship between free brain 
concentrations and free plasma concentrations. The value of Kp,uu, brain 
indicates the extent of the drug that crossed the blood-brain barrier and 
is highly related to the effect. The parameter that describes the 
distribution of the drug in brain is Vu, brain. The brain may be divided in 
two different compartments, extracellular fluid (ECF) and intracellular 
fluid (ICF). The ECF+ICF real volume is the minimum volume in 
which the drug may be distributed if it does not bind to the cells 
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components. If the drug is accumulated in cells, then Vu, brain is greater 
than (ECF+ICF) volume. The experimental determination of these 
three parameters required different and independent experimental 
setups. fu, plasma is determined in vitro, Kpuu, brain requires in vivo 
microdialysis studies to estimate the ECF and plasma concentrations 
and Vu, brain may also be obtained using in vitro methods [4]. 
 
Correlations 
All the correlations in vitro versus in vivo parameters were done 
using the three proposed correlation methods, i.e. from the Papp at the 
lowest concentrations, by averaging the in vitro estimates at all the 
concentrations and from the extrapolation strategy. The last method 
produced the best correlations (higher correlation coefficients) in both 
cell lines. 
MDCKII 
 In this cell line in vitro fu,p calculated from permeability values 
and  in vivo fu, plasma presented a good correlation (Figure 15) in ten 
compounds tested (R=0.93).  In vitro Kpuu, brain and in vivo human Kpuu, 
CSF correlation (Figure 16) was obtained with an R=0.85.  Human Kpuu, 
CSF data were better correlated than rat Kpuu, brain values (R=0.25), 
probably due to the less transporter expression in MDCKII and human 
Blood-cerebrospinal fluid barrier (BCSFB). Good Vu, brain correlation 
(Figure 17) was observed between in vitro Vu, brain and in vivo Vu ,brain 
(R=0.99). 
MDCKII-MDR1 
 In the MDR1 transfected cell line, in vitro and in vivo fu,plasma 
correlation (Figure 18) was less accurate and precise. A Pearson 
correlation coefficient of 0.66 is lower than observed than in MDCKII 
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cell line (R=0.93). In vitro Kpuu, brain and in vivo Kpuu, brain correlation 
(Figure 19) was obtained with an R=0.66, removing Ethyl-phenyl 
malonamide data. Rat Kpuu, brain data were better correlated than human 
Kpuu, CSF values (R=0.30), but a good correlation was not achieved with 
any of the in vivo Kpuu values. The higher expression level of P-gp in this 
cell line might not reflect the in vivo expression levels in BBB. Good Vu, 
brain correlation (Figure 20) was observed between in vitro Vu, brain and in 
vivo Vu, brain (R=0.92). Similar behavior in rank order was observed as 
explained in MDCKII.  
Comparing both cell lines, in general the prediction 
performance of MDCKII cell lines is better than the MDCK-MDR1. 
Nevertheless the worst predicted compounds are the same in both cell 
lines at least for Kpuu and for fu, plasma. For instance Zidovudine and 
Ethyl-phenylmalonamide in vivo Kpuu are underestimated in both cell 
lines while Propranolol and Atenolol are over estimated. 
Diphenhydramine fu, plasma is underestimated in both cell lines. The 
reason for the deviation is not clear but it does not seem to be related 
with the different expression level of P-gp that is the most relevant 
difference between both cell lines. 
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1. Modified Non-Sink equation (Mangas-Casabó method) is a 
precise and accurate equation for calculating the apparent 
unidirectional permeability in any type of profile and under 
different scenarios of variability, as well as sink and non-sink 
conditions, while the Non-Sink equation fails in obtaining good 
permeability estimates in those situations in which the initial 
permeation rate is altered.  
 
2. Linear regression models (S and SC), are not valid under strong 
non-sink conditions as expected as the underlying assumptions 
(sink conditions) do not hold but also in situations in which sink 
conditions are fulfilled but the system variability is high.  
 
3. MSN method would be the recommended one as it 
accommodates not only sink and non-sink conditions but also 
all type of profiles with altered initial rates. Sink corrected could 
be a good approximation (in slightly non sink conditions) even 
better than Non Sink method because NS does not fit well the 
atypical profiles. 
 
4. The sub-culturing protocols, passage number and days after 
seeding before the experiment have an important influence in 
permeability values and in their variability.  
 
5. SOP 1 (with collagen coating) at intermediate passage number 
seems to be the best experimental conditions in our laboratory 
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and cell lines to compare drugs absorbed by passive diffusion 
by transcellular route. 
 
6. The differences in SOP 1 and 2 regarding the effect of passage 
number on the different permeation routes show the 
complexity of the involved mechanisms. For P-gp interaction 
studies in this case would be more convenient SOP 2 at 
intermediate or late passage numbers.  
 
7. The variability in permeability estimation showed a trend to 
decrease in MDCK and Caco-2 cells with SOP1 but a tendency 
to increase in SOP 2. MDCK-Mdr1 showed the lower variability 
in both protocols (ranged between 5 and 7% as average values), 
without any relevant change with passage number. 
 
8. The time post seeding had the expected effect in particular in 
Rhodamine permeability for which higher maturation times lead 
to a higher expression of the transporter Nevertheless for 
passive diffusion transported drugs there is not a clear trend 
neither in permeability values nor in variability. These results 
support the idea of developing “fast maturation” models that 
can be useful for screening compounds absorbed by passive 
mechanism. 
 
9. In our study, the average variability observed in permeability 
values in all cell lines is around 10%-15% that means that for 
detecting a 15% difference in permeability values the required 
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number of individual estimations would be between 8 and 12, 
i.e. one plate of 12 wells. 
 
10. The in vitro cell monolayer system (in MDCK and MDCK-
MDR1) with albumin in apical chamber in comparison with the 
standard system without albumin allows the estimation of the 
fraction unbound in plasma. 
 
11. The inclusion of brain homogenate in the basolateral chamber 
allows the estimation of fu, brain by comparison of the 
permeability values obtained with and without brain 
homogenate in the system. The most adequate ratio in terms of 
adherence, sampling feasibility and physiological resemblance 
was a 3:1 ratio of buffer/brain homogenate. 
 
12. In vitro fu, plasma, Kpuu, brain and Vu, brain calculated with the apparent 
permeabilities Papp in the proposed cell culure system 
presented a good correlation with in vivo fu, plasma, Kp,uu, brain and 
Vu, brain published values. Despite its simplicity the predictive 
performance is fairly good considering the reduced number of 
tested compounds with different physicochemical and transport 
properties.  
 
13. In summary, a innovative “three step” whole in vitro cell 
monolayer system have been developed including a standard set 
up of apical and basolateral chamber of same composition a 
second model with albumin in apical chamber and a third step 
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with brain homogenate in basolateral chamber. The comparison 
of the effective permeabilities in the three steps allows the 
estimation of the relevant kinetic parameters for Blood Brain 
Barrier with the proposed mathematical analysis. 
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